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Abstract
This thesis provides an additional perspective of the Merger Paradox, namely that
mergers and acquisitions (M&A) continue to be transacted when historically their
results seem to be disappointing overall.
The thesis shows that when a theoretically sound basis (related to the Resource
Based View and expressed as twelve design principles) is used to design a
performance measurement framework, then there is no association between a
firm's post-acquisition performance and the scale of a firm's previous acquisitions;
the thesis then shows, by contrast, that there is a positive association between
firms with an above-average level of past acquisitions (by value) and higher
financial performance. This divergence provides both a motive and an ability to
continue to undertake M&A, despite a lack of association of acquisitions with
longer-term operational performance and very strong evidence of diseconomy of
scale in the most crucial business process, for the case examined, which is the
research and development (R&D) process in the research-based pharmaceutical
sector. Additionally, the thesis examines the relative merits of Return on Sales
and Return on Assets as financial metrics of performance, and establishes
statistically significant differences in the measurement of performance by these
two metrics.
The thesis also establishes a contrast between the findings at the level of the firm
and at the level of the sector, namely acquisitions considered in aggregate are
associated with gains at the sector level, even though this association was not
observed when acquisition was considered at the level of the acquiring firm.
The thesis provides a new application of Data Envelopment Analysis and
establishes a scale efficiency relationship for the pharmaceutical R&D process. A
further empirical contribution is the examination of the statistical distribution of
acquisitions in the pharmaceutical sector and confirmation of the consistency of
that distribution with a power-law.
xv
Glossary
ADME Absorption, Distribution, Metabolism and Excretion
BCC Banker, Charnes and Cooper
CCR Charnes, Cooper and Rhodes
CRS Constant Returns to Scale
DEA Data Envelopment Analysis
DMU Decision Making Unit
DRS Decreasing Returns to Scale
IC Intellectual Capital
ICT Information and Communications Technology
IND Investigational New Drug
IRS Increasing Returns to Scale
KPI Key Performance Indicator
M&A Mergers and Acquisitions
MCT Measure of Central Tendency
Merger Paradox M&As continue to be transacted when historically their
results seem to be disappointing overall
NAIC North American Industry Code
NDA New Drug Application
xvi
NDV Normalised Deal Value
p-value The probability, computed assuming that the null
hypothesis is true, of observing a value of a test statistic
that is at least as contradictory to the null hypothesis as
the value actually computed from the sample data
(adapted from Bowerman et al., 2011: 359)
PAP Post-Acquisition Performance
PMF Performance Measurement Framework
R&D Research & Development
R&D (Average) Average Research & Development expenditure for a firm
from 2001 to 2006
R&D (Current) Research & Development expenditure for a firm in 2006
R&D (Historic) Average Research & Development expenditure for a firm
from 2001 to 2005
RBV Resource Based View
ROA Return on Assets
ROE Return on Equity
ROS Return on Sales
SDV Sum of Deal Value
SOA Sales over Assets
xvii
US$ United States dollar. Official currency of the United
States of America and several other countries
VRIN Valuable to the company, Rare, Imperfectly imitable and
Non-substitutable
VRS Variable Returns to Scale
11 Introduction
1.1 Research Aim
Angwin (2007) posits a fundamental question for research into mergers and
acquisitions (M&A), which is often termed the ‘Merger Paradox’, namely why
M&A continue to be transacted when historically their results seem to be
disappointing overall. That paper goes on to suggest that there are many
objectives for M&A and one should not judge a transaction to be a failure on
the basis of a particular measure of performance. This thesis examines the
Merger Paradox from the stance of measurement rather than from the motive
itself (although the two are related), and seeks to demonstrate that differences
in the measures used to determine post-acquisition performance (PAP) could
explain the continuing popularity of M&A despite M&A not being associated
with improved long-term performance in crucial business processes.
The literature review for this thesis has identified PAP literature dating back to
1968 and from the very start the issue of multiple stakeholders and dubious
PAP was fully recognised. Over 40 years of research later, across several
disciplines, Zollo & Meier (2008) noted the absence of a convergence of
findings even within disciplines and identified the use of 12 types of measures
of PAP. Despite the variety of measures, in a recent investigation using
multiple criteria, Papadakis & Thanos (2010) noted disappointing outcomes in
over half of cases, which then leads to the Merger Paradox of why acquisitions
remain popular when, in most cases, they seem to be unsuccessful.
It is against this background of voluminous, diverse but pessimistic literature
that this thesis adds new contributions by initially focusing on the principles of
performance measurement, noting that PAP is an intellectual construct and
2taking heed of Venkatraman & Grant (1986) who observe that in strategic
management the principle of measurement of a construct is often ignored in
favour of content development. In essence, PAP itself can never be
considered directly, but only through proxies for PAP expressed in a chosen
measure. Given this, the selection of any measure requires a theoretical basis.
The Resource Based View (RBV) of a firm is used here as the theoretical
basis for measure selection. Currently, RBV is a long-established approach to
strategic management. The Journal of Management in September 2011
dedicated a special issue to reviewing resource based theory to
commemorate its previous special issue that introduced the theory 20 years
earlier; in the most recent special issue, Barney et al. (2011) considered it had
reached maturity and was capable of further development to satisfy its critics.
The focus of the RBV is on the linkage of competitive advantage to the
differences between firms in the same market, as opposed to the factors
affecting profitability in the market as a whole (the focus of the Industrial
Organisation approach to strategy). The focus of RBV on relating the
competitive advantage of a firm to its special factors (some of which will be
measurable) has made its literature a natural basis from which to develop a
systematic means to identify a set of performance measures that can be
related to long-term performance. In the thesis, a performance measure is
used to assess the comparative efficiency of key processes of firms in a
particular sector and it is used as a measure of relative non-financial
performance. This performance measure is then associated with the
acquisition history of the firms and used to test a series of hypotheses for
mergers in aggregate as well as cross-sector and cross-border mergers. In
order to shed new light on the Merger Paradox, the outcome of the analysis is
compared with a similar exercise using a common accounting measure.
3Finally, the effect of M&A on sector performance and whether particular
alternative financial measures provide a consistent view on PAP are
examined.
1.2 Choice of Sector and Need for Research
The research-based pharmaceutical sector offers several advantages for this
research:
– The resources of a firm, in the RBV sense that includes both inputs and
outputs of the research and development (R&D) process, are clearly
defined because products cannot be developed without formal regulation
and identification, nor can they be sold without marketing approval.
– The R&D process is generic across the whole industry (because of
regulatory constraints) and this gives rise to a comparable process that
allows efficiency to be measured.
– Data on the industry are widely available.
These characteristics do not apply to all research-based industries, for
example the Information and Communications Technology (ICT) sector has
diverse R&D processes.
Furthermore, the research-based pharmaceutical sector offers compelling
public policy reasons to undertake research: rising healthcare costs are a
feature of the economies of the developed world and the ethical
pharmaceutical sector is both a cause of, and a potential solution to, these
costs; yet there is concern that it is facing a productivity crisis, for example
Cockburn (2006), and a rising cost per new compound, for example DiMasi et
al. (2003).
41.3 Research Approach
Firstly, because the focus of the research is on how the assessment of PAP
depends on the choice of measure, it is necessary to first develop a
systematic and rigorous way to select performance measures; as indicated in
Section 1.1, this is based upon the RBV. The selection process leads to a
vector of measures that can be used to measure R&D efficiency.
Secondly, having defined a vector of measures, a number of Data
Envelopment Analysis (DEA) models were built with the selected measures to
measure comparative efficiency of the R&D process between firms, in order to
establish relative performance; in order to do this it was necessary to test for
returns to scale, after populating the models with data on the inputs and
outputs to the process. The different models had different selections of inputs
that gave rise to different assessments of efficiency.
Thirdly, data on acquisitions of the major pharmaceutical firms were collected
and the deals were also classified according to whether the acquisition
involved diversification into different nations or sectors. The data on M&A
values were summated for each of the firms and also normalised by dividing
by the cost of sales of the firm to relate the deals to the size of the firm.
Fourthly, this acquisition history of the firms was associated with their
efficiency as measured by DEA and used to test three merger-related
hypotheses relating to: acquisitions in total, acquisitions of new product
resources, and acquisitions of new market resources. This was done for more
than one DEA model and the differences in outcomes were related to typical
behaviours following a merger.
5Fifthly, the financial efficiency of the firms was measured by Return on Sales
(ROS) and Return on Assets (ROA), for the same firms and this was used to
test the same three hypotheses. This was then compared with the outcomes
of the hypothesis tests using the DEA methods and this led to a further
explanation of the Merger Paradox.
Sixthly, the acquisition statistics on mergers of the firm were analysed without
the application of a normalisation factor to examine the effect of mergers on
efficiency at the sectoral level; this was done in order to compare the outcome
with financial methods of analysis in which differences are observed for the
PAP of the shareholders acquiring the firm alone and the shareholders of the
acquiring and acquired firm together.
Seventhly, the statistic Sales over Assets (SOA) was tested in order to
understand if the acquisition process had an effect on common financial
metrics that could be used to measure PAP and an effect was detected.
Some of these steps required hypothesis testing. The research hypotheses
are described in the next section (1.4). The research hypotheses were
developed after consideration of the literature on PAP and will be related to
the literature in the final chapters of the thesis.
1.4 Research Hypotheses
The hypotheses are based on testing the difference in a measure of central
tendency (MCT) between two samples, using both a parametric and a non-
parametric test. All the hypotheses follow a conventional format, whereby the
null hypothesis represents the case of no difference between the means of
two samples; the alternative hypothesis is therefore that there is a difference
between the means of the two samples and it is the alternative hypothesis that
6is tested to establish a statistically significant difference between the means of
the two samples.
In the case of the first set of hypotheses, there is a single null hypothesis that
scale does not vary with size: constant returns to scale (CRS) exist for a
process. The alternative hypothesis is that there are variable returns to scale
(VRS) and this is tested by examining whether statistically significant
differences in size exist between two groups comprising firms with above-
median and below-median efficiency scores.
The second set of hypotheses (a set of three) examines technical efficiency.
The null hypothesis is taken to represent the situation that a history of M&A
transactions, normalised for the size of the firm, is not associated with a
change in efficiency. The alternative hypothesis is that efficiency does change
as a result of M&A and as the objective is to test the Merger Paradox, the
statistical test is one-sided: M&A is associated with lower technical efficiency.
A similar test is undertaken for a third set of three hypotheses that examines
financial efficiency (as measured by both ROS and ROA), except that the
direction of the alternative hypothesis is that M&A is associated with higher
ROS and ROA that would provide a financial motive, or at least a qualifying
factor, for the deal.
A fourth set of three hypotheses considers the association of acquisitions in
total, without normalisation for the size of the firm, with technical efficiency.
These hypotheses follow a similar format to those in the second set.
Finally there is a fifth set hypotheses that examines different financial metrics.
The null hypothesis is that SOA is unchanged, and the alternative hypothesis
is that M&A is associated with lower SOA, as additional intangible assets
7become recognised in the M&A process. A fourth hypothesis is added to this
set, a non-directional hypothesis, to clarify one of the findings.
There are therefore 14 hypotheses in all.
1.5 Technical Challenges and Contributions to Knowledge
1.5.1 Measurement of Intangibles
The difficulty in quantifying intangibles has posed various challenges to this
research. One example of an intangible factor is the nature of the output of the
R&D process, however, the sector was chosen so a regulatory process
circumvented the difficulty of recognising the worth of an output. A further
aspect relates to the attempts to measure diversification, for example M&A
deals have been categorised in order to examine the effects of diversification,
however in order to do so there needs to be a measure of relatedness. A
measure of relatedness was achieved by identifying whether the acquired
company was located in the same country or had the same industrial
classification as the acquiring company; nonetheless it is recognised that
these simple classifications do not account for a more nuanced situation.
1.5.2 Longitudinal Nature of R&D Pipeline
The use of DEA to measure the comparative efficiency of the pharmaceutical
R&D pipeline between firms in the M&A context is novel1. One possible reason
is because of the difficulties presented by the longitudinal nature of the
pharmaceutical R&D pipeline, whereby outputs in the current time period
depend on inputs in the previous time periods. This research has sought to
address this problem by collecting input data that cover the majority of the
1 It has however been used as a means of R&D productivity measurement in other sectors, unrelated to
M&A, for example in selection of projects within a portfolio of a firm (Oral et al., 1991; Eilat et al., 2006).
8duration of the multiphase R&D pipeline and which exceeds the duration of
any single phase of the multiphase pipeline.
1.5.3 Variety of Outputs
Earlier literature on measurement of R&D efficiency has used a wide variety of
examples of potential outputs from the R&D process, including revenue,
patents and New Drug Applications (NDAs). This variety of outputs has
contributed to the diversity of findings.
The advantage of DEA is that multiple outputs can be considered, so that an
arbitrary choice between potentially valid output parameters does not have to
be made. The selection of the multiple output parameters is undertaken using
the 12 Design Principles (the model design is discussed further in
Section 4.2).
1.5.4 Types of Contributions to Knowledge
The research has produced the following contributions:
 Two theoretical contributions by offering:
o additional insight into the Merger Paradox, based on the
divergence of outcomes when PAP is measured in different
ways;
o a theoretically based approach to the selection of multiple
performance measures.
 A methodological contribution by introducing a novel means of
assessment of PAP, combining a longitudinal view of M&A history and
a cross-sectional view of comparative efficiency (that itself accounts for
9the longitudinal nature of the R&D pipeline and the multiple outputs of
the R&D process).
 Three empirical contributions regarding:
o scale factors for the R&D pharmaceutical pipeline;
o the statistical distribution of M&A in the pharmaceutical sector;
o differences in measurement of PAP exhibited when ROA and
ROS are used as measures of financial efficiency.
To these can be added a confirmation of a further aspect of the Merger
Paradox, namely that although M&A does not seem to be associated with
higher performance to the acquiring firm, M&A value in total is associated with
more efficient firms (possible reasons for this are elaborated upon later in the
thesis).
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2 Overview of Pharmaceutical Sector
2.1 Introduction
This chapter provides an overview of the research-based pharmaceutical
sector, highlighting the unique characteristics of the R&D process and relating
them to the research methodology.
The R&D process, which is common to all research-based firms in the sector
due to the regulatory environment, is defined. The market structure of the
sector that existed at the time of the analysis (2006 and the preceding decade)
is then summarised. Finally, a review of the merger activity follows, including
expert industry opinion on the motivations of the mergers and their
consequences to the sector and the firms involved, as recorded in published
reports accessed from the University databases.
2.2 R&D Processes
The pharmaceutical R&D process is unusually well-defined and recorded. This
is because of the need to be confident of the safety of future compounds by
undertaking tests on the human population. This has a dual advantage for this
research in that well-defined R&D processes allow measurement of
comparative efficiency and the metrics used in the measurement are publicly
available.
Sweeny (2002: 4) provides a full summary of the pipeline:
– Discovery/Basic Research: Synthesis and Extraction – the process of
identifying new molecules with the potential to produce a desired change
in a biological system; Biological Screening and Pharmacological Testing
11
– studies to explore the pharmacological activity and therapeutic potential
of compounds.
– Preclinical Testing: Toxicology and Safety Testing – tests to determine
the potential risk a compound poses to humans and the environment
involve use of animals, tissue cultures or other test systems;
Pharmaceutical Dosage Formulation and Stability – the process of turning
an active compound into a form and strength suitable for human use.
– Regulatory Review: Application to regulatory authority to use compound
in human testing. In the USA the compound is then called an
Investigational New Drug (IND).
– Phase I Clinical Trials. Testing of a new compound in 20–80 healthy
human volunteers to determine tolerance, pharmacological effects, and
absorption, distribution, metabolism and excretion (ADME) patterns.
– Phase II Clinical Trials. Trials in 100–300 patients with the targeted
condition to determine effectiveness in treating disease or medical
condition and short-term risks.
– Phase III Clinical Trials. Trials on 1000–5000 patients to determine
clinical benefit and incidence of adverse reactions.
– Process Development for Manufacturing and Quality Control. Engineering
and manufacturing design activities to establish capacity to produce in
large volumes and to ensure stability, uniformity and overall quality.
– Bioavailability Studies. Use of healthy volunteers to show that formulation
used in trials is equivalent to product to be marketed.
12
– Regulatory Review: NDA. Application for approval to market a new drug.
In the USA this is called a NDA.
– Phase IV. Post-marketing trials to identify undetected adverse effects and
long-term morbidity and mortality profile.
This process is universally called the ‘pipeline’ and compounds move through
the pipeline in stages. Measurement of a drug in the pipeline can occur at the
following stages: Preclinical, Phase 1, Phase II, Phase III and Awaiting
Approval (i.e. the Phase III trial has been successively completed but
Marketing Authorisation for the NDA has yet to be given).
In practice the pipeline resembles a funnel, with many compounds entering
the start and fewer emerging because the remainder fail to clear the hurdles of
clinical trials. The management of the pipeline is a ‘race against time’. The
patents on which the compound are originally based generally have a 30 year
life, after which any company can produce the drugs on which the patent is
based, in other words it becomes ‘generic’ in the lexicon of the industry. The
longer a compound stays in the pipeline the shorter the exclusive
manufacturing and marketing period; this leads to a considerable loss of
income.
These time factors can lead to variations in approaches to management of
clinical trials. A trial is focused on the use of a compound for a particular
‘indication’: treatment of a condition. Some companies choose to proceed with
trials for as many indications as possible in the hope of gaining multiple
marketing approvals early in the patent lifetime. However, this is also an
expensive strategy because clinical trials are expensive; an alternative
approach is to proceed with trials for major indications only.
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The timing and technology of the clinical trial part of the pipeline has tended to
remain relatively static, with the increase in terms of the reporting
requirements being offset by advances in ICT. However the preclinical stages
of the pipeline have benefited from major technological changes on two fronts:
– product technology, moving from traditional ‘small molecule’ chemical
compounds to biotechnology, where the compounds are large molecules,
derived from biological processes;
– process technology, which has allowed increased productivity in the
screening of potential drug candidates prior to clinical trials.
The latter change has implications, discussed later, for the relevance of
examining R&D inputs to the process in the low productivity era.
2.3 Market Structure and Acquisition Activity
Two industry surveys, Sykes (1999) published near the start of the period of
examination of M&A activity within this thesis and Hamilton (2005) published
near the end, summarise the main issues facing the industry in this period.
Sykes (1999) specifically considers merger waves in the industry, correctly
identifying the start of the third wave which is the focus of this study. M&A
activity frequently follows waves as noted by Schoenberg & Reeves (1999)
who proposed five factors that may affect acquisition activity: industry
profitability, industry growth, industry concentration, capital intensity and
industry deregulation; such factors have been observed in the pharmaceutical
sector, as discussed below. The first M&A wave occurred in 1988–89 and led
to the consolidation of a number of middling companies into top-tier firms. The
second M&A wave focused on ‘mergers of equals’ or horizontal mergers
intended to reduce fixed costs and increase funds available for R&D. Three
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drivers of M&A activity were apparent: improved R&D, improved sales and
marketing cost reduction, and the desire to preserve independence.
Companies were also identified as having different views on M&A, classified
as merger-bent, merger-averse and merger-resistant, the last group preferring
co-licensing deals to full-blown acquisition. As Sykes (1999) was going to
press, the third wave commenced, with mergers involving Astra and Zeneca,
Sanofi, and Aventis. Hamilton’s (2005) study was written at the end of this
merger wave that left the industry in a challenged state: “the pharmaceutical
industry continues to experience problems in all aspects of its business”. R&D
productivity had declined and some major drugs had been withdrawn from the
market following safety concerns. At that time, the major opportunities were
seen to be the emerging markets of China and India, and growing ageing and
obese populations across the globe. The importance of linking the R&D
strategy to commercial priorities was also emphasised, rather than focusing on
exploiting new development technologies as had occurred previously.
2.4 Key Metrics
The performance of the pharmaceutical industry is measured by financial
metrics similar to those used in other sectors; however, there is one particular
metric that is given universal prominence in the sector, namely R&D
expenditure as a proportion of revenue. For example Pharmaceutical
Research and Manufacturers of America (2010) cites the statistic on its
opening ‘Key Facts’ page, and the synopsis of the sector provided by the
Association of the British Pharmaceutical Industry (2010) remarks: “Research
and development lies at the heart of the pharmaceutical industry. It invests 30
per cent of its sales in research…” and then goes on to tabulate R&D as a
proportion of sales over time for the sector and to compare the statistic
between sectors.
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At the firm level, the metric R&D as a percentage of sales is frequently used to
rank companies by their long-term potential, on the presumption that higher
R&D expenditure leads to greater prospects of future success at the
preclinical stage.
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3 Literature Review
3.1 Introduction
The literature review for this research encompasses:
– the PAP literature from 1968 onwards, including DEA-related literature;
– the RBV, which is the theoretical basis for the selection of performance
measures;
– multidimensional measurement, especially as regards the measurement
of intangibles;
– the application of the RBV in the pharmaceutical sector;
– the small subset of the large DEA literature that considers M&A, R&D or
the pharmaceutical sector.
On analysing the literature it becomes apparent that many topics themselves
are multidisciplinary. M&A in general and PAP in particular have been
considered differently by different academic disciplines; performance
management itself is multidisciplinary, as made clear by an extensive literature
review in Neely et al. (1995). Given this, the literature review concludes with a
synthesis of the various strands of literature as they relate to this thesis.
3.2 PAP
3.2.1 History
The academic literature on PAP has been accumulating for the past four
decades. Weston & Mansinghka (1971) were one of the first to publish on the
performance of conglomerates and were able to cite only three prior papers.
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This paper and the references set the tone for the subsequent decades. The
paper found that in a sample of 63 firms, active acquirers had lower
profitability than a random sample. Of the prior papers, Reid (1968) found
active acquirers scored higher on criteria related to managers’ interests than
owners’ interests. Smith & Schreiner (1969) found that investment companies
were better at portfolio management than corporate acquirers. Lorie & Halpern
(1970) examined if ‘deception of investors’ in the acquired firm took place but
found the concerns to be unfounded with above-index returns to shareholders
of the acquired firm. Therefore from very early on in the M&A literature the
issues of multiple stakeholders and dubious PAP, at least for the acquiring
firm as distinct from the acquired, were fully recognised.
3.2.2 Meta-Analyses
It is now recognised that PAP is an intellectual construct subject to a variety of
interpretations, and for the past decade there has been an emerging sense of
the need for integration of the literature seeking to unite at least some of the
several theoretical perspectives. Larsson & Finkelstein (1999) seek to do this
by using a structural equation model to assess how synergy realisation is
affected by combination potential, organisation integration and employee
resistance. Nonetheless they recognise that the synergy realisation measure
is less objective than financial or accounting measures. This search for an
integrative approach has also encompassed performance measures
specifically: Zollo & Meier (2008) examined some but not all aspects of this
construct (the ‘Performs for whom?’ question was not posed) when they
undertook a meta-analysis of 87 academic articles on M&A. These papers
have been subject to further analysis as discussed later. This meta-analysis
revealed three broad academic disciplines: strategic management, corporate
finance and organizational behaviour. The 87 studies in the meta-analysis
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used 12 different types of performance measures. The largest group (41%) of
the total used a short-term window financial event-study approach, a method
that typically relies on stock market measures, as do the long-term window
studies (18%) that are finding increasing application in finance journals. The
next most frequent type of measure is the accounting measure (29%), which is
found in the strategic management and organizational behaviour journals,
whose analysis term is a matter of choice but comprises one or more years.
Other approaches attempt a more general assessment of acquisition
performance, including subjective surveys and panels (14%); none of the
remaining approaches total more than 7% of the total. Three broad categories
of measures are therefore observed: finance (short- or long-term window,
59%), accounting (variable term, 29%) and subjective surveys (14%).
Zollo & Meier (2008) add further dimensions to their meta-analysis; firstly they
consider the time dimension by using a two-way taxonomy of short and long
term, acknowledging that acquisitions may be a response to immediate
incentives but whose long-term effect is uncertain. In a second dimension,
Zollo & Meier (2008) also propose a three-level taxonomy: firstly, tasks
involved in the acquisition, secondly the acquisition itself and thirdly the
longer-term performance of the acquiring firm. Considering this three-by-two
classification of measures, Zollo & Meier (2008) then provide plausible
scenarios where the measures of performance may diverge: they establish
that different measures may measure different aspects of the PAP construct
and can be expected to diverge under certain circumstances.
Many of the 87 papers considered multiple measures and 13 examined
accounting performance and one other parameter, as this thesis does;
however, in no case were both accounting and operational efficiency
measures for intangibles considered, which is the subject of this thesis. This
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preference for multiple measures in the literature is an indirect endorsement of
the benefits of multidimensional performance measurement and later in this
review specific literature that confirms the benefit is identified.
Table 3.1 provides a chronological analysis of the Zollo & Meier (2008) papers
(this analysis was not presented in the original paper) and displays the types
of measures used, with some papers considering up to three measures.
Table 3.1 Choice of Measures in Acquisition Meta-Analysis 1983–2006
Author Year First
Measure
Second
Measure
Third
Measure
Eckbo 1983 S
Jensen and Ruback 1983 S
Wansley et al. 1983 S
Buono et al. 1985 I O
Kusewitt 1985 A L
Chatterjee 1986 A S
Montgomery and Wilson 1986 V
Lubatkin 1987 L S
Ravenscraft and Scherer 1987 A
Singh and Montgomery 1987 L
Travlos 1987 S
Amit and Livnat 1988 A
Capon et al. 1988 A
Morck et al. 1988 A
Shelton 1988 S
Walsh 1988 E
Fowler and Schmidt 1989 A L
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Walsh 1989 E
Datta and Grant 1990 O
Hunt 1990 I O
Lahey and Conn 1990 L
Seth 1990b S
Chatterjee 1991 S
Datta 1991 I O
Franks et al. 1991 S
Harris and Ravenscraft 1991 S
Harrison et al. 1991 A
Hitt et al. 1991 V
Schweiger and Denisi 1991 E
Slusky and Caves 1991 S
Chatterjee 1992 L
Chatterjee et al. 1992 S
Shanley and Correa 1992 I O
Travlos and Waegelein 1992 S
Agrawal et al. 1992 L
Cannella and Hambrick 1993 O A
Hambrick and Cannella 1993 E
Hoskisson et al. 1993 A L
Bruton et al. 1994 O
Clark and Ofek 1994 A L
Markides and Ittner 1994 S
Pennings et al. 1994 V
Berger and Ofek 1995 S
Brush 1996 A M
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Chang 1996 A
Hitt et al. 1996 A V
Vermeulen and Barkema 1996 V
Weber 1996 I A
Anand and Singh 1997 A
Barber and Lyon 1997 L S
Covin et al. 1997 E
Hayward and Hambrick 1997 S
Holl and Kyriazis 1997 S
Krishnan et al. 1997 A
Kroll et al. 1997 S
Loughran and Vijh 1997 L
Lubatkin et al. 1997 L S
Ramaswamy 1997 A
Hitt et al. 1998 A V
Morosini et al. 1998 A
Bresman et al. 1999 I K
Capron 1999 I O
Haleblian and Finkelstein 1999 S
Larsson and Finkelstein 1999 I O
Thakor 1999 Y
Palich et al. 2000 A L S
Walker 2000 S
Ahuja and Katila 2001 N
Bergh 2001 V
Krug and Hegarty 2001 E
Beckman and Haunschild 2002 S
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Capron and Pistre 2002 S
Hayward 2002 O S
Heron and Lie 2002 A
Seth et al. 2002 S
Carow et al. 2004 L S
DeLong and DeYoung 2004 A S
Feea and Thomas 2004 A S
Moeller et al. 2004 S
Pangarkar 2004 S
Zollo and Singh 2004 A
Harrison et al. 2005 L S
Shahrur 2005 S
Zollo and Reuer 2005 A L
Homburg and Bucerius 2006 O
Puranam et al. 2006 O
Kapoor and Lim 2007 N
Key to columns 3, 4 and 5:
I = Integration process performance; O = Overall acquisition performance; E =
Employee retention; A = Accounting performance; L = Long-term financial
performance; S = Short-term financial performance; V = Acquisition survival; N
= Innovation performance; K = Knowledge transfer; Y = Systems conversion;
M = Variation in market share.
Table 3.1 shows some trends in scholarship in the examination of PAP. For
the first five years, there are 2.2 papers per year and an average of 1.36
measures per paper. In the next five years output increased to 4.8 papers per
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year but with an average of 1.2 measures per paper (i.e. adopting a one-
dimensional view of merger performance). In the past ten years we see a
steady 1.4 measures per paper and an average output of 3.2 papers per year.
Over time therefore the intensity of research has slightly declined but there
has been a greater effort to obtain a multiparameter view.
Another recent meta-analysis of performance measures in PAP is Papadakis
& Thanos (2010), which extended work by Schoenberg (2006) and generally
confirmed its results, showing merger success rates below 50%. Schoenberg
(2006) found no correlation between accounting measures, financial returns
and managers’ subjective assessments, whereas Papadakis & Thanos (2010)
found a correlation between accounting-based measures and managers’
subjective assessments. However, the possibility that the latter (received in a
single semi-structured interview) may have been influenced by the former was
not discussed in the paper. That paper considers case studies explicitly,
although these can be considered a variation on a survey of subjective
assessments, with a sample size of one, with the justification that each merger
is so unique that any attempt at categorisation of findings into measures would
risk distortion.
Another recent meta-analysis by King et al. (2004) considered whether the
acquisition was by a conglomerate, whether it was related by sector, method
of payment and prior experience; it also established the relative popularity of
accounting measures: 29 studies using ROA, 14 using Return on Equity
(ROE) and 9 using ROS. This confirms the preference of ROA to ROE as a
measure of capital efficiency because it does not depend upon the capital
structure of the firm. The relative merits of ROA and ROS as a measure of
financial efficiency are considered later.
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Having established that there are four approaches to the measurement of PAP
(or three, if a case study is regarded as a subjective survey with a sample size
of one) and there is little or no correlation between them, it only becomes
possible to choose between them by considering the purpose for which the
measures are being applied. For this thesis, one objective is to examine the
Merger Paradox, namely why M&A continue to be transacted when historically
their results seem to be disappointing overall. The major references and the
strengths and weakness of each method are summarised below so that
judgement can be subsequently made on the most appropriate method for
examination of the Merger Paradox.
3.2.3 Summary of Main Approaches
The theoretical foundation for financial performance is provided by Fama et
al.’s (1969) definition of the event study and Fama’s (1970) definition of the
efficient capital market hypothesis. Forty years later the validity of the
hypothesis is still much discussed, however it has since become the
cornerstone of modern corporate finance theory. The ‘strong’ version of the
hypothesis states that prices reflect all information on a company, whether the
information is public or not. If the hypothesis is true, then the ‘abnormal gains’
of share prices following a merger announcement can be considered the best
possible judgment on its future performance, as expressed as the best
estimation of the value created by that merger. The advantage of the method
is that data are publicly available and the sample sizes are large. Several
studies have suggested that mergers ‘create value’, for example
Jensen & Ruback (1983), Seth (1990b) and Singh & Montgomery (1987).
However, other studies indicate that it is the shareholders of the acquired
companies who have the most consistent gains, for example
Chatterjee (1986), Datta (1991), Datta et al. (1992), Seth (1990a), Singh &
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Montgomery (1987) and Sirower (1997). There are however two difficulties
with the approach. The first is that the efficient capital markets hypothesis is
still a hypothesis, especially in its strong form (the weak form states only that
prices reflect public information). The second is more fundamental, namely
whether a gain in wealth by the shareholders by the acquired firm (the only
consistent observation) represents a genuine creation of economic value or is
simply a case of overpayment, which will subsequently burden the merged
firm. This raises the multistakeholder question of ‘performance for whom?’
Regarding accounting measures, these also use publicly available data and
large sample sizes are available, and it is possible to monitor performance
over an extended period of time. The use of accounting measures does,
however, have its critics, for example it ignores risks, it treats the cost of equity
and debt finance differently and the measures are historical but not forward
looking, as noted by Montgomery & Wilson (1986). Notwithstanding these
shortcomings, accounting measures are used by managers for decision
making on the future of the firm, including decisions on acquisitions, and by
financial analysts to inform forecasts that affect share prices.
The use of surveys, whether of expert panels or managers, faces the generic
strengths and weaknesses of this approach. Perhaps the greatest strength is
that it is possible to account in the survey for the original motives of the merger
against which to assess success or failure, and Angwin (2007) stresses the
importance of motive in explanation of merger decision making. Set against
this is the potential for subjectivity and selectivity in survey design and tactical
responses to survey questions. The case study reflects an extreme example of
a survey, able to take account of the unique nuances of each acquisition and
its motives, however, it is very susceptible to subjectivity and difficulties in
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generalisation. Examples of this research approach include Haspeslagh &
Jemison (1991), Marks & Mirvis (1998) and Shanley & Correa (1992).
From the preceding discussion on the strengths and weaknesses of
measurement methods and the earlier discussion on meta-analyses of studies
in assessing PAP and the Merger Paradox, two important themes emerge.
The first is to understand what those who initiated the merger expected from it
and the second is the need to understand what happened over a significant
period of time.
3.2.4 Motive and Synergy
Brouthers et al. (1998) established that the top three motives for M&A were to
‘pursue market power’, ‘increase profitability’ and ‘marketing economies of
scale’ in that order. These three motives have guided the design of this
research. Firstly, the reference to ‘profitability’ suggests that accounting
measures are paramount in managers’ minds, and analysis of accounting
performance has been used to illuminate further the Merger Paradox
(significantly ‘profitability’ rather than ‘shareholder value’ was mentioned in the
top three motives, possibly because the latter is seen as being influenced by
exogenous factors); in this thesis, profitability has been measured by both
ROA and ROS. Secondly, regarding ‘market power’ and ‘marketing’, in the
pharmaceutical sector this is tightly coupled with the R&D process because
authorisation for particular markets or applications of compounds can only be
obtained through successful completion of the clinical trial process. Therefore
in this thesis, efficiency of the R&D process has been selected for examination
of the PAP.
Furthermore ‘market power’ is synonymous with ‘collusive synergy’, one of
three types of synergy (the other two being operational synergy and financial
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synergy) and the RBV provides a theoretical base for the examination of
synergies. Overall, synergies should be positive for an acquisition to proceed
and Penrose (1959) (the earliest RBV-related paper) noted the initial
presumption should be that synergies are negative unless there is a special
reason otherwise. However, Rumelt (1984) notes the presence of synergies
where companies diversify into areas where there are common factors.
However, the potential for synergy may not always be realised, and Angwin &
Vaara (2005) suggest there is an appreciation of the need to examine the
degree of integration or connectivity with the firm.
Notwithstanding the multiple motives that are possible for a deal, Ambrosini et
al. (2010) have found that acquirers that opted for a single value creation
strategy, for example consolidation of costs or leverage of resources across a
larger firm, experience higher PAP than those which pursue multiple
strategies. In the pharmaceutical sector this has been confirmed by Higgins &
Rodriguez (2006) who noted positive financial returns to companies that
sought to outsource R&D through the use of M&A to acquire technological
resources.
3.2.5 Diversification Literature
The diversification literature considered synergies in more detail. Chatterjee
(1986) concluded in the Abstract: “collusive synergy is, on average,
associated with the highest value. Further, the resources behind financial
synergy tend to create more value than the resources behind operational
synergy”.
This observation is highly pertinent to the comparison between the financial
efficiency (ROA and ROS) scores, which include all three synergies, and the
technical efficiency (DEA) scores, which consider operational synergies alone.
28
Examining the diversification literature more generally, there is a strong
similarity with the acquisition literature. A lengthy period of research, mostly
based on cross-sectional studies, has given rise to conflicting results that are
now the subject of meta-analyses noting the evolution of the research. For
example Martin & Sayrak (2003) note there was initially a view that there was
a discount associated with diversification, there then followed a phase where it
was accepted that a discount existed but that it could be accounted for by
other factors, with the final conclusion that there may actually be a premium
associated with diversification but there is a problem with ‘noisy proxies’ used
to measure diversification, that is the principles for the measurement of
diversification are being queried.
Some authors suggest that relatedness improves performance: Kitching
(1967), Elgers & Clark (1980), Kusewitt (1985), Singh & Montgomery (1987),
Shelton (1988) and Healy et al. (1997). However, as remarked previously, in
some cases the ‘gains’ have included gains to target shareholders and this
may simply reflect overpayment. Therefore there seems to be a consensus
that some relatedness may be beneficial to the extraction of synergy, even
though the earlier view that diversification lowered value is now being
questioned.
Regarding cross-border diversification specifically, Seth et al. (2000) estimated
total gains to be 7.6% of pre-acquisition value (i.e. including gains to target
shareholders), which is comparable with the Bradley et al. (1988) figure for
domestic acquisitions (i.e. there is no special advantage for cross-border
acquisition) and indeed less than that observed in Eun et al. (1996), although
this research did find positive total gains for cross-border deals.
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3.3 RBV
3.3.1 Early Definition of the RBV
Although Penrose (1959) and Rumelt (1984) are now considered to be part of
the RBV literature, the modern variant of the RBV was launched by Wernerfelt
(1984) who defined resources as any factor that was a strength or weakness
of a firm. Some examples are given of attractive resources: Machine Capacity,
Customer Loyalty, Production Experience and Technological Leads. These
particular examples have the characteristics of assets and refer to both
tangible and intangible assets; these parameters are potentially measurable.
Rumelt (1984) highlighted the need to consider ‘isolating mechanisms’ that
hinder the imitation of resources and cites ten factors: Causal ambiguity,
Specialised assets, Switching and search costs, Consumer and producer
learning, Team embodied skills, Unique resources, Special information,
Patents and trademarks, Reputation and image, and Legal restrictions on
entry.
Isolating mechanisms complicate the task of the external evaluator: it is not
sufficient to identify and measure a resource, or even to compare this
measurement with that of another organisation (e.g. as occurs in competitor
benchmarking), but one has to anticipate the potential for imitation.
The RBV was interpreted for practitioners by Prahalad and Hamel (1990) who
proposed the concept of a ‘core competency’: defined as an entity that
provides access to a wide variety of markets, and `makes a significant
contribution to perceived customer benefits and is difficult for a competitor to
imitate.
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3.3.2 Qualification of Resources
In the mature phase of the RBV, the perspective moved beyond proposing
candidates for resources to establishing that resources had to have particular
qualities if they were deliver competitive advantage. Barney (1991) proposed
four essential characteristics of resources: Valuable to the company, Rare,
Imperfectly imitable and Non-substitutable (VRIN). These qualities can be
used to screen potential candidates for their relevance to performance
measurement.
Peteraf (1993) provided an alternative set of qualifying factors for resources
when she cited the ‘four cornerstones’ to the RBV:
 the heterogeneity of firms, noting that unique resources allow firms to
earn economic rent as opposed to break even;
 ex-post limits to competition that limit competition for rents once
resources have been acquired;
 imperfect mobility of resources, in terms of their trade;
 ex-ante limits to competition, namely that there is limited competition
for resources prior to their acquisition, so as to avoid the potential
profits from being competed away by bidding for the resource.
These economically orientated factors are especially relevant to the selection
of measures because they translate the qualitative concept of competitive
advantage into a quantitative concept of economic rents. This is also highly
relevant to the pharmaceutical industry that can be viewed as earning an
economic rent on intellectual property, namely patented and approved
compounds.
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3.3.3 Dynamic RBV
In the evolution of the RBV it was becoming recognised that having a stock of
resources may be necessary for competitive advantage but it was not
sufficient because resources needed to be deployed: there must be a
corresponding flow, or use, of the resources for some purpose, as Dierickx
and Cool (1989) noted. Amit and Schoemaker (1993) provided a linkage
between the emerging RBV and the earlier Industrial Organisation perspective
framework, and introduced the concepts of ‘capabilities’ that were defined as
the capacity to deploy resources.
The introduction of the concepts of stocks and flows into the RBV is of direct
relevance to performance measurement. One can measure both a stock and a
flow but care must be taken in mixing the two when building a model to
evaluate efficiency.
Teece et al. (1997) highlighted the role of routines and skills in the firm in
regards to the effective deployment of resources, although these factors may
pose a particular challenge to measurement, especially for an external
evaluator.
3.3.4 Critiques of the RBV
There have been a number of critiques of the RBV, for example Foss (1997)
and Williamson (1999), and also a dialogue between Priem & Butler (2001a,
b) and Barney (2001), regarding the Barney (1991) paper. The criticisms
include: the RBV is tautological (instead of explaining how resources lead to
competitive advantage, it assumes the point) and this makes it difficult to
verify, and the RBV does not link resources to value nor does it consider the
causality of how resources lead to competitive advantage.
32
This thesis addresses this weakness directly. Beginning with the observation
that for a company to be in the top 50 by turnover, it must de facto be
competitive, it then derives the resources that contribute to this success and
uses this as a basis for a performance measurement framework (PMF).
A reassessment of the RBV was also provided by Foss & Knudsen (2003) that
considered the papers of Barney (1991) and Peteraf (1993) as the core
foundations of the RBV, providing the strategic management and economic
bases respectively. However, these two bases were not entirely consistent,
furthermore there were only two necessary conditions for sustainable
competitive advantage: uncertainty and immobility. Peteraf & Barney (2003)
replied, stating in the abstract that: “Unless Resource Based Theory is
understood as a resource-level and efficiency orientated tool its contribution
cannot be understood fully” and suggest a narrower definition of competitive
advantage that focused on intra-industry advantage. This reply is entirely in
sympathy with the approach taken in this paper, where the focus is on
resource-level measurement to assist in the quantification of performance
relative to competition within a single industry.
In conclusion this research accepts the limits to RBV proposed by its founders:
its focus on intra-industry efficiency analysis. In addition, this research seeks
to develop a new perspective for RBV: establishing the causality of resource
possession and competitive advantage. This research is also supported by the
finding in Crook et al. (2008) of a positive association of measures and
performance when those measures are selected by the criteria laid out in the
RBV.
More recently, Kraaijenbrink et al. 2010 identified eight criticisms of which
three were considered to merit further attention; these three were two basic
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concepts that resource and value required a more detailed definition and there
was a narrow view taken of competitive advantage.
3.3.5 Recent Retrospective on the RBV
As noted previously, the Journal of Management in September 2011
dedicated a special issue to reviewing resource based theory to
commemorate its previous special issue that introduced the theory 20 years
earlier; in the most recent special issue, Barney et al. (2011) considered it had
reached maturity and was capable of further development to satisfy its critics.
The topic of measurement was also specifically addressed by Molloy et al.
(2011) who examined empirical tests of the RBV and found a lack of
theoretical justification for the selection of the measures chosen, noting in the
opening paragraph:
Resource-based theory (RBT) indicates that intangible
resources, or intangibles, underlie value creation (Penrose,
1959). A paradox of RBT is that these very resources that
underlie value creation elude examination (Barney, 2001).
Indeed, since intangibles are immaterial, scholars cannot
easily isolate, observe, or measure them (Lev, 2007). How
then are scholars to advance RBT through empirical research
that examines intangibles?
Molloy et al. (2011) propose a multidisciplinary assessment process that
draws on the strengths of both economics and psychology. This thesis adopts
an alternative approach of identifying factors relevant to competitive
advantage that are accessible to an external evaluator.
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3.3.6 Summary of Key Issues for Performance Measurement
Later in this thesis a set of Design Principles and a Construction Process that
have been derived from the RBV is described, and as a prelude the
contributions made by the main authors of the RBV to the measurement of
resources is summarised in Table 3.2 following their original definition.
Table 3.2 Contributions of the Major RBV Authors to Performance
Measurement
Phase Author Contribution to Measurement
Early Wernerfelt (1984) a) Resources are the
differentiating factors
Rumelt (1984) b) Isolating mechanisms with
examples
Consolidation Barney (1991) c) VRIN tests: Valuable Rare
Imperfectly imitable Non-
substitutable
Peteraf (1993) d) Link to value and rent
generation
Dynamic Dierickx and Cool (1989) e) Importance of deployment as
opposed to possession
(prelude to process)
Amit & Schoemaker (1993) f) Capabilities (recognition of
intangible aspect to
resources)
Teece et al. (1997) g) Paths, Positions and
Processes
Reassessment Peteraf & Barney (2003) h) Efficiency perspective
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We now discuss the topic of performance measurement in more detail,
beginning with consideration of the benefits of additional multiple measures.
3.4 PMFs
3.4.1 Theoretical Benefit of Additional Information
The benefits of multiple parameter measurement for business management
are considered in the next section but first we summarise the theoretical
evidence. Blackwell (1951) reports that multiparameter measurement could be
no worse than single-parameter measurement (although this presumed
additional information was costless) but there was no view on the scale of the
additional benefit. Further support comes from Holmström (1979) who
considered the role of asymmetric information in a principal–agent
relationship, and found that any additional information, no matter how noisy,
would have a positive value. In the case of a PMF, the user of the PMF could
be considered an agent, and this finding suggests that any additional
information could be beneficial to either an internal or external evaluator.
This establishes a mathematical basis for the assertion that additional costless
information cannot be detrimental, although it must be borne in mind that there
may be a cost associated with the interpretation of the additional information
and in comparative efficiency modelling additional parameters in a model can
be detrimental, for example by creating the need for a larger sample.
An analogue can also be drawn with the ‘mosaic theory’ defined by Pozen
(2005: 630):
… a basic precept of intelligence gathering: Disparate items of
information, though individually of limited or no utility to their
possessor, can take on added significance when combined
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with other items of information. Combining the items
illuminates their interrelationships and breeds analytic
synergies, so that the resulting mosaic of information is worth
more than the sum of its parts.
Having established the theoretical benefit of additional information, the next
issue is how to relate this to the assessment of business performance.
3.4.2 Benefits of PMFs
PMFs are intended to provide a balanced view of the performance of the firm.
In this regard there have been positive findings on the usefulness of non-
financial information to supplement conventional financial measures, for
example Davis & Albright (2004) in a cross-sectional study of bank branches
found better financial performance for branches implementing the Balanced
Scorecard than others. Ittner & Larcker (2003) showed that a higher ROA was
associated with organisations that used PMFs than was the case with those
that did not.
Ittner et al. (2003) examined financial services firms and stated (in the
Abstract):
…we find consistent evidence that firms making more
extensive use of a broad set of financial and (particularly) non-
financial measures than firms with similar strategies or value
drivers have a higher measurement system satisfaction and
stock market returns.
Banker et al. (2000) showed that including customer satisfaction as part of an
incentive plan increased customer satisfaction and this led to increased
revenues in a hotel chain. This finding suggests that managers can use
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measures to influence behaviour and act to improve performance, thus
establishing a causal link between PMFs and improved financial performance,
as well as an association.
PMFs offer the opportunity to include measures indicating likely future financial
performance as well as retrospective financial performance. Ittner & Larcker
(1998) reported a statically significant positive relation between customer
satisfaction measures and future accounting performance. Furthermore they
found evidence that customer satisfaction is a leading measure for financial
performance, even when measured from outside the firm. There is further
evidence that the benefit of leading measures is not confined to customer-
related metrics. Rucci et al. (1998) found that an improvement in employee
attitude translated into better customer satisfaction and revenue growth in a
retail company, suggesting that the casual link extended from employee to
customer to a financial measure.
3.4.3 The Balanced Scorecard and its Evolution
The Balanced Scorecard is a widely recognised form of multidimensional
performance measurement proposed by Kaplan and Norton (1992, 1996) who
advocated its use as a strategic management system. The Balanced
Scorecard is developed by an organisation’s management to agree the
organisation’s goals, to measure and communicate progress, enrich the
business plan and feedback performance to adapt strategy. The key features
of the Balanced Scorecard include the need for a balanced set of measures as
opposed to a single measure (four perspectives are suggested to recognise
the multiple stakeholders: finance, operations, customer and employee
learning) and for leading measures as well as lagging measures to be
included. The relationships between measures should be expressed as a
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performance model and the Scorecard should act as a second feedback loop,
typically operating at an annual or quarterly period, to supplement the weekly
or monthly operational feedback loops. Notwithstanding the remarks on
feedback, the Scorecard is intended as a communication tool, intended to
assist strategy deployment, not a control tool. Nonetheless some companies
cascade the Scorecard down the company, assigning more detailed
Scorecards to processes and even to individuals.
The Balanced Scorecard concept is not entirely original; according to Malo
(1995), French companies have been using the tableau de bord since 1932.
Bourguignon et al. (2004) suggest however that there are differences between
the two that reflect cultural differences between French and American society;
certainly the Balanced Scorecard is shown to have more theoretical structure,
in terms of categories and causal modelling, however this might also reflect
that it is the later development, rather than any of the cultural differences
suggested. It is perhaps significant that two other reports of the Balanced
Scorecard implementation in northern and southern continental Europe,
Braam & Nijssen (2004) and Papalexandris et al. (2005), respectively, did not
refer to specific national cultures.
The Balanced Scorecard has evolved over time with attempts to define three
phases of evolution. For example Speckbacher et al. (2003) see the first
phase comprising a multidimensional framework, combining financial and non-
financial measures, a second describes strategy using cause and effect
relationships, and a third that implements strategy by defining objectives,
plans, outcomes and incentives; this conforms quite closely to the original
concepts. Lawrie & Cobbold (2004) consider the first phase as comprising the
original Kaplan/Norton concepts, for example ‘balance’ and use of leading
measures. The second phase is the selection of measures to be applied to
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specific strategic objectives and the use of visual documentation of major
causal relationships. The final stage involves the use of a ‘destination
statement’ for the company and the development of an ‘outcome’ perspective
to replace ‘financial’ and ‘customer’ perspectives, and an ‘activity’ perspective
to replace ‘learning’ and ‘process’ perspectives. The last evolutions are
intended to make the Scorecard more relevant to the public sector. Most of
these are less concerned with the selection of measures than with their
presentation and their link to change management.
Finally, in the original Scorecard there is no measure of risk and this was
remarked upon by Kaplan (2010) in an interview:
If I had to say there was one thing missing that has been
revealed in the last few years, it’s that there’s nothing about
risk assessment and risk management.
Table 3.3 summarises the main lessons for performance management that
arise from the Balanced Scorecard.
Table 3.3 Summary of Balanced Scorecard Concepts
Kaplan & Norton (1992)
Kaplan & Norton (1992)
Kaplan & Norton (1996)
Kaplan (interview 2010)
i) Need for non-financial measures
ii) Use of leading measures
iii) Causal links between measures
iv) Need to measure risk
The previous sources considered the benefits of particular measures with an
emphasis on establishing that certain non-financial measures were leading
measures of performance, however, this is not the only consideration. There is
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also the question of populating the PMFs with measures, which is considered
below.
3.4.4 Choice of Measures
Malina & Selto (2004) consider the choice of measures from the stance of
management control theory and identify eight attributes, the first five being
‘design’ attributes and the remainder ‘use’ attributes. Specifically, measures
should be: 1) Diverse and complementary, 2) Objective and accurate, 3)
Informative, 4) More beneficial than costly, 5) Causally related, 6) Strategic
Communication devices, 7) Incentives for improvement and 8) Supportive of
improved decisions.
However there still remains the question of which measures should be
chosen. Abernethy et al. (2005) proposed the building of causal performance
maps to identify Key Success Factors but this is clearly difficult for an external
evaluator to undertake. However, the concept of Key Success Factors seems
to be closely related to Critical Success Factors that were first defined by
Rockart (1979: 85) as: “the limited number of areas in which results, if they are
satisfactory, will ensure successful competitive performance for the
organization”, which could be assessed by an external evaluator.
Methods for the systematic design of PMFs have been developed, even to the
point of the publication of a workbook for the application of a systematic
process, as described by Neely (2000). Neely at al. (2002) have developed
this further into the ‘Performance Prism’. However, in these cases there was a
presumption that the designers of the PMF were working with the active co-
operation of the firm’s management to produce a PMF for their use; we now
consider the case of PMFs designed for the use of external evaluators.
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3.4.5 External Evaluation of Intellectual Capital
PMFs are also of use to external evaluators, especially for benchmarking
purposes. Lebas & Euske (2002: 73) noted that the needs of the internal and
external evaluators differ:
Performance does not have the same meaning if the evaluator
is inside or outside the organisation. The operations
management remain a black box for the outsider while the
insider operationalizes performance in cooperation with other
actors.
Where the primary audience for the non-financial measures is external, then
the design of a PMF is often considered through the lens of the external
reporting of a firm’s Intellectual Capital (IC). Marr et al. (2004) first consider
why companies should measure IC and conclude that there is a need for more
testing of the benefits, especially through longitudinal studies as opposed to
cross-sectional studies (echoing similar trends in M&A research where long-
term performance is an issue). Marr et al. (2004) then consider how to
construct a PMF for IC, noting a sequence of definition in IC over time from
Hall (1992) where IC was considered to comprise assets and skills, through
Edvinsson & Sullivan (1996), Brooking (1996), Sveiby (1997), Roos et al.
(1997), Stewart (1997), Edvinsson & Malone (1997), Bontis et al. (1999), Lev
(2001) until Marr & Schiuma (2001) arrive at a view whereby IC is seen as
comprising knowledge-based assets located either in relationships or
infrastructure. This cannot be considered an entirely linear sequence of
thinking (e.g. Brooking and Stewart seek focus on the financial aspects of IC).
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The later papers have also sought to produce systematic reporting
frameworks, including the IC Index (Roos et al., 1997), the IC Audit Model
(Brooking, 1996) and the Intangible Asset Model (Sveiby, 1997).
However the most commercialised framework is the Skandia Model, described
by Edvinsson & Malone (1997), which divides Market Value into Financial
Capital and IC. IC is divided into Human Capital and Structural Capital, which
itself comprises Customer Capital and Organisational Capital, with subsequent
subdivisions of the latter. These categories can be used to group resources
and act as a basis for measurement, although Roos et al. (1997) propose the
aggregation of measurement into a single IC Index.
The previous literature is not sector-specific, although the use of IC
frameworks in research organisations was described by Leitner & Warden
(2004) and indeed Leitner et al. (2005) experimented with the use of DEA to
measure the productivity of Austrian universities, concluding it was a useful
consulting tool. However, although IC frameworks provide a basis for
classification of measures, they do not assist in the identification of
performance measures for the external evaluation of companies in a specific
sector for a specific purpose, as required by this research.
There is a major practitioner initiative led by the Enhanced Business Reporting
Consortium that has links to the accounting profession. Enhanced Business
Reporting Consortium (2006) is a framework for non-financial reporting that
has been influenced by the language of the RBV, for example it suggests
reporting upon ‘Competencies and Resources’. The next step is to produce
industry-specific Key Performance Indicators (KPIs), although this has not yet
happened. This work is being undertaken in conjunction with the World
Intellectual Capital Initiative.
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Extended business reporting is already common in regulated industries where
it is used to support comparative efficiency assessments; in the UK, the Water
Services Regulation Authority collects extensive non-financial information
annually, in the form of the June returns, whose purpose is summarised in
OFWAT (2005); some of this information includes intangible parameters, such
as quality of service. An example of quarterly reporting of a PMF in the
Balanced Scorecard format is the National Rail Monitor, published by the
Office of Rail Regulation; the design of the PMF is described in ORR (2004).
Also in the UK, the application of extended business reporting principles to the
public sector has been supported by the National Audit Office by the issuing of
the ‘FABRIC’ guidelines (Focused, Appropriate, Balanced, Robust, Integrative,
Cost Effective), as summarised in H.M. Treasury et al. (2001), and
commissioning independent research (Accenture, 2009) on the design of
PMFs that comprise both financial and non-financial measures.
Separately efforts have been made to link the non-financial measurement of
IC and financial measurement. Financially, IC can be considered the Market
Value Added of the company: the difference between the Market Value and
net book value of the tangible assets. Stewart (1997) has suggested a
parameter termed Economic Value Added as a proxy for this, to be used as a
managerial incentive, although Kramer & Pushner (1997) have questioned the
evidence supporting this. Economic Value Added was intended to make
adjustments to conventional accounting data to rectify some of its limitations of
use as a measure, and there is no doubt that these are especially significant
as regards accounting for intangibles in the context of mergers, and Canibano
et al. (2000) provide a literature review on accounting for intangibles. The
main issue is that internally generated intangible assets are not recognised as
such, although externally acquired intangibles can be recognised as assets.
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Thus an acquisition can lead to the recognition of assets in parameters such
as ROA and result in this being a biased indicator for acquisition performance.
Boekestein (2009) has already noted the impact of M&A on the valuation of
accounting value of assets in the pharmaceutical industry and this thesis
explores it further.
To summarise, although various IC initiatives, whether academic or
practitioner, may use the language and the concepts of the RBV to assist in
their goal for standardised external reporting, they still leave open how the
non-financial measures would be selected for a particular sector, for example
the World Class Competitive Intelligence forum has yet to produce a draft set
of KPIs for the pharmaceutical sector. The contribution of this thesis is to go
beyond the use of RBV terminology and to propose a systematic approach to
the design of a PMF that can be applied to any sector and then to apply it to
the pharmaceutical sector specifically.
First however, we consider how the RBV has been used in the pharmaceutical
sector specifically and the lesson this provides for the design of a PMF that is
suitable for a comparative efficiency assessment.
3.5 Use of the RBV to Measure Performance in Pharmaceuticals
Yeoh and Roth (1999) defined the relevant resources and capabilities for a
pharmaceutical firm: 1) R&D expenditures, 2) Sales force expenditure, 3)
Internal R&D efforts, 4) Therapeutic market focus, 5) Approval success and 6)
Radical innovations. This confirms the criticality of the R&D process because
all factors except sales force expenditure are contributory factors to a single
type of output, namely approved compounds at progressive stages in the
pipeline, and sales force expenditure itself is only useful when a compound
has finally emerged from the pipeline with marketing approval.
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DeCarolis & Deeds (1999) examined the effect of stocks and flows of
organizational knowledge on firm performance. Table 3.4 shows the various
measures that were identified as being relevant to examining the paper’s
hypotheses.
Table 3.4 Parameters and Metrics Cited in DeCarolis & Deeds (1999)
Parameter Metric
Firm performance Market value
Location Munificence of location of corporate HQ, based on factor
analysis
Alliances Number of active alliances
R&D intensity R&D expenditure as % total expenditure.
R&D pipeline
contents
Number of products at each stage
Patents Number of patents
Citation data Number of citations by senior personnel
Using these metrics, data from 98 firms were collected and regression models
were used to test six hypotheses. The outcome is shown in Table 3.5.
Regarding the ‘supported or ‘mixed’ factors, ‘location’ refers to being based in
a ‘geographic cluster’ of high performing pharmaceutical companies, as
opposed to a national location, and is not relevant to this research. The
remaining parameters that are found to be significant are patent citations (but
not patents), the number of drugs in the pipeline and R&D intensity (i.e.
expenditure). Patents themselves were not found to be linked to performance,
possibly reflecting the variety of reasons for taking out a patent (including
defensive reasons) and for not taking out a patent (e.g. confidentiality or
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expense). However, citation analysis is not without its drawbacks. For example
Meyer (2001: 166) notes:
First of all, one should be aware of the general limitations of
patent citation data…citations establish only a mediated
linkage…it is not possible to derive any insight as to the
direction of potential knowledge flows.
Table 3.5 Outcomes of Hypotheses Testing in DeCarolis & Deeds (1999)
Hypothesis Outcome
Location affects performance Supported
No. alliances affects performance Not supported
R&D intensity affects performance Mixed results
No. new drugs in pipeline affects performance Supported
No. patents controlled affects performance Not supported
No. citations affects performance Supported
Furthermore, and most significantly, DeCarolis & Deeds (1999) simply
summed the contents of the pipeline from Preclinical to Phase 3, which
represents a significant distortion given the attrition rates between the
successive stages of the pipeline, which means that compounds in the later
stages have a higher value than compounds at an early stage in the pipeline.
DeCarolis (2003) also examined firm performance. The metrics used are
shown in Table 3.6.
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Table 3.6 Parameters and Metrics in DeCarolis (2003)
Parameter Metric
Firm
performance
Return on Assets
Market-to-Book Value
Technical
competence
A measure calculated as follows: the firm issues N patents in
a given year and within two years M patents had cited these
N patents and of these M citations, X were self-citations. The
ratio of X/N is the measure of competence.
Imitability A measure calculated as follows: the firm issues N patents in
a given year and within two years M patents had cited these
N patents and of these M citations Y were by other
companies. The ratio of Y/N is the measure imitability.
Marketing
competency
Advertising/Sales
Regulatory
competency
Number of new drugs per year per firm
Regression models were used to ascertain if there was any link between the
dependent variable, firm performance, and the four other dependent variables.
The models were built with ROA and Market-to-Book Value. The results of the
hypotheses testing are summarised in Table 3.7.
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Table 3.7 Outcomes of Hypotheses from DeCarolis (2003)
Firm Performance Return on Assets Market-to-Book Value
Technical competency Positive Negative
Imitability Negative Negative
Marketing competency Not supported Positive
Regulatory competency Positive Positive
The surprising feature of the results is the difference between the results for
technical competence, depending on the choice of dependent variables, with
the negative correlation for Market-to-Book Value being counterintuitive.
DeCarolis (2003) provided an explanation for this by suggesting that building
on the firm’s existing knowledge may be seen as developing future rigidities.
However, an alternative explanation lies in the limitations of the self-citation
analysis that is the basis for measurement of technical competence; it is also
noteworthy that the strength of the pipeline or its efficiency was not used to
assess technical competence.
In the following chapter the lessons learnt from these pharmaceutical-related
papers are used to design a PMF to support the analysis of R&D efficiency.
Prior to this however, we review the DEA literature with particular reference to
acquisitions and R&D.
3.6 Relevant DEA Literature
Taveres (2002) identified 3,203 DEA publications in the period 1978 to 2002.
Only five were concerned with M&A and none were concerned with R&D or
the Balanced Scorecard. In the past therefore, it seems that neither topic was
of major interest, however, more recently there have been additions to the
literature as discussed below.
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We consider the DEA merger literature first and start with financial institutions.
Avrikan (1999) found acquiring banks are more efficient than target banks but
efficiency was not always maintained. Sufian (2004) examined scale efficiency
in the Malaysian bank industry and found both positive and negative scale
effects, with smaller banks benefiting from mergers. Worthington (2004) uses
DEA to identify the determinants of merger activity in Australian cooperative
deposit-taking institutions.
Another active area of DEA merger research has been hospitals. Ozgen and
Ozcan (2000) used DEA to examine scale effects in hospitals and found it to
be the dominant source of efficiency improvements following mergers but
technical efficiency was not affected. Ferrier & Valmanis (2004) used DEA to
compare merged and non-merged hospitals and found that mergers did not
have a sustained advantage in productive performance. The focus of DEA
M&A research on banks and hospitals reflects the availability of data in these
institutions to undertake comparative efficiency analysis, especially as regards
a large number of Decision Making Units (DMUs) with readily identifiable
inputs and outputs.
R&D is less susceptible to this form of analysis, however, there has been
some recent research. Linton et al. (2002) applied DEA to the portfolio
optimisation of projects at Bell Laboratories. SubbaNarasimha et al. (2003)
used DEA to examine the efficiency of deployment of technology knowledge;
they used a composite income measure and patent-related output measure as
the variables in the study.
Chen et al. (2004) in their DEA study found that R&D productivity in
Taiwanese semiconductor firms could be improved by an increase in scale.
Eilat et al. (2008) and Eilat et al. (2006) provided a multicriteria approach for
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evaluating R&D projects within a portfolio at different stages in their lifecycle
with some relevance to the computer technology industry (the papers were not
explicit about the sector). Hashimoto & Haneda (2008) used DEA to measure
changes in the productivity of the Japanese pharmaceutical industry over time
and they found that it was monotonically decreasing. A single input was used,
namely R&D expenditure, and the three outputs were patents, sales and
operating profit, and they explained their choice as the best available.
DEA was also used to examine R&D productivity at a national level.
Sharma & Thomas (2008) use DEA to examine R&D between nations. Lee
and Park (2005) undertook a similar international comparison for Asian
economies.
DEA has also been used in conjunction with the Balanced Scorecard. Banker
et al. (2004) found some trade-off in a Balanced Scorecard between ROA and
non-financial measures linked to future development in the US
telecommunications industry. There is a further recent Balanced Scorecard
application in the field of R&D: Garcia-Valderrama et al. (2009) used a
Balanced Scorecard and DEA approach to analyse comparative performance
of 90 companies in R&D in a variety of sectors in Spain.
Finally, the only truly comparable DEA study to this research is
Hashimoto & Haneda (2008) in which the DEA outputs are actually financial
parameters only loosely associated with one DEA input: R&D expenditure.
3.7 Synthesis
The focus of this thesis on the measurement principles and parameters that
determine PAP is fully contemporary for the M&A field. The potential for
diversity includes:
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– Differing motives for the M&A deal that may include market power,
financial performance or efficiency.
– A choice of different parameters for measuring progress towards the
same objective, for example ROA or ROS, often made without a clear
explanation.
– Potential bias of some metrics for measuring crucial aspects of
performance, for example accounting conventions not to record internally
generated intangible assets.
– Different approaches for the measurement of efficiency, including the
processes included and the inputs and outputs considered, which can be
especially challenging when their outputs are intangible and their
production has an element of uncertainty, as is the case with R&D.
In the face of this diversity, the approach of this thesis has been to adopt a
rigorous approach to the selection of measures used in the analysis. The
rigour began with first establishing that multiple measures are beneficial and
having done so establishing a theoretical basis for the selection of measures
for the purposes of external evaluation. The verification by Crook et al. (2008)
of a link between a firm’s financial performance and its resources as identified
by the RBV is confirmation of the suitability in principle of the RBV as a means
for the identification of non-financial measures to populate a PMF.
Furthermore, because the RBV has accumulated literature over two decades it
also provides a source of practical guidance for the design of a set of
principles for the selection of measures, as well as examples of measures that
have been used in the pharmaceutical sector in the past. We now describe a
practical set of RBV-based principles for the design of a PMF.
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4 Design of PMF
4.1 Introduction
This chapter of the thesis develops a systematic approach to the design of a
PMF:
– The first step is to develop a general set of Design Principles, derived
from the RBV and the Balanced Scorecard literature reviewed in Chapter
3, which can be used to develop a PMF in any sector in a structured way.
– The second step is to apply the Design Principles to the pharmaceutical
sector in order to produce a PMF; this is compared with prior literature to
demonstrate that the Design Principles represent an advance on previous
thinking.
– Finally, a reduced set of measures is selected that is suited to the
application of DEA to the pharmaceutical R&D process, along with an
explanation of why that process was selected.
We begin with describing the creation of the Design Principles from a
theoretical basis.
4.2 PMF Design Principles
The lessons for the design of a PMF have been annotated (a) to (h) in Table
3.2 and (i) to (iv) in Table 3.3 with reference to academic authors. The sources
in these 2 tables have provided 12 lessons and they are arranged in Table 4.1
by topic and they retain the original table references.
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Table 4.1 Design Principles
Category No. Principle Ref.
Scope and Structure
Stakeholders 1 Recognise requirements of major stakeholders
of the firm (e.g. the firm’s owner and customers)
with non-financial measures.
(i)
Leading
measures
2 Include at least one leading measure (typically
non-financial).
(ii)
Risk 3 Risk exposure should be measured. (iv)
Resources and Barriers
Differences 4 The PMF should measure the critical few
differences between firms.
(a)
VRIN 5 Measures should be on how resources are
VRIN.
(c)
Link to value 6 Measures should consider how resources are
linked to value creation or economic rent.
(d)
Intangibles 7 Capabilities, or intangible resources, should be
measured where possible.
(f)
Barriers 8 Barriers to imitation that affect the value of a
resource should be measured.
(b)
Processes and Positions
Deployment 9 Deployment of resources, through processes,
should be measured.
(e)
Dynamic links 10 Causal links between measures should be
identified to provide a time dimension.
(iii)
Static positions 11 Static positions are candidates for
measurement.
(g)
Efficiency and Benchmarking
Benchmarking 12 Efficiency should be measured, recognising
prior paths of development, for benchmarking.
(h)
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The relatively few references to measurement within the core RBV texts
allowed these references to be included without selectivity; the scarcity of
references to measurement is perhaps unsurprising given the comments of
Kraaijenbrink et al. 2010 that resources require closer definition. Given this
ambiguity, the issue of measurement has been to the forefront.
In the case of the Balanced Scorecard, the issue was the opposite, namely
there exists a superfluity of commentary on measure selection, albeit for an
evaluator with access to the internal working of the firm. The approach here
was therefore to identify the main principles of the Scorecard (the balanced
provided by multiple perspectives and leading and lagging indicators) and the
need to understand the inter-relationships between the measures; to this was
added Kaplan’s view on the main omission, namely risk.
The grouping of the twelve principles into four headings was not driven by the
literature itself but by identifying major association. However there are also
secondary associations and these are shown graphically in Figure 4.1. This
figure summarises the relationship between the principles and the major
references, while also showing the primary and secondary linkages (the
secondary linkages are shown with a dotted line) and the key references from
the literature review (whose attachment is marked by a small circular symbol).
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Figure 4.1 Summary of Design Principles
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Having derived the 12 Design Principles from the academic literature, without
regard to the availability of information, it is now necessary to confirm this
availability, if the principles are to be of practical use to an external evaluator.
4.3 Availability of Information
4.3.1 Practicality
The availability of information is discussed below, by considering each
heading in turn.
4.3.2 Scope and Structure
Stakeholders
The identification of stakeholders should be straightforward but there may be
complications, for example different classes of shareholders may have
different interests (especially as regards exposure to risk, for example ordinary
versus preference shareholders) and these might need to be recognised.
The customers of a company are usually evident to an external evaluator,
although complications can arise; this is especially so in the pharmaceutical
industry where the eventual consumer of a product, the patient, may well differ
from the purchaser. However, the actual identities of the consumer and
purchaser are typically known. Other common stakeholders include
employees and society as a whole, whose interests may be represented by
regulators.
A good understanding of stakeholders is essential because they are the
medium through which competition is felt, for example competition for
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customers, employees or scarce resources. Ultimately ‘value’ derives from
satisfying stakeholder requirements (primarily those of the paying customer)
and later principles require the link to value to be established.
Leading Measures
Leading measures of performance often include measures of stakeholder
satisfaction, both customer and employee; the challenge is the collection of
information, although polling is one option that has been used by investors
where there is a matter for concern.
Other leading measures might include the results of a product development
programme or the emergence of substitutes.
Risk
Assessment of risk exposure for an external evaluator is more straightforward
for publicly quoted companies because there are disclosure requirements, for
example in the USA, the Annual 10K form required by the Securities and
Exchange Commission gives disclosure of major risks in ‘Item 1A – Risk
Factors’. Otherwise some form of due diligence is required, for example to
detect overdependence on certain products or customers.
4.3.3 Resources and Barriers
Critical Differences
The next step is fundamental to the entire PMF design, and it requires the
identification of Resources and this requires some sector knowledge even if
specific company knowledge is only incompletely known to the external
evaluator. Nonetheless, some company-specific knowledge is also essential
because the RBV focuses on the differences between firms competing in the
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same market. For public companies there are minimum disclosure
requirements. For companies quoted in the USA, Form 10-K, discloses
tangible assets in ‘Item 2 – Properties’ and ‘Item 1 - Business’ provides a
comprehensive list of products, markets and customers. Similar disclosures
are made in other jurisdictions.
Fortunately, in publicly quoted firms the management often see that it is in
their interest to publicly disclose some of the unique strengths of their
companies beyond the minimum required in annual reports thus enabling
establishment of a fuller picture of resources.
VRIN (Valuable, Rare, Imperfectly imitable and Non-substitutable)
The VRIN tests are used to screen potential candidates for measurement.
Although a potential parameter may seem valuable it might not be a useful
addition to PMF, for example if it is easily imitated.
Link to Value
Even if a resource is VRIN, it may not merit measurement if its link to value
creation is obscure, for example the possession of prestige premises. The
most direct link to economic value derives from the satisfaction of customers’
requirements and the fulfilment of a product or service.
Intangibles
Identification of intangible resources may be less straightforward, although
details of patents and trademarks are in the public domain. The most elusive
intangible is knowledge, especially tacit knowledge.
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Barriers
In some cases, barriers to imitation of resources will be sufficiently important
to be an object of measurement in their own right. For example, for a
technology company the remaining life on a patent is a crucial measure.
Similarly, where brand strength is crucial, then monitoring of major brands by
independent valuation may be merited.
4.3.4 Processes and Positions
Deployment
Resources are deployed through processes and these offer an opportunity for
measurement; they need to be identified and placed in the context of the wider
supply chain outside the firm. Order fulfilment processes are externally visible
through the delivery of products and services, although product and market
development processes may be less visible (fortunately this is not the case in
the pharmaceutical sector). In selecting process measures, the external
evaluator, as Lebas & Euske (2002) noted, is less interested in ‘action
variables’ used for process management but in the ‘critical few’ variables, to
use the phrase of Murray & Richardson (2000): parameters of process
performance that are crucial to the success of the organisation.
Dynamic Links
The presence of multiple measures in a PMF can be a source of confusion if
their dependencies are not understood. Identifying associations between
measures has an additional potential advantage of understanding positive or
negative interdependencies that arise from underlying business processes.
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Static Positions
In many cases performance will not depend on accumulation of past
performance into the present position. Generally, the interest of an external
evaluator will be in the firm’s position relative to competitors and there is a rich
source of academic and practitioner literature on competitor intelligence, for
example Lackman et al. (2000) provide a comparison of 16 competitor
intelligence functions. The widespread presence of such functions is evidence
not only of the feasibility of collecting information on a company from an
external perspective but also demonstrates the usefulness of the information
obtained.
4.3.5 Efficiency
Benchmarking
Efficiency measurement and benchmarking requires information on both
inputs and outputs of a process that are often expressed as a ratio. Financial
ratios are a type of efficiency analysis where information is readily available,
although ratios formed with at least one non-financial parameter can also be
illuminating (e.g. sales per employee). Trends in efficiency ratios are often of
equal interest.
Another approach to efficiency analysis, adopted in this thesis, is comparative
efficiency in which the efficiency of a company relative to its peers is
measured.
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4.4 Application of Design Principles to the Pharmaceutical Sector
4.4.1 Demonstration of Use
Having established the practicality of using the Design Principles to populate a
PMF in general, there remains the task to apply it to the pharmaceutical sector
and demonstrate that the results are superior to less systematic methods.
The application of the Design Principles to the pharmaceutical sector is
considered below and the resulting PMF presented in the following section.
4.4.2 Scope and Structure
Stakeholders
The following stakeholders were identified:
– The shareholders or owner of the company, who are concerned with
financial performance. Earnings per Share is of prime interest and is
linked to share price through the Price Earnings ratio for the sector.
– The customer stakeholders are unusually complex with different
customers having different priorities, for example national health
authorities and hospitals will be relatively more cost-conscious, whereas
the patient and physicians will be concerned about the efficacy of the
formulation. Notwithstanding the structural complexity of the stakeholders,
satisfaction however can be measured by market share in particular
therapeutic categories, reflecting the efficacy of the treatment and its
affordability, although loss of share can occur through lapse of patents,
allowing low-cost competition to erode market share, or the existence of
product substitutes in therapeutic categories that themselves may not be
patent-protected.
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– The employees are natural stakeholders but are a diverse group with
some groups such as research workers being crucial. The turnover of this
group is of special interest, as is the value-added per employee in total
(the difference in revenue and costs excluding payroll), to understand the
average financial contribution of each employee.
– Society is a key stakeholder for the pharmaceutical industry with a need
for a supply of new and better formulations and also expectations that
dangerous formulations will not be released. This stakeholder is
represented by the regulatory authorities (e.g. the Food and Drug
Administration in the USA) who serve adverse reports and notices when
society is judged to be at risk.
Four internal and external stakeholders have therefore been identified, to
which is added Process. Although not a stakeholder in its own right, process
efficiency is a necessary condition for satisfaction of the other stakeholders
and all stakeholders will have an interest in it.
Leading Measures
The R&D process is an obvious source of leading measures and it might be
thought that a patent with a 30-year life is also a potential candidate for a
measure, given the legal protection against imitation. However, the number of
patents was not used because of criticisms in the academic literature,
including the pharmaceutical R&D literature, of the usefulness of this measure.
To amplify, DeCarolis & Deeds (1999) established the lack of correlation
between patents and a firm’s performance and identified patent citations as an
alternative. However, the counterintuitive results in DeCarolis (2003) regarding
the negative correlation between technical competence and Market-to-Book
Value raises questions over the use of citation analysis, so this variant of
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patent analysis was not used, especially given the criticism of citation analysis
by Meyer (2001).
Given the rejection of patents as a measure, the measurement of outputs
therefore focuses on the number of compounds that have passed the hurdle of
approval by the regulatory authorities.
Risk
The decisions of the regulatory authorities also represent major risks to the
company and merit measurement; fortunately adverse reports on products
and facilities are publicised.
There is also a further negative factor that requires recognition, namely
litigation. Major pharmaceutical companies are usually engaged in large
litigation suits and of these some are opportunistic.
4.4.3 Resources and Barriers
Differences
The primary differentiation for a research-based pharmaceutical company is
current and future product portfolio, the latter being represented by its R&D
pipeline.
The benefit of the current portfolio is visible through the ROS and market
share and the latter can be seen as a measure of competence in marketing.
Regarding production facilities, the role of this tangible resource is to ensure
continuity of supply.
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VRIN, Link to Value & Intangibles
The previous discussion on focusing on differences between the firms
highlights the importance of seeking measures that focus on the current and
future product portfolio, as evidenced by ROS and the R&D pipeline
respectively. Measures in these areas already pass the tests on VRIN,
establishing a link to value and give full recognition to intangibles, as do any
measures related to research employees, for example retention measures.
However production facilities are usually not rare and production can be
outsourced; manufacturing competence is expressed as the avoidance of
regulatory censure while ensuring continuity of supply.
Barriers
The prime isolating mechanism for a research-based pharmaceutical company
is the patent. However these have a fixed life (30 years) so the barrier to
imitation erodes with time. Products can also be grouped into therapeutic
categories that address particular medical conditions; the specificity of the
action of a drug is an isolating mechanism because a drug does not compete
against drugs as a whole, but only against those that treat the same condition.
4.4.4 Processes and Positions
Deployment and Dynamic Links
For the pharmaceutical sector, key processes include:
 Discovering new drugs (i.e. New Chemical Entities) that successfully
pass through preclinical development.
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 Rapidly and successfully progressing them through the clinical trials
process to maximise the useful patent life. This depends on the
avoidance of unnecessary delay in communication with regulatory
authorities.
 Communicating with and satisfying regulatory agencies.
 Marketing the drugs in as many markets as possible and identifying as
many indications of a drug for different medical conditions as possible.
These topics have largely been addressed in the preceding discussion except
for the dynamic aspect: the avoidance of regulatory delay while a compound is
in the R&D pipeline and the need to address not only the number of drugs
produced but also the number of clinical trials for multiple indications. Both
these additional factors need to be addressed by the PMF.
Static Positions
The static position of a company in a market is best observed by its revenue in
general and by its market share in therapeutic categories specifically.
However, the prime concern of the industry is the erosion of a static position
by patent expiry.
4.4.5 Efficiency
Benchmarking
Regarding efficiency ratios, the prime concern in the industry is availability of
funds to invest in R&D with R&D as a proportion of sales being seen as a
prime metric of a firm’s commitment to the future. Consequently ROS to fund
the expenditure on R&D is seen as the key financial metric.
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4.5 Proposed Pharmaceutical PMF
4.5.1 Outcome of Design Principles
The outcome of the application of the Design Principles is shown in Table 4.2.
The measures have been grouped by stakeholder, rather than linked back to
the category of the Design Principles by which they were created, so as to
present a view on the coverage and balance of measures by the stakeholders
identified in Subsection 4.4.2.
Table 4.2 Proposed Pharmaceutical PMF
Owners Customers Employees Processes Regulatory
►Return 
on Sales
 ►Earning 
per Share
►Litigation 
liability (-
ve)
►Market 
share by
therapeutic
category
►Future loss 
of sales to
therapeutic
substitutes
(-ve)
►Future loss 
of sales to
expiring
patents (-ve)
►Research 
employees as
% total
►Value added 
per employee
►Employee 
turnover (-ve)
►# compounds in 
pipeline, by stage
►# clinical trials 
in pipeline, by
stage
►R&D/Sales 
►Marketing/Sales
►Attrition rates in 
pipeline (-ve)
► Patent life 
lost to
submission
process (-ve)
► # adverse 
drug reports
(-ve)
► # adverse 
manufacturing
reports
(-ve)
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Although Table 4.2 represents an illustration of the concept of the design
principles, the question arises whether the scorecard is a useful set of
measures for measurement of pharmaceutical performance or an advance on
contemporary practice.
An opportunity for comparison was provided by Stankevicien & Svidersk
(2010). The scorecard was designed by a German subsidiary of an Italian
company described thus (Stankevicien & Svidersk, 2010: 242): “The Italian
Group enjoys an outstanding reputation worldwide as an efficient and reliable
partner. This applies both to the development of new drugs and to the
communication of scientific insights”. The company designed the scorecard
shown in Table 4.3.
Table 4.3 Scorecard for Pharmaceutical Company
High Performance
Organization
Systematic
Execution &
Implementation of
System
Requirements
Stakeholder
Service
Excellence
Excellence in
Financial
Performance
 Employee
satisfaction
rate
 Training
compliance
rate
 Successful job
rotation
 Audit
recommendation
 Implementation
score
 Information
sharing score
 Business
improvement
rate
 Management
satisfaction
rate
 External
rating score
 Risk
management
score
 Expense
spending
control
 Performance
score
 Target
achievement
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rate
Comparison of the two tables suggest that the Design Principles have led to a
scorecard whose measures focus on the competitive position of the company
rather than process compliance and improvement, which are the natural
concerns of the management of a subsidiary.
4.5.2 Use of Negative Indicators
A feature of the PMF produced by the Design Principles is its inclusion of large
numbers of negative indicators; this is uncommon in the Scorecard literature in
which emphasis is placed upon a monitoring rate of strategic deployment.
However, the RBV stresses the importance of barriers to competition and the
lessening of barriers has an important influence on the value of resources and
these represent a negative indicator for future performance. In recognition of
this, one of the measures listed in Table 4.2 relates to future sales lost to
patent expiry.
Litigation risks over consumer harm and patent infringements are also major
topics of interest and represent a leading measure of performance.
The inclusion of negative indicators can be seen as fully contemporary in its
recognition of risk to the business, as noted in an interview with Kaplan, held
in 2010, as discussed previously.
4.5.3 Choice of Financial Measures
ROS has been selected rather than ROA. The first reason concerns the
limitation of ROA in this sector: the denominator in ROA without an acquisition
history will include only tangible assets, as internally generated intangible
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assets are not shown according to accounting conventions. The measure is
therefore of limited relevance in a sector where profitability depends on
earning a return on intangible assets.
ROS by contrast allows the profitability of the company to be expressed as a
percentage of revenue, allowing for inter-firm comparison, and shows the
funds available for investment in R&D, with R&D as a percentage of revenue
being an accepted approach for comparisons of research-based
pharmaceutical companies, for example Grabowski et al. (2002).
Despite the advantages in ROS, this research does consider ROA in parallel
to the ROS to further examine the relative merit of the two measures.
4.6 Focus on R&D and Adaptation to DEA
Comparative efficiency is measured at the level of the DMU however this still
leaves some discretion whether to measure the comparative efficiency of an
entire firm or a particular process within the firm. If one opts for the entire firm,
then there is the possibility of blurring the analysis by aggregation of many
factors, whereas the application of the analysis to one element of a firm, such
as an individual process, risks overlooking important interdependencies
between processes that can affect performance. In this thesis the decision has
been to apply the analysis of comparative efficiency at the level of a major
business process within the firm, at a high-enough level so that the impact on
the firm’s competitiveness can be understood, while isolating the intangible
production processes from the other parts of the firm.
The selection of the R&D process for examination was made because a
necessary but not sufficient condition for the success of an ethical
pharmaceutical firm is its R&D core competence, as evidenced by an efficient
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R&D pipeline. This pipeline is the process that provides deployment of
capabilities that generate resources that can be most easily converted to
income. These resources are the multiple outputs of the pipeline: compounds
at progressive stages of the pipeline that meet the VRIN tests required by the
RBV by virtue of patent protection. This protection ensures an economic rent
is earned once a compound has progressed to the end of the pipeline and is
granted marketing approval. Once marketing approval has been granted,
additional competences become important, especially marketing to maximise
revenue during the period of patent protection and manufacturing, to ensure
continuity of supply. However before marketing-related resources can become
valuable there must be compounds to produce and hence the primary focus
for an evaluator is the efficiency of the R&D pipeline.
Once the R&D process has been selected for examination of comparative
efficiency, there remains the task of choosing from Table 4.2 a mix of input
and output parameters relevant to the R&D process. The candidates are:
 Inputs: Research employees, % R&D expenditure.
 Outputs: Compounds, Trials, Attrition rates (negative).
These are the measures used in the analysis, except the number of research
employees is not available so the total number of employees has been used
instead. This does have the advantage of recognising the indirect input of non-
research employees to the operation of the R&D pipeline; the total number of
staff may also be relevant in examining the link to acquisition history because
acquisitions are generally followed by staff reductions.
The attrition rates were not included in the DEA model for two reasons,
namely the difficulty in collecting information on failed trials over the historical
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period and the difficulty of including outputs with a negative influence on
productivity into a DEA model (one option is to include a reciprocal of the
output but this itself poses a problem where there is zero attrition).
4.7 Conclusion
This chapter has outlined a set of measurement principles for an external
evaluator to measure the performance of a pharmaceutical company with a
comparative efficiency technique. The focus is on the R&D process and inputs
and outputs have been selected on the basis of a RBV-derived process and
comparison with prior literature.
Future chapters will develop these principles into a DEA model that will enable
the modelling of comparative efficiency from an external perspective.
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5 Research Methodology
5.1 Introduction
This chapter describes the research methodology that has been used to
examine the association between a pharmaceutical firm’s history of
acquisitions and the efficiency of its R&D process.
The first step was to consider the range of possible efficiency and productivity
analysis approaches, and the decision to opt for a DEA approach is explained.
Several DEA models have been developed within the literature and the
selected model types are explained, along with their mathematical formulation.
Weight restrictions have been applied to the DEA model and their implications
are considered.
Returns to scale for the pharmaceutical R&D process has been investigated
and tested as a preliminary step. The primary focus of the research however is
the association between efficiency and acquisition history. Statistics on
acquisition history were collected and their distributions analysed prior to the
development of a typology to support the subsequent analysis.
Various hypotheses have been proposed and their testing requires an
approach that avoids the difficulty that arises from statistical testing of DEA
scores directly; this is then defined, followed by the application to the testing of
the scale hypothesis and the acquisition-related hypotheses. Finally, the
treatment of outliers is also discussed.
5.2 Efficiency and Productivity Analysis Approaches
Efficiency and productivity measurement (the terms are not synonymous but
have been used interchangeably in the literature) has a long history and one
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of the earliest measures is unit cost. The seminal author in the field of
measurement of productive efficiency is Farrell (1957) who introduced the
distinction between technical and allocative efficiencies. Despite this early
work, the analysis of R&D efficiency has been largely confined to examining
the technical aspect through the consideration of unit costs: dividing an output
measure (typically number of approved compounds) by an input measure
(typically expenditure). However, unit costs cannot measure the efficiency of a
productive unit with multiple inputs or outputs. Unit costs were not employed in
this research because the R&D process has multiple outputs.
An approach which is able to consider multiple inputs and outputs is to use
‘parametric’ methods, whose characteristic is an assumption of the form of the
production function relating inputs to outputs. The simplest parametric method
is Ordinary Least Squares regression and more sophisticated approaches
include Stochastic Frontier Analysis (Kumbhakar, 1988) that separates the
effect of noise (e.g. from measurement error) from variation in efficiency. If the
form of the production function is known, then parametric analysis confers
several advantages for econometric analysis (as noted by Cubbin &
Tzanidakis, 1998). However in this case, the form of the production function
linking R&D expenditures (inputs) to the outputs of the process is not known.
Therefore a parametric approach was not adopted for the efficiency analysis in
this research.
Given the presence of multiple inputs and outputs and the lack of knowledge
of the production function, the natural choice for the efficiency measurement is
DEA, which is not a statistical or econometric technique but has its origins in
Operations Research.
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The formulation of the DEA models is described below, once the mathematical
notation used in the thesis has been defined. DEA has been selected for the
evaluation of R&D productivity because it is able to analyse multiple inputs
and outputs and does not require the production function to be specified. In
this section we specify several DEA models that:
– Recognise the longitudinal nature of pharmaceutical R&D, namely that it
may take many years of R&D to produce a measurable output. Therefore
R&D over several years has been considered.
– Have the potential to consider both financial and non-financial outputs,
while investigating the differing restrictions on the weights given to these
two different types of outputs.
We now define the structure of the model in more detail and in particular how
the longitudinal aspect of the pipeline is addressed.
Following this, the design of the acquisition typology, used to analyse
acquisition history, is summarised.
5.3 Summary of DEA Model
5.3.1 Orientation of Model
There is a distinction between an input-orientated model (that examines
efficiency from the viewpoint of minimising resources used for a given level of
output) and an output-orientated model (that examines efficiency from the
viewpoint of maximising output for a given level of resources consumed). The
output-orientated model is more relevant to pharmaceutical R&D because the
generic strategy within the industry is to ‘speculate to accumulate’: to spend
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available surplus on R&D in the hope of discovering new compounds to
secure the future of the company.
5.3.2 Inputs and Outputs
For all the models used, the inputs included were R&D (current), that is
expenditure in 2006, and R&D (historic), that is expenditure in the previous
five years (2001–2005), expressed in US dollars; the definition of this is likely
to be relatively standard between firms and include all the operating costs of a
firm’s R&D facilities, including staff. Although R&D expenditure is the prime
monetary input to the creation of preclinical compounds and the progression of
compounds through the R&D pipeline, it is necessary to consider a sufficient
number of years of expenditure to relate the input to outputs in all stages of
the pipeline.
However, other factors are also required for pharmaceutical R&D, for example
activity on dealing with regulatory agencies, staff recruitment and retention,
and raising finance and so on. These may need to be reflected in the inputs in
some way, therefore number of staff was also considered an additional input
in one of the DEA models.
In the DEA model used for association with acquisitions, the outputs are:
– the number of compounds in Preclinical phase (i.e. yet to gain approval
for clinical trials to commence);
– the number of compounds in Phase 1 clinical trials;
– the number of compounds in Phase 2 clinical trials, having passed
Phase 1;
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– the number of compounds in Phase 3 clinical trials, having passed
Phase 2;
– the number of compounds awaiting approval for marketing, having
passed Phase 3.
An alternative model considering the number of clinical trials was also
considered for comparison, although after examination of the trends in the
ratio of trials to compounds it was considered less representative of R&D
process efficiency and more reflective of marketing strategy.
5.4 Longitudinal Dimension
Pharmaceutical compounds take time to develop, so R&D expenditure is
unlikely to produce a preclinical compound in the same year because it takes
many years for a drug to move from discovery to the market place.
DiMasi & Grabowski (2007) provide a contemporary summary of the times and
costs involved (see table below).
Table 5.1 Time and Costs of R&D Development
Testing Phase Duration (months) Monthly cost ($m, 2005)
Preclinical 52.0 1.15
Phase I 19.5 1.66
Phase II 29.3 1.08
Phase III 32.9 1.38
Six years, or 72 months, of R&D expenditure has been collected for this
thesis. This period not only covers the majority of the duration of the pipeline
(which is 133.7 months) but also is greater than any phase of the pipeline (a
maximum of 52 months), so therefore the inputs can be related to each output.
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Table 5.1 also shows that monthly costs per phase are comparable between
phases and therefore the measured input (R&D expenditure) for 72 months
should be representative of the cost required to support the pipeline
production process as a whole. Further evidence to support this is given by
the analysis of the descriptive statistic for R&D expenditure which shows that
R&D expenditure as a proportion of sales varies little year-on-year.
Including R&D expenditure relating to years prior to 2001 could be misleading
because this expenditure would relate to the discovery and preclinical stages
of compounds now in the later stages of the pipeline. The advent of
combinatorial chemistry for screening in the decade prior to the year 2000 had
a major impact on the productivity of this stage in the pipeline as noted by
Sweeny (2002: 10)
This was a major rate-limiting step in developing new drugs
and has seen remarkable increases in productivity over the
past ten years or so through the use of combinatorial chemistry
linked to high throughput screening.
5.5 Definition of Notation
5.5.1 MCT
There are two MCT that are relevant to this research: the arithmetic mean and
the median; the first is pertinent to the parametric test for the difference
between two means (used in the statistical testing) and the second is relevant
to the non-parametric test. Both measures have been used for statistical
testing of the mean for the parametric tests and the median for the non-
parametric test. Where appropriate, the acronym ‘MCT’ (i.e. Measure of
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Central Tendency) has been used in the terminology below; the choice of
MCT was determined by the test used: parametric or non-parametric.
5.5.2 Normalisation Factor
In quantifying merger history for a particular firm, it is necessary to establish a
normalisation factor for the firm because firms vary considerably in size. There
are various options for the selection of a normalisation factor. A natural choice
of the normalisation factor would be the assets of the company because an
acquisition involves an expansion of the asset base; however this presents
some technical difficulties because many assets were acquired in times of
different asset prices and have been subject to varying depreciation policies.
Furthermore the figure does not include many of the self-generated intangible
assets on which pharmaceutical companies earn a return (these criticisms
affect the usefulness of the ROA as a performance measure despite its
popularity). Because pharmaceutical companies earn a return on intangible
assets through the sale of medicines whose price reflects the value of those
assets, the normalisation factor could be based on the profitability of the firm;
however, profitability, being the difference between cost of sales and revenue,
can vary considerably between years. Revenue itself is also a commonly used
scaling factor in industry analysis and is often used to compare R&D intensity
between firms, however it can be affected by competitive conditions not
related to the underlying scale of assets or processes of the firm. Therefore
cost of sales, which is usually of comparable magnitude to revenue and has
an underlying proportionality to the maintenance of the tangible and intangible
assets, has been selected. The sum of the deal value over the period in
question has been divided by the annual cost of sales of the surviving
company at the end of the period. This allows the significance of the merger
history to be expressed independently of the size of the resulting company.
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In the notation below the acronym ‘NDV’ (i.e. Normalised Deal Value) is used
to denote the cumulative values of deals of a firm over the analysis period
(chosen to include an entire merger wave and economic cycle) divided by the
revenue scaling factor.
5.5.3 Algebraic Notation for Efficiency Analysis
Tables 5.2 sets out the algebraic notation used in the DEA modelling.
(Subentry Tables 5.3 to 5.5 define further algebraic notation; the notation is
first defined completely so that the equations can then be considered without
interruption of further definition of terms).
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Table 5.2 Algebraic Notation for DEA Models
Symbol General Meaning Specific Meaning # Elements
in Variable
S # output measures Number of compounds at
different stages of pipeline
(value = 5)
1
M # input measures Number of input measures;
(these are R&D current, R&D
historic, and staff numbers) i.e.
value = 3)
1
N # DMUs Number of firms in sample after
exclusion of two outliers (value
= 48)
1
yik Value of output
measure i (i = 1, …,
s) for DMU k (k = 1,
…, n)
Compounds or clinical trials for
each firm (i=1, Preclinical; i=2,
Phase 1; i=3, Phase 2; i=4,
Phase 3; i=5, Awaiting
Approval)
5 × 48
xjk Value (≥ 0) of input 
measure j (j = 1, …,
m) for DMU k (k =
1, …, n)
R&D spend for each firm (j=1,
Current; j=2, Historical) and
staff numbers where used (j=3)
3 × 48
ui Weight (> 0) of
output measure i (i
= 1, …, s)
Weight given to each compound
or clinical trial for each firm
5
vj Weight (> 0) of Weight given to R&D current, 2
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input measure j (j =
1, …, m)
R&D historic or staff numbers
for each firm
d'k Optimal objective
function value for
each DMU
Reciprocal of technical output
efficiency for CRS model
48
d’’k Optimal objective
function value for
each DMU
Reciprocal of technical output
efficiency for VRS model
48
ηk Relative technical
output efficiency of
each DMU (CRS)
Technical output efficiency
score for each firm from CRS
model
48
θk Relative pure
technical output
efficiency of each
DMU (VRS)
Pure technical output efficiency
score for each firm from VRS
model
48
rk Financial efficiency
of each DMU
ROS or ROA or SOA for each
firm
48
5.5.4 Form of DEA Equations
The equations defining DEA can be expressed in three forms. The first is the
original Fractional Programming form in which the efficiency of each DMU is
expressed in the form of a ratio. These equations can be restated in Linear
Programming form of which there are two variants: one is called the Multiplier
form, and there is also a dual form termed the Envelopment form. In this thesis
the Multiplier form is used.
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5.5.5 Algebraic Notation for Examination of Returns to Scale
Table 5.3 sets out the algebraic notation used in the examination of returns to
scale based on the use of the average of the Current R&D expenditure and
the Historic R&D expenditure as an R&D-specific scale factor.
Table 5.3 Algebraic Notation for Examining Returns to Scale
Symbol Specific Meaning #
Elements
in Variable
ek Scale efficiency of each DMU, Ek = ηk / θk, for k = 1 … n 48
wk Mean of Current and Historic R&D expenditure of each
DMU
48
wl Mean of wk with below-median scale efficiency, ek 1
wh Mean of wk with above-median scale efficiency, ek 1
Var(w)l Variance of average of Current R&D and Historic R&D
expenditure of DMUs with below-median scale
efficiency, ek
Var(w)h Variance of average Current R&D and Historic R&D
expenditure of DMUs with above-median scale
efficiency, ek
5.5.6 Algebraic Notation for Classification of Acquisition History
Table 5.4 sets out the algebraic notation used in the examination of acquisition
history.
83
Table 5.4 Algebraic Notation for Classification of Acquisition History
Symbol Specific Meaning # elements in
Variable
Ak Sum of all deal values for DMUk, for k = 1 … n 48
Bk Sum of cross-border deal values for DMUk for k = 1
… n
48
Ck Sum of cross-sector deal values for DMUk for k = 1
… n
48
Fk Annual Cost of Sales for DMUk for k = 1 … n 48
ak NDVs for DMUk for k = 1 … n 48
bk NDVs of cross-border deals for DMUk for k = 1 … n 48
ck NDVs of cross-sector deal for DMUk for k = 1 … n 48
al MCT of ak for those DMUs with below-median θk 1
bl MCT of bk for those DMUs with below-median θk 1
cl MCT of ck for those DMUs with below-median θk 1
ah MCT of ak for those DMUs with above-median θk 1
bh MCT of bk for those DMUs with above-median θk 1
ch MCT of ck for those DMUs with above-median θk 1
a'l MCT of ak for those DMUs with below-median rk 1
b’l MCT of bk for those DMUs with below-median rk 1
c’l MCT of ck for those DMUs with below-median rk 1
a’h MCT of ak for those DMUs with above-median rk 1
b’h MCT of bk for those DMUs with above-median rk 1
c’h MCT of ck for those DMUs with above-median rk 1
Var(a)l Variance of ak for those DMUs with below-median θk 1
Var(b)l Variance of bk for those DMUs with below-median θk 1
Var(c)l Variance of ck for those DMUs with below-median θk 1
Var(a)h Variance of ak for those DMUs with above-median
θk
1
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Var(b)h Variance of bk for those DMUs with above-median
θk
1
Var(c)h Variance of ck for those DMUs with above-median θk 1
Var(a)'l Variance of ak for those DMUs with below-median rk 1
Var(b)’l Variance of bk for those DMUs with below-median rk 1
Var(c)’l Variance of ck for those DMUs with below-median rk 1
Var(a)’h Variance of ak for those DMUs with above-median rk 1
Var(b)’h Variance of bk for those DMUs with above-median rk 1
Var(c)’h Variance of ck for those DMUs with above-median rk 1
5.5.7 Algebraic Notation for Statistical Testing
It is necessary to avoid the statistical testing of DEA scores directly because
they are not independent observations. To avoid the testing of scores the
approach adopted has been to use the DEA parameter to divide the
population into two groups on the basis of the DEA scores: one a group with a
below-median DEA efficiency and the other group with an above-median DEA
efficiency. Table 5.5 defines the notation used to describe the variables used
in the statistical tests employed for hypothesis testing using this approach.
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Table 5.5 Algebraic Notation for Hypothesis Testing
Symbol General Meaning
µl Mean of below-median group
µh Mean of above-median group
σl
2 Variance of below-median group
σh
2 Variance of above-median group
πl Number in below-median group
πh Number in above-median group
T t test statistic
Rl Sum of ranks for lower-median group
Rh Sum of ranks for upper-median group
Ul U-test statistic for lower-median group
Uh U-test statistic for upper-median group
U U = min (Ul, Uh)
Z z-test statistic
5.6 DEA
DEA was proposed by Charnes et al. (1978) in a paper that began “This paper
is concerned with developing measures of ‘decision making efficiency’’” and
coined the term DMU; in this research DMU refers to 1 of 48 pharmaceutical
firms. The paper then defined what has since been termed the Charnes,
Cooper & Rhodes (CCR) model in the Fractional Programming form and the
two Linear Programming forms.
There is a choice to be made between the input- and output-orientated form of
the DEA model. The output-orientated model maximises the outputs for a
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given level of input whereas the input-orientated model minimises the input for
a given level of output. Because a pharmaceutical firm ‘speculates to
accumulate’ and commits surplus resource to R&D to maximise R&D output,
the output-orientated form is the more appropriate and has been selected.
An output-orientated form of the CCR model is described below. Also
described is a later model that was developed to accommodate VRS.
5.7 CCR Model
The original CCR model calculates an efficiency score for each DMU, based
on its ratio of multiple outputs to its multiple inputs, weighted so as to
maximise its efficiency, subject to constraints that all the DMUs have an
efficiency less than or equal to unity. DEA can therefore be seen as an
extended formulation of unit cost analysis.
The output-oriented form of the CCR model is summarised below in the
multiplier form that establishes the relative efficiency for the DMU under
consideration: DMU0 (as opposed to an absolute efficiency based on technical
standards).
s
Min d’0 = Σ vj xio Eq. (1)
i = 1
s
Subject to: Σ uj yio = 1
i = 1
s m
Σ uj yik   ≤  Σ vj xik k = 1 ... n
j = 1 j =1
ui > 0 i = 1 … s
vj > 0 j = 1 … m
where the subscript ‘0’ refers to the element of any variable relating to
the DMU under analysis.
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A Linear Programming equation has three aspects: an objective function to be
optimised, a set of variables and some constraints. In the equation above, the
optimisation relates to the efficiency of the DMU under analysis and the value
of d0’ is the reciprocal of the technical output efficiency score, η0. The variables
are the weights and the operation of the DEA optimisation algorithm assigns
weights to each DMU that maximises its efficiency (although later in this
section we discuss the inclusion of weight restrictions). The constraints ensure
that the efficiencies of all the DMUs are less than or equal to unity with the
chosen weights. The optimised choice of weights will allow the efficiency of
each DMU to be the highest possible and at least one DMU will lie on the
‘efficiency frontier’ (i.e. be technically efficient whereas typically some others
are relatively inefficient) and have a score of d’k = 1.
A basic property of the CCR model is that it assumes there are no economies
or diseconomies of scale: it assumes CRS. Subsequently alternative DEA
models have been developed, one of which allows VRS and is described
below. In this research the CCR model is used only to establish economies of
scale by comparing the CRS efficiency scores with the VRS efficiency scores.
5.8 BCC Model
The model used for the acquisition hypothesis testing is the Banker, Charnes
and Cooper (BCC) model, defined by Banker et al. (1984). This is an
extension to the CCR model (Eq. 1) that accommodates VRS through the
addition of an additional free scalar variable. The output-orientated BCC
model is defined below:
m
Min d’’j’ = Σ vj xio – v0 Eq. (2)
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j = 1
s
Subject to: Σ uj yio = 1
j = 1
s m
Σ uj yik   ≤  Σ vj xik + v0 k = 1… n
j = 1 j=1
ui > 0 i = 1 … s
vj > 0 j = 1 … m
where the subscript ‘0’ refers to the element of any variable relating to
the DMU under analysis.
It can be seen that the BCC model has an additional term, v0. The value of d’’0
is the reciprocal of the technical output efficiency score, θk. The firms on the
efficiency frontier will have a value of d’’k = 1.
5.9 Output Weight Restrictions
Weight restrictions are a means of incorporating subjective judgements into a
DEA model and may be of two types: absolute or relative. Without restrictions
it is possible for DEA to generate weights that conflict with the judgements of
the DMUs’ decision makers; an example from this research would be for a
lower weight to be given to a compound in a late stage in the R&D pipeline,
compared with a weight in an earlier stage in the pipeline, when the latter must
still face cost and uncertainty to moving forward to subsequent stages (i.e.
uj-1 < uj, for j = 2 … 5).
Weight restrictions improve the credibility of the model in the eyes of decision
makers but the subjective judgements involved must be defended. In this
case, simple relative output weight restrictions have been applied along the
lines indicated by Wong & Beasley (1990). Specifically four restrictions have
been applied:
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uj ≥ uj-1 for j = 2 ... 5, Eq. (3)
where j = 5 represents the output relating to the compound at
the final stage of development
These output weight restrictions are applied to both the VRS and CRS
models.
5.10 Input Weight Restrictions
It has been found that the current CRS and VRS models tend to often assign
zero weights to one or the other of the two inputs in the current models:
Historical R&D (i.e. the annual historical average) and Current R&D
expenditure, whose magnitudes are similar. Input weight restrictions have
been added that limit the extent to which either input can be reduced to zero to
recognise that both inputs are required to produce the outputs. The restrictions
are:
u1 ≥ 0.5 u 2 and u2 ≥ 0.5 u 1 Eqs (4 & 5)
These input weight restrictions are applied to both the VRS and CRS models
and have the effect of ensuring both R&D inputs have a material effect on the
model, while allowing each input to be up to two times as significant as the
other. However, the introduction of the input weights given in Eqs (4 and 5)
had only a minor observed effect on the efficiency scores and given this minor
effect further variations on the arbitrary 0.5 factor in Eqs 4 & 5 were not made.
5.11 Returns to Scale
The research afforded an opportunity for a fresh examination of returns to
scale in pharmaceutical R&D using DEA. Banker et al. (1984) suggested the
possibility of the use of the CCR model to relate returns to scale to the size of
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the firm and introduced the concept of scale efficiency as defined in Eq. 6,
which is calculated by reference to the technical output efficiency produced by
the CRS model (Eq. 1) and pure technical output efficiency produced by a
VRS model (Eq. 2), or in mathematical form:
ek = ηk ÷ θk k = 1 … n Eq. (6)
where the subscript k represents the DMU under analysis
The scale efficiencies do not in themselves provide a test for whether there
are returns to scale. A statistical test for investigating this is described below,
following a description of the analysis of acquisition history.
5.12 Design and Population of Acquisition Typology
5.12.1 Identification of Acquisitions
The Thomson One Banker database has been used to identify all acquisitions
over a ten-year period with a deal value exceeding $100 million, where the
acquiring company was in the North American Industry Code (NAIC) for
“Medicinal and Botanical Manufacturing, Pharmaceutical Preparation
Manufacturing, In-Vitro Diagnostic Substance Manufacturing, Biological
Product (except Diagnostic) Manufacturing”.
Corporate acquisitions are one of many means by which a firm may purchase
technological or marketing resources. Licences are preferred for minor
acquisitions of resources which represent a stream of activity that would be
undetected by the research methodology. From 1998 to 2002 the average
value of a licensing deal was $84.5m (Pharmaventures, 2003). To exclude
alternative means of resource acquisition from the study, for this thesis a $100
million threshold was set on the M&A analysis to ensure that the effects of
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alternative lower-value means of acquiring resources, such as licensing, would
not affect the analysis of the scale of historical resource acquisition for each
firm.
For the M&A analysis, a period from 1993 to 2005 was selected; this spans at
least an entire merger wave (commencing in 1993) and also approximates to
the length of a typical economic cycle. The year in which R&D outputs are
measured is the following year, namely 2006, to avoid the M&A activity
affecting the collection of data on R&D outputs. The selection criteria used to
identify deals in the Thomson One database are given in Table 5.6.
Table 5.6 Selection Criteria
Search Term Scope
Acquirer NAIC
or
Acquirer Ultimate Parent
Primary NAIC (Code)
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance
Manufacturing
Biological Product (except Diagnostic)
Manufacturing
Date Unconditional 01/01/1993 to 31/12/2005
Ranking Value inc. Net
Debt of Target ($Mil)
100 upwards
Per cent of Shares
Owned after Transaction
51 upwards
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The searching process led to 591 acquisitions which met the criteria.
5.12.2 Classification of Acquisitions
The initial classification of acquisitions is as follows:
– The name of the acquirer.
– The size of the acquisition is measured by the ‘Ranking Deal Value’: a
parameter used by the Thomson database to identify the value of the
acquisition (in essence the amount paid by the acquirer after adjustment
for debt).
– A binary value indicating whether the acquirer and the target are in the
same country (i.e. a cross-border acquisition).
– A binary value indicating if the target is in the same NAIC code as the
acquirer, or not (i.e. a cross-sector acquisition).
This classification makes it possible to calculate the sum of the deal values in
total for each named acquirer, and in addition the sum of the cross-border deal
values and cross-sector deals for each acquirer, as required by the research
methodology.
The identification of cross-border and cross-sector acquisitions is amplified
further below.
5.12.3 Identification of Cross-border and Cross-sector Acquisitions
The simple binary classification of cross-border and cross-sector deals has the
advantage of data being readily available and reflects the additional
complexity involved in acquiring a company in a different nation, for example
dealing with different jurisdictions, the additional complexity of accounting and
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control procedures and more costly logistics. It might be argued that the
classification neglects:
– Geographic distance, however in practice information flows are now
instantaneous.
– Language differences, however English is now the lingua franca for the
pharmaceutical industry.
– Cultural differences. This is a significant issue, for example a US/UK or a
Swiss/German acquisition is likely to encounter fewer cultural obstacles
than say, a US/Japanese acquisition. Although techniques exist to
measure cultural distances between nations their application is
complicated by firm-specific differences and a resolution of these
differences is impractical.
The simple binary classification is then used to select out the cross-border
acquisitions from the total and these are then linked to the major
pharmaceutical companies.
Regarding cross-sector acquisitions, pharmaceutical companies have a
number of acquisition options available to them:
– To remain within their current field but to acquire emerging technologies,
for example a traditional chemically based company choosing to acquire
more contemporary biotechnology expertise.
– To acquire closely associated non-pharmacological technology, for
example acquiring delivery devices for the administration of medicines
being produced by the company.
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– To diversify into related businesses within the same value-chain, for
example by acquiring the means of distribution of its products.
– To undertake unrelated diversifications.
This research has adopted a relatively simple classification of diversification: a
binary classification that would classify the first of these four options as
undiversified and the remaining options as a full diversification.
The primary reason for opting for a simple classification relates to sample size.
Although the various types of diversification listed above could be subjectively
assessed and categorised reliably, the size of the sample in each category
would be very small, especially because pharmaceutical companies have
generally had an aversion to making acquisitions outside their core business.
It would have therefore been difficult to obtain statistically significant results
with a more granular classification of cross-border and cross-sector deals.
5.12.4 Linkage to Major Pharmaceutical Companies
The top 50 pharmaceutical companies were identified based on their health-
care revenue generated during 2006, as recorded in Pharmalive (2007). Of
these, details of the R&D pipeline were available for 48 that were the focus of
the research and termed the ‘major’ companies below. Access to the database
on which the report was based was also purchased and specific queries were
resolved with the company. It is possible to check specific items of data on the
database against public records.
Not all of the major companies had undertaken acquisitions and not all
acquisitions were undertaken by these companies. However, out of the 591
acquisitions identified by the Thomson database in the sector during the 10
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years’ history, 140 related to the major pharmaceutical companies, of which 64
were cross-border and 29 were cross-sector acquisitions.
The resulting analysis measures M&A history where an acquiring company
has since been acquired by a ‘surviving’ major company, (e.g. the acquisitions
allocated to AstraZeneca include those for both Astra and Zeneca).
5.13 Analysis of M&A History
The collection of data of acquisitions and the boundaries set on the size of
deal and the periods considered are described in Chapter 6 along with the
acquisition typology. The key terms in the merger typology are defined in
Table 5.7.
Once populated, the deal values for all deals, cross-border deals and cross-
sector deals, are summed to arrive at the SDV values, Ak, Bk, Ck respectively,
for k = 1 … 48, for the three cases. These are then divided by the annual cost
of sales for the firms, Dk, to arrive at the NDV, ak, bk, ck, for k = 1 … 48, for
each of three cases. Both the SDV and the NDV that are applied in the
statistical test approach are described in the following section.
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Table 5.7 Key Terms for Acquisition Typology
Term Meaning
Cross-
border
A deal where the acquirer and the acquired have headquarters in
different nations
Deals An acquisition which results in majority control of the acquired firm
by the acquiring firm
Deal
Value
The ‘ranking deal value’ of the deal as specified on the Thomson
One database. Broadly, this is the amount paid for the acquisition
used in ‘ranking’ the deal in league tables
Firm One of the Top 50 pharmaceutical companies existing in 2006 that
has not been eliminated as an outlier
SDV The sum of the deal values for an acquirer
NDV SDV divided by the annual cost of sales of that firm
Cross-
sector
A deal where the acquired company does not have a
pharmaceutical Standard Industry Code
5.14 Statistical Test Approach
Traditional statistical testing, for example differences in mean DEA scores, (by
parametric methods) is problematic because the scores are not independent.
Grosskopf (1996) discussed approaches to the resolution of this problem;
however, the approach in this thesis has been to circumvent the problem
entirely by applying statistical tests to independent variables that were not
themselves derived from DEA.
The hypothesis testing was initially undertaken using a test of significance
based on a variation of the Student t test, a test proposed by Welch (1947),
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suitable for testing two samples with unequal variances (the variances were
calculated and shown to be unequal). This test is used to establish the
confidence with which the difference between the two group means could be
considered significant (a one-tailed or two-tailed test was used as appropriate,
reflecting the phrasing of the null and the alternative hypotheses).
The t test depends on the calculation of a test statistic, T, given by:
To = (µh - µl) (σl2/πl + σh2/πh)-0.5 Eq. (7)
where the terms are as defined in Table 5.5 and the subscript ‘0’ refers
to the element of any variable relating to the DMU under analysis.
In this thesis, n = 48 and is even, so πl = πh = n/2. The T statistic is used to
calculate the p-value by reference to the integral of the probability density
function of the Student’s t distribution. That p-value is then used in the
hypothesis testing and compared with thresholds, as defined by
Bowerman et al. (2011: 360).
In order to undertake the test for returns to scale for the R&D process the total
set firms were divided into two subgroups: one with below-median scale
efficiency and the other with above-median scale efficiency. For each group
the mean of R&D current (x1k, for k = 1 … n) for firms in the pair of groups was
calculated, wl and wh, for the below-median and above-median groups
respectively. In Eq. (7), µl to µh were set equal to wl and wh respectively and
the variances σl
2 and σh
2 were set equal to Var(w)l and Var(w)h respectively.
In order to test the association between acquisition history and pure technical
output efficiency a similar process was followed, namely θk, for k = 1 … n was
used to divide the firms into two subgroups with lower-median and upper-
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median values of θk. For each group, the statistics ak, bk, ck, namely the NDVs
for all deals, cross-border and cross-sector respectively, were used to
calculate the mean values for the lower-median and upper-median groups. In
Eq. (7):
 the value of µl was set equal to al, bl, cl;
 the value of µh was set equal to ah, bh, ch;
 the variance σl
2 and were set equal to Var(a)l, Var(b)l, and Var(c)l;
 the variance σh
2 was set equal to Var(a)h, Var(b)h, and Var(c)h.
The testing of the ROS-related hypotheses followed an identical form to the
testing of pure technical efficiency.
There was a second stage in the significance testing. A visual inspection of
the distribution of the variables xk ak, bk and ck indicated a non-normal
distribution. This was confirmed by the use of an Anderson–Darling test
(1952). An additional significance test was therefore undertaken using a non-
parametric test, namely the Mann–Whitney U test (Mann & Whitney, 1947),
shown in Eq. (8).
Ul = πl πh + 0.5 πl (πl + 1) – Rl Eq. (8)
Uh = πl πh + 0.5 πh (πh + 1) – Rh
U = min (Ul, Uh)
To apply the test, the ranks of the parameters of the two groups were
calculated and the sums of the ranks in the two subgroups (Rl and Rh in Eq. 8)
were calculated for each; Ul and Uh are then calculated and the lower value is
used for the statistical test (in this case πl = πh = n/2 because n is even).
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For samples where there are over 20 items in each group (i.e. n/2 > 20), as is
the case in this research, the U statistic can be considered to be normally
distributed and the z statistic can be calculated as shown in Eq. (9):
z = (U – 0.5 πl πh ) (πl πh (πl + πh + 1)/12)-0.5 Eq. (9)
where the terms are as defined in Table 5.5 and the subscript ‘0’ refers
to the element of any variable relating to the DMU under analysis.
The z statistic is then used to generate a p-value by reference to the normal
distribution and the p-value is used for hypothesis testing as described earlier
for the parametric tests.
Both the parametric Welch test and the non-parametric Mann–Whitney test
were used for testing because some assumptions were violated in both
(normality in the first and equal variances in the second); Zimmerman (1998)
compares the approaches under the violation of assumptions. The paper
found that non-parametric methods may not be acceptable substitutes for
parametric methods when parametric assumptions are violated, and the
approach in this thesis has therefore been to use both methods.
5.15 Incomplete Data
There were two cases of companies that appeared in the ‘Top 50’ list of global
pharmaceutical companies, where it was not possible to establish their
pharmaceutical R&D expenditure. Therefore these companies were excluded
from the analysis, leaving a sample of 48 companies.
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6 Data and Descriptive Statistics
6.1 Introduction
This chapter describes:
 the data used as inputs and outputs of the DEA models;
 the results from the DEA models that are used to examine the
association with acquisition history;
 the financial data ROS, ROA and SOA are also described;
 the calculation of the acquisition history statistics, SDV and NDV.
The DEA model data are presented in tables given in Appendix D and the full
acquisition data are presented in Appendix E, where the acquisition typology
is populated for deals in aggregate, cross-border deals and cross-sector
deals.
Having described the data, descriptive statistics are provided for:
 the R&D process, including the relation between scale efficiency and
the R&D scale variable and the distribution of the R&D scale variable;
 the parameters used as DEA outputs: an assessment of the
differences between the numbers of clinical trials and numbers of
compounds;
 acquisitions in the sector, to establish the relation between size and
frequency, and the NDV of major firms.
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In some cases this analysis produces empirical findings in its own right and in
the remaining cases it is preparatory work for the statistical testing of
hypotheses. This chapter concludes with a summary of the main findings.
6.2 Available Input Data for the DEA Models
The available input data (not all the data are used in all the DEA models) are
presented in Table D.1. The third column presents R&D expenditure for 2006
in $million. The fourth column shows a calculated figure for the historical
expenditure that is expressed in 2006 currency values; the calculation
principles are described in Appendix A and in summary comprise adjusting
historical data for R&D expenditure back to 2001 for inflation and the ratio of
R&D expenditure to sales. The fifth column is a figure for staff levels, based on
a five year average of staffing levels, and the data for the calculations are
shown in Appendix B.
Table D.1 also defines an abbreviated code for each company and the codes
are used in later tables.
6.3 Available Output Data for the DEA Models
There are two possible output sets for the DEA models: the number of
compounds produced for approval and the number of applications of those
compounds either within the clinical trial process or awaiting approval. The
numbers of compounds are shown in Table D.2.
Table D.3 shows the number of clinical trials at each stage of the pipeline and
the ratio of trials to compounds at each stage. The ratios of trials to
compounds at different stages of the pipeline can be used to draw inferences
on which parameter is the most appropriate to use as an output for a DEA
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model to examine R&D efficiency, although both models are built for both
cases and their results compared.
6.4 Comparing CRS and VRS Efficiency Scores
The input data in Table D.1 relating to R&D only and the output data in
Table D.2 were applied to both a VRS and a CRS output-orientated model.
The resultant VRS and CRS efficiency scores, by firm, are shown in the
second and third columns of Table D.4. The fourth column gives the
calculated scale efficiency and the fifth column the natural logarithm of that
parameter. The sixth column shows the natural logarithm of the mean of the
two R&D inputs.
Table D.5 shows similar information to Table D.4 except that the outputs of the
DEA model are the number of clinical trials as opposed to the number of
compounds.
6.5 DEA Model Results: Comparing Input Assumptions
The previous results of the VRS DEA models did not include staff as an input.
Table D.6 shows a comparison of R&D expenditure (current and historical) as
inputs and then additionally with staff numbers as an additional input. In both
cases, the outputs were the number of compounds (as opposed to the number
of clinical trials).
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6.6 Financial Efficiency Data
The ROS, ROA and SOA (formed by dividing ROS by ROA) are shown in
Table D.7 for each firm.
6.7 Acquisition and NDV Data
The full acquisition data, extracted from the Thomson One Banker database,
are provided in Appendix E. It comprises details on the deals and permits
analysis by size, nation of acquirer and acquired, and the sector of the
acquirer and acquired. Table D.8 gives the total value number of acquisitions
for each company: SDV, the normalising factor (cost of sales and NDV), and
the resulting NDV for each company.
Descriptive statistics on acquisitions and NDVs are provided later.
6.8 Association of M&A and Technical Efficiency
The bisection of the acquisition history statistics into two subgroups, below-
median and above-median pure technical efficiency is shown in Tables D.9,
D.10 and D.11.
Tables D.9 and D.10 list NDV and they show the bisection based on two
different DEA models, and Table D.11 shows the bisection of SDV using the
base model. In the table headings ‘<M’ is the abbreviation for below median
and ‘>M’ is the abbreviation for above median.
Table D.9 shows the bisection based on the VRS technical efficiencies that
are calculated using the number of compounds as an output and R&D
expenditure alone as an input. This is the base model used for comparisons
with alternatives.
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Table D.10 shows the bisection based on the VRS technical efficiencies using
the number of compounds as an output and both R&D expenditure as well as
staff numbers as inputs.
The outcome of the hypothesis testing is when the two different DEA models
are later compared.
6.9 Association of M&A and Financial Efficiency
The bisection of the acquisition history statistics into two subgroups on the
basis of financial efficiency is shown in Tables D.12, D.13 and D.14.
Table D.12 shows the bisection based on ROS, Table D.13 shows the
bisection for ROA and Table D.14 shows the bisection based on SOA.
6.10 Descriptive Statistics of the DEA Model Outputs
The initial choice of outputs for the measurement framework was made with
reference to the RBV and the consideration of what constitutes a resource of
the firm. On this basis the number of compounds and the number of clinical
trials within the R&D pipeline were both identified as resources because they
represented potential future revenue. However, it was not possible to use the
RBV further to make a choice between these options as to which would be the
better parameter to use to measure R&D productivity. It may be the case that
a higher ratio of trials to compounds indicates that a firm is producing more
productive compounds, or it may simply be the case that the firm is choosing
to incur higher development costs for higher eventual return from the
compounds they have available.
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It is, however, possible to examine the data of the proportions of compounds
to trials and draw inferences. Table 6.1 shows the mean and standard
deviation of the ratio of clinical trials to compounds through the pipeline.
Table 6.1 Descriptive Statistics of Ratio of Trials to Compounds
Phase PreClinical Phase I Phase II Phase III Awaiting Approval
Mean 1.16 1.26 1.56 1.65 1.35
Std Dev 0.25 0.36 0.54 0.60 0.58
Table 6.1 shows a small ratio in the Preclinical and Phase 1 stages, where the
interaction between the compound and a human is first examined. After this,
the ratio increases as does the variance, as the compound enters subsequent
more expensive phases. The results for the ‘Awaiting Approval’ may indicate
that where large numbers of trials have been commissioned then some of the
more speculative trials did not produce the intended results.
This qualitative reasoning was supported by a series of paired two-tailed t
tests undertaken between the ratios of compounds at each stage of the
pipeline on whether they were taken from the same sample (see Table 6.2).
Table 6.2 t test on Ratios of Trials to Compounds in Successive Phases
Phase Preclinical/Phase 1 Phase I/II Phase II/III Phase III/AA
p-value 34% 0.003% 38% 0.7%
These statistics are consistent with the hypothesis that the safety of a
compound on humans is first confirmed in Preclinical and Phase 1, with no
statistical significant difference between the ratios of compounds per trial. A
commercial decision is then made as to whether to incur considerable
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expense funding multiple trials in Phase II and Phase III, or to adopt a more
cautious approach by restricting the more expensive clinical trials to the most
promising indications. Finally there seems to be confirmation that some
degree of caution in commissioning trials is justified because the ratio of trials
to compounds going forward for eventual approval drops back, and there is a
statically significant difference between the ratio for Phase 3 and Awaiting
Approval (by contrast to the absence of a difference between Phase II and
phase III).
Given this analysis, the primary examination of R&D efficiency has been
undertaken by considering the number of compounds as the output of the
R&D process, as opposed to the number of clinical trials.
6.11 Descriptive Statistics of the R&D Process
Figure 6.1 shows a plot of the logarithm of the scale efficiency and the
logarithm of the average of the current and historic annual R&D expenditure
for the 48 firms. The graph shows that there is an apparent linear relationship
between the two variables when the output of the DEA model is considered to
be the number of compounds. A regression line is also given as a visual aid,
although no formal regression was undertaken.
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Figure 6.1. Graph of Scale Efficiency Versus Mean R&D (Compounds as
Output)
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Figure 6.2 shows an equivalent graph but with the number of trials as an
output. The linear relationship is still apparent but the degree of scatter is
higher. This could imply that there are fewer exogenous influences on
production when the output of the R&D processes is taken to be the number of
compounds as opposed to the number of trials.
Figure 6.2 Graph of Scale Efficiency Versus Mean R&D (Trials as Output)
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The graphs above do not in themselves test for scale, although they are
strongly suggestive that scale effects exist. To test for scale, the model with
the number of compounds as an output was used. The scale efficiencies of
the firms was used to bisect the sample into two subgroups of above-median
and below-median efficiency. The mean of the R&D expenditure of the firms in
the two subgroups was then tested for a statistically significant difference.
The distribution of R&D expenditure for the two groups is shown in Figure 6.3
Figure 6.3 Distribution of R&D Expenditure of Above- and Below-Median
Efficiency
Visually it is apparent that the subgroups have markedly different distributions
however formal hypothesis testing is problematic. The subgroup with below-
median scale efficiency does not have a normal distribution and therefore the
assumptions of the Welch test, which requires normally distributed data, have
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been violated. The non-parametric Mann–Whitney test can be used, however
this requires equal variances in the subgroups and in the sample above the
variances differ by 40%. Therefore a triangulation approach has been
employed, using both a parametric approach and a non-parametric approach,
with the results being compared (as explained further in Section 7.2).
6.12 Descriptive Statistics of M&A
Park et al. (2010) have asserted that the distribution of size of M&A versus
frequency follows a power law: the logarithm of the size of an occurrence is
proportional to the increase of the frequency. This research offered the
opportunity to examine this claim in the context of the pharmaceutical sector.
The distribution of M&A deal size in the acquisitions for the 510
pharmaceutical acquisitions in the full sample was examined by plotting
logarithm of value by frequency, as shown in Figure 6.4.
Figure 6.4 Frequency of M&A Deals by Value
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The results generally are consistent with a power law (as indicated by the
linear trendline on log/log scales), however it must be stressed the evidence is
not conclusive because other distributions can show a similar relationship (see
Appendix C). It can be seen that for very large acquisitions the linear
relationship breaks down, with a disproportionate number of ‘mega-mergers’
(four) in the top category in Figure 6.4 and a dearth of numbers of mergers in
the categories immediately below (although this effect might depend on the
threshold of adjacent categories used in that figure). Of the four mega-
mergers two were undertaken by Pfizer, one by Sanofi-Aventis and one by
GlaxoSmithKline. Pfizers’ ROS was close to mean, GlaxoSmithKline’s near
the top of the range and Sanofi-Aventis’s relatively poor. This is consistent
with a diversity of motive for the mega-mergers, with Pfizer acting as a
profitable predator and the Sanofi-Aventis deal being a defensive merger
(which was actually encouraged by the French government to preserve a
French major pharmaceutical company2).
NDV has been used as a measure of acquisition history for the individual firm
and the distribution of this parameter was also examined. Park et al. (2010)
note that when examining acquisition frequency a Poisson distribution is
commonly assumed, and given acquisitions are discrete events this is not
implausible.
A goodness-of-fit test for a Poisson distribution was performed and the
expected versus observed values showed a higher than expected number of
zeros (shown in column 1, Figure 6.4). If the 11 zeros are removed and the
square root of the remaining NDV’s is subject to a normality test (McCullagh &
Nelder, 1989: 196, explain that a feature of the Poisson distribution is that the
2 http://news.bbc.co.uk/1/hi/business/3658639.stm
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square root of the distribution may approximate normal), then the resulting p-
value is close to 5%, as Figure 6.5 confirms.
Figure 6.5 Normality Test for Square Root of NDV less Zeros
The establishment that the square root of NDV is normally distributed once
zeros are removed is an interesting finding that suggests that the use of Zero-
Inflated Poisson models may have some future application in analysing
merger behaviour or undertaking statistical tests, however this was not taken
further in this thesis.
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6.13 Summary
The differences in measures of mean NDV, which will be tested in the next
chapter, are summarised in Table 6.3 for technical efficiency and Table 6.4 for
financial efficiency.
Table 6.3 Summary of Association of Acquisition History with Technical
Efficiency
Table
Ref.
ak
θk <M
ak
θk >M
bk
θk <M
bk
θk >M
ck
θk <M
ck
θk >M
NDV, DEA Base Model 6.9 0.74 0.91 0.33 0.21 0.06 0.03
NDV, DEA Staff Model 6.10 0.72 0.92 0.36 0.18 0.06 0.03
SDV, DEA Base Model 6.11 4345 19174 1056 4442 472 744
Table 6.4 Summary of Association of Acquisition History with Financial
Efficiency
Table
Ref.
a’k
θk <M
a’k
θk >M
b’k
θk <M
b’k
θk >M
c’k
θk <M
c’k
θk >M
NDV, ROS 6.12 0.50 1.15 0.13 0.41 0.06 0.02
ROA 6.13 0.70 0.95 0.28 0.26 0.044 0.041
SOA 6.14 1.03 0.62 0.31 0.23 0.02 0.07
The MCTs of the subgroups with above and below efficiencies are now
subject to statistical testing (see Chapter 7).
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7 Hypothesis Testing
7.1 Scope of Hypothesis Testing
7.1.1 Classical Hypothesis Testing Model
The hypotheses have been divided into five sets, as explained in Section 1.4.
The hypotheses are tested using p-values derived from parametric and non-
parametric tests, using what Sheshkin (2011: 57) terms the ‘classical
hypothesis testing model’, which is a fusion of the work of Fisher (1925) who
proposed the concept of the null hypothesis and Neyman & Pearson (1933)
who developed the concept of the alternative hypothesis. There were
substantial differences between Fisher (1925) and Neyman and Pearson
(1933) and the hybrid development (that is now termed the ‘classical
hypothesis testing model’) was developed in subsequent text books; Lehmann
(1993) examines the consistency of the hybrid and considers there is
statistical consistency.
A comprehensive contemporary textbook, Sheskin (2011: 58) outlines the key
terms of the classical model, beginning with the null hypothesis which is
defined as “a statement of no effect or no difference’. In this thesis, the null
hypothesis is therefore taken to correspond to the status of the literature prior
to the research. Having defined the null hypothesis, Sheskin (2011: 58) then
defines the second key concept: “The alternative hypothesis, on the other
hand, represents a statistics statement indicating the presence of an effect or
a difference”. The null and alternative hypotheses are exclusive; it is the
alternative hypothesis that is tested and any conclusion regarding the null
hypothesis is drawn by inference.
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The classical model also requires a significance level to be chosen, although it
should be noted Neyman & Pearson (1933) opposed the use of an arbitrary
significance level, believing the researcher should choose the level in order to
balance the risk of Type I and Type II errors. Fisher (1925) proposed 1% and
5%, although Fisher (1955) stated that it was not necessary to stipulate a
significance level before an experiment (a modification of his earlier stance)
and if the result was considered significant by the researcher, then the result
should be reported along with its probability value (or p-value). Fisher’s
concluding comment in that paper was: “We have the duty of formulating, of
summarising, and of communicating our conclusions, in intelligible form, in
recognition of the right of other free minds to utilize them in making their own
decisions” seems to be a call for transparency as opposed to an arbitrary
selection of a significance levels.
To avoid arbitrariness in this thesis, a probability level for the statistical test (‘p-
level’) is calculated using both parametric and non-parametric tests and then
interpreted. For guidance in interpretation, Bowerman et al. (2011: 360)
provide the following interpretations of p-values: “0.1, some evidence; 0.05,
strong evidence; 0.01, very strong evidence; 0.001, extremely strong
evidence”, however the authors go onto note: “there are no really sharp
borders between different weights of evidence. Rather, there is only
increasingly strong evidence...as the p-value decreases”.
In the unusual cases here there is divergence in interpretation between the
parametric and non-parametric tests, then each case is considered on its
merits and a retrospective check has been made for consistency of
interpretation across cases.
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In summary the method proposed by Fisher (1955) and the terminology of
Bowerman et al. (2011) has been drawn upon to develop an approach to the
interpretation of both the parametric and non-parametric results.
7.1.2 Set 1, Hypothesis 1: Returns to Scale
Hypothesis 1 is to establish whether pharmaceutical R&D demonstrates CRS
or VRS. This allows for the selection of the most appropriate form of DEA
model to be used in the subsequent hypothesis tests and is a necessary step
in this research because previous literature has provided disparate results,
with a sector-specific reference: Graves & Langowitz (1993) indicating
Decreasing Returns to Scale (DRS) in contrast to the generic Schumpeterian
hypothesis of Increasing Returns to Scale (IRS) for R&D, as originally
proposed in Schumpeter (1950).
Given the conflicting prior references on DRS and IRS, the null hypothesis
does not presume either and is:
H1n: There are CRS for pharmaceutical R&D.
The alternative hypothesis, which will be tested, is:
H1a: There are VRS for pharmaceutical R&D.
A testing approach has been developed that avoids the statistical testing of
DEA scores by using the DEA scores to form two subgroups of the more
efficient and less efficient, and testing the difference of the means of the R&D
expenditure of the two subgroups.
The testing approach does presume that IRS and DRS do not exist
simultaneously for different sizes of firms in the sample. However, examination
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of the descriptive statistics in Figure 6.1 shows a decreasing monotonic
relationship between scale efficiency and size of R&D expenditure (average).
7.1.3 Set 2, Hypotheses 2, 3 & 4: Firm Acquisition History and
Technical Efficiency
The main focus of the research is the association between acquisition history
and the technical efficiency of the R&D process. The null hypothesis is that
firms with above-median efficiency and below-median efficiency have similar
merger history, as measured by the parameter NDV: the sum of M&A value
over time divided by a normalisation factor that represents the size of the firm.
The set of firms is divided into two equal-sized subgroups of above- and
below-average efficiency and the MCT, that is the mean or median3, of NDV
for each subgroup is calculated. The null hypothesis is:
H2n: Firms with an above-median technical efficiency have the same
MCT of NDV as those with below-median technical efficiency.
The alternative hypothesis, which will be tested, is one-sided to reflect the
Merger Paradox and is:
H2a: Firms with an above-median technical efficiency have a lower
MCT of NDV than those with below-median technical efficiency.
Less formally, this states that companies that are more merger-prone are less
efficient, as is consistent with the Merger Paradox.
3 The term MCT is used in preference to either mean or median because both parametric and non-
parametric tests have been used to test the differences in MCT between samples, with the former testing
mean and the latter testing median.
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Two further hypotheses examined diversifications to gain resources in new
markets (i.e. cross-border acquisitions) and new sectors (i.e. cross-sector
acquisitions). The two hypotheses consider each of these types of
diversification and follow a similar format to that considering acquisitions in
general. The two null hypotheses are:
H3n: Firms with an above-median technical efficiency have the same
MCT of NDV for cross-border deals as those with below-median
technical efficiency.
H4n: Firms with an above-median technical efficiency have the same
MCT of NDV for cross-sector deals as those with below-median
technical efficiency.
The corresponding alternative hypotheses are:
H3a: Firms with an above-median technical efficiency have a lower
MCT of NDV for cross-border deals than those with below-median
technical efficiency.
H4a: Firms with an above-median technical efficiency have a lower
MCT of NDV for cross-sector deals than those with below-median
technical efficiency.
The outcomes of the testing of these alternative hypotheses are then
compared with the outcomes of the tests examining financial efficiency, as
described below.
7.1.4 Set 3, Hypotheses 5, 6 & 7: Deal History and Financial Efficiency
The null hypotheses H5n, H6n and H7n are restatements of H2n, H3n and
H4n but with ‘technical efficiency’ replaced with ‘financial efficiency’. However
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the alternative hypotheses are phrased in the opposite direction, namely that
above-median financial efficiency is associated with a higher MCT of NDV, as
might be expected if the M&A deal is allowed to proceed and indeed Higgins
& Rodriguez (2006) confirm improved financial performance following
acquisitions in the pharmaceutical industry.
The alternative hypotheses are:
H5a: Firms with an above-median financial efficiency have a higher
MCT of NDV than those with below-median financial efficiency.
H6a: Firms with an above-median financial efficiency have a higher
MCT of NDV for cross-border deals than those with below-median
technical efficiency.
H7a: Firms with an above-median financial efficiency have a higher
MCT of NDV for cross-sector deals than those with below-median
technical efficiency.
Financial efficiency is measured by ROS and ROA so six tests are undertaken
on the three alternative hypotheses.
7.1.5 Set 4, Hypotheses 8, 9 & 10: Acquisition History and Sectoral
Efficiency
Hypotheses H8n, H9n and H10n are restatements of H2n, H3n and H4n but
with NDV replaced by Sum of Deal Value (SDV). SDV omits the normalisation
used to express the sum of previous acquisitions in a form relative to the size
of the firm. Efficiency is still measured at firm level at the firm but all the
acquisitions in the sector are associated with firms grouped into the more
efficient and the less efficient. In practice the larger acquisitions made by the
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larger firms overshadow the smaller acquisitions made by the smaller firms.
The effect is to examine if the sector’s acquisitions as a whole are associated
with higher or lower efficiency at firm level and hence consider the effect of
acquisitions on the sector in aggregate.
The direction of the alternative hypotheses reflects findings in the financial
M&A literature that M&A could benefit the sector as a whole, if not the
acquiring firm; that is, the hypotheses are one-sided in the direction indicated
by Seth et al. (2000) who found M&A provides benefits if the gains of the
acquirer and acquired are considered together
The null hypotheses are that there is no difference in distribution of acquisition
value between the more efficient and the less efficient companies. The
alternative hypotheses, which will be tested, are:
H8a: Firms with an above-median technical efficiency have a higher
MCT of SDV than those with below-median technical efficiency.
H9a: Firms with an above-median technical efficiency have a higher
MCT of SDV for cross-border deals than those with below-median
technical efficiency.
H10a: Firms with an above-median technical efficiency have a higher
MCT of SDV for cross-sector deals than those with below-median
technical efficiency.
The outcomes of the testing of these alternative hypotheses are then used to
examine the Merger Paradox at sector-level.
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7.1.6 Set 5, Hypotheses 11, 12, 13 & 14: Acquisition History and Sales
over Assets
The purpose of H11 is to examine the effect of M&A on financial metrics. The
null hypothesis for M&A is that there is no difference in the acquisition history
of firms between those with above-median SOA and those with below-median
SOA (there is no reason to expect a difference to occur) and the hypothesis
for M&A in aggregate is:
H11n: Firms with an above-median SOA have the same MCT of NDV
as those with below-median SOA.
The null hypotheses for cross-border and cross-sector deals, H12 and H13
respectively, are similar.
The alternative hypotheses, which will be tested, are one-sided in the direction
indicated by Boekestein (2009), and are:
H11a: Firms with an above-median SOA have a lower MCT of NDV
than those with below-median SOA.
H12a: Firms with an above-median SOA have a lower MCT of NDV for
cross-border deals than those with below-median SOA.
H13a: Firms with an above-median SOA have a lower MCT of NDV for
cross-sector deals than those with below-median SOA.
This presumes that M&A leads to a greater recognition of intangible assets
and hence a lowering of SOA, as Boekestein (2009) noted.
It transpires that in the last case the alternative hypothesis is ‘accepted’ but in
the reverse direction, which undermines the basis for a unidirectional test.
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Therefore a fourteenth non-directional alternative hypothesis has been
formulated:
H14a: Firms with an above-median SOA do not have the same MCT of
NDV for cross-sector deals as those with below-median SOA.
H14n is identical to H13n, which is similar to H11n, as shown above.
7.2 Returns to Scale (H1)
The relationship between scale efficiency and an R&D scale variable has
already been examined graphically and a monotonic relationship observed
between the log of the R&D scale variable and the log of the scale efficiency,
indicating VRS (more specifically, DRS). The hypothesis of CRS is now
formally tested.
A two-sided parametric Welch test and a two-sided non-parametric Mann–
Whitney test for H1a was undertaken and in both cases H1a was accepted for
p < 0.1%. Because the alternative hypothesis was accepted, the null
hypothesis of CRS was rejected with strong statistical evidence.
The testing results are summarised in Table 7.1
Table 7.1 Results of Tests on Hypothesis H1a
Test P-value Interpretation
Non-parametric < 0.1% Extremely Strong Evidence to Accept
Parametric < 0.1% Extremely Strong Evidence to Accept
In summary there is extremely strong evidence for accepting VRS and the
descriptive statistics confirm show this to be monotonic DRS and the null
hypothesis H1n is rejected.
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7.3 M&A and Technical Efficiency (H2, H3, H4)
7.3.1 Hypothesis 2
For the base model, the mean of the NDV for the companies with above-
median efficiency is 0.91 and the mean NDV for the companies with below-
median efficiency is 0.74, the reverse of that indicated in the alternative
hypothesis. Testing for the significance of the reverse of H2a using a one-
sided Mann–Whitney test gives a p-value of 28%. A one-sided Welch test
gives a p-value of 30%. We conclude that there is no statistical evidence to
accept the reverse of H2a on the basis of the DEA scores of the base model.
For the model with staff as an input, the mean of the NDV for the companies
with above-median efficiency is 0.92 and the mean NDV for the companies
with below-median efficiency is 0.72, a slightly larger difference than the base
model, and the reverse of that indicated in the alternative hypothesis. Testing
for the significance for the reverse of H2a using a one-sided Mann–Whitney
test gives a p-value of 24%. A one-sided Welch test gives a p-value of 28%.
We conclude that there is no statistical evidence to accept the reverse of H2a
on the basis of the DEA scores of the DEA model with staff inputs.
The testing results for H2a are summarised in Table 7.2:
Table 7.2 Results of Tests on Hypothesis H2a
Test Model Direction P-value Interpretation
Non-parametric, H2a Base Reverse 28% No Evidence
Parametric, H2a Base Reverse 30% No Evidence
Non-parametric, H2a Staff Input Reverse 24% No Evidence
Parametric, H2a Staff Input Reverse 28% No Evidence
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In summary, in each case there is no statistical evidence to accept the reverse
of the alternative hypothesis with either DEA model and the null hypothesis
H2n therefore stands.
7.3.2 Hypothesis 3
For the base model, the mean of the NDV for the companies with above-
median efficiency is 0.21 and the mean NDV for the companies with below-
median efficiency is 0.33, in the direction of that indicated in the alternative
hypothesis. Testing for significance using a Mann–Whitney test gives a p-
value of 40%. A one-sided Welch test gives a p-value of 28%. We conclude
that there is no statistical evidence to accept H3a on the basis of the DEA
scores of the base model.
For the model with staff as an input, the mean of the NDV for the companies
with above-median efficiency is 0.18 and the mean NDV for the companies
with below-median efficiency is 0.36, in the direction of that indicated in the
alternative hypothesis. Testing for significance using a Mann–Whitney test
gives a p-value of 47%. A one-sided Welch test gives a p-value of 20%. We
conclude there is no statistical evidence to accept H3a on the basis of either
test and therefore the null hypothesis stands.
The testing results for H3a are summarised in Table 7.3:
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Table 7.3 Results of Tests on Hypothesis H3a
Test Model Direction P-value Interpretation
Non-parametric, H3a Base Standard 40% No Evidence
Parametric, H3a Base Standard 28% No Evidence
Non-parametric, H3a Staff Input Standard 47% No Evidence
Parametric, H3a Staff Input Standard 20% No Evidence
In summary, in each case there is no statistical evidence to accept the
alternative hypothesis with either DEA model and the null hypothesis H3n
therefore stands.
7.3.3 Hypothesis 4
For the base model, the mean of the NDV for the companies with above-
median efficiency is 0.03 and the mean NDV for the companies with below-
median efficiency is 0.06, in the direction of that indicated in the alternative
hypothesis. Testing for significance using a Mann–Whitney test gives a p-
value of 30%. A one-sided Welch test gives a p-value of 11%. We conclude,
although there is formally no evidence on the basis of the parametric test
(although the p-value is close to the 10% threshold), and no evidence from the
non-parametric test, taking the tests together, there is not sufficient statistical
evidence to accept the alternative hypothesis. The null hypothesis therefore
stands.
For the model with staff as an input, the mean of the NDV for the companies
with above-median efficiency is 0.03 and the mean NDV for the companies
with lower-median efficiency is 0.06, in the direction of that indicated in the
alternative hypothesis. Testing for significance using a Mann–Whitney test
gives a p-value of 31%. A one-sided Welch gives a p-value of 12%. We
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conclude that there is not sufficient statistical evidence to accept the
alternative hypothesis. The null hypothesis therefore stands.
The testing results for H4a are summarised in Table 7.4:
Table 7.4 Results of Tests on Hypothesis H4a
Test Model Direction P-value Interpretation
Non-parametric, H4a Base Standard 30% No Evidence
Parametric, H4a Base Standard 11% No Evidence
Non-parametric, H4a Staff Input Standard 31% No Evidence
Parametric, H4a Staff Input Standard 12% No Evidence
In summary, in each case there is no statistical evidence to accept the
alternative hypothesis with either DEA model and the null hypothesis H4n
therefore stands.
7.3.4 Summary of the Set
The main finding is that the DEA efficiency scores, for either DEA model, do
not provide statistically significant evidence to accept the alternative
hypothesis (or, where appropriate its reverse). Therefore the null hypothesis
stands for all the three cases, namely M&A deals in aggregate, or cross-
border and cross-sector deals, specifically are not associated with changes in
technical efficiency.
Furthermore, the p-values for testing with the R&D-only model and the model
with staff inputs are similar, and this suggests that any staff reduction effect is
small. Therefore the base model alone is used in later hypothesis testing.
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7.4 M&A and Financial Efficiency (H5, H6, H7)
7.4.1 Hypothesis 5
When financial efficiency is measured with ROS, the mean of the NDV for the
companies with above-median efficiency is 1.15 and the mean NDV for the
companies with below-median efficiency is 0.5, in the direction indicated by
the alternative hypothesis. Testing for significance using a Mann–Whitney test
gives a p-value of 20%. However a one-sided Welch test gives a p-value of
3%, which indicates strong evidence. Given the disparity between strong and
no evidence, the interpretation of the results is that there is some evidence
(we note the average of the scores in the region of 10%, the threshold for
‘some evidence’).
When financial efficiency is measured with ROA, the mean of the NDV for the
companies with above-median efficiency is 0.95 and the mean NDV for the
companies with below-median efficiency is 0.7, again in the direction indicated
in the alternative hypothesis. Testing for significance using a Mann–Whitney
test gives a p-value of 33%. A one-sided Welch test on the NDV gives a p-
value of 23%. We conclude that there is no statistical evidence to accept H5a
for ROA and the null hypothesis stands.
The testing results for H5a are summarised in Table 7.5:
127
Table 7.5 Results of Tests on Hypothesis H5a
Test Model Direction P-value Interpretation
Non-parametric, H5a ROS Standard 20% No Evidence
Parametric, H5a ROS Standard 3% Strong Evidence
Non-parametric, H5a ROA Standard 33% No Evidence
Parametric, H5a ROA Standard 23% No Evidence
In summary, following the discussion above, there is some statistical evidence
to accept the alternative hypothesis when ROS is used but not when ROA is
used to measure financial efficiency. The null hypothesis H5n is therefore
rejected for ROS but stands for ROA.
7.4.2 Hypothesis 6
When financial efficiency is measured with ROS, the mean of the cross-border
NDV for the companies with above-median efficiency is 0.41 and the mean
NDV for the companies with below-median efficiency is 0.13, in the direction of
that indicated in the alternative hypothesis. Testing for significance using a
Mann–Whitney test gives a p-value of 12% for acceptance of the alternative
hypothesis. A one-sided Welch test gives a p-value of 8%. Taking both results
together, the parametric result indicates some evidence although the non-
parametric does not; however the non-parametric result is only slightly over
the threshold and the mean of the results is on the threshold. On this basis,
there is some statistical evidence to accept H6a and on the basis of the ROS
scores and reject the null hypothesis.
When financial efficiency is measured with ROA, the mean of the cross-border
NDV for the companies with above-median efficiency is 0.26 and the mean
NDV for the companies with below-median efficiency is 0.28, the reverse of
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that indicated in H6a. Testing the reverse of H6A for significance using a
Mann–Whitney test gives a p-value of 22%. A one-sided Welch test gives a p-
value of 47%. We conclude that for ROA there is no statistical evidence to
accept the reverse of H6a on the basis of either a parametric or a non-
parametric test.
The testing results for H2a are summarised in Table 7.6.
Table 7.6 Results of Tests on Hypothesis H6a
Test Model Direction P-value Interpretation
Non-parametric, H6a ROS Standard 12% No Evidence
Parametric, H6a ROS Standard 8% Some Evidence
Non-parametric, H6a ROA Reverse 22% No Evidence
Parametric, H6a ROA Reverse 47% No Evidence
In summary, there is some statistical evidence to accept the alternative
hypothesis H6a when ROS is used but not to accept the reverse of H6a when
ROA is used to measure financial efficiency. Therefore where ROS is used the
null hypothesis H6n is rejected but it stands when ROA is used.
7.4.3 Hypothesis 7
When financial efficiency is measured with ROS, the mean of the cross-sector
NDV for the companies with above-median efficiency is 0.02 and the mean
NDV for the companies with below-median efficiency is 0.06, the reverse of
the direction indicated in the alternative hypothesis. Testing the reverse of H7a
using a Mann–Whitney test gives a p-value of 33% and a one-sided Welch
test gives a p-value of 8%. The results do diverge, however the non-
parametric test is close to the 10% threshold and the mean of the results
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exceeds the threshold by a factor of two. Given this there is no reliable
statistical evidence to accept the reverse of hypothesis H7a.
When financial efficiency is measured with ROA, the mean of the cross-sector
NDV for the companies with above-median efficiency is 0.044 and the mean
NDV for the companies with below-median efficiency is 0.041: close to equal
but the reverse of that indicated in H7a. A one-sided Welch test of the reverse
of H7a gives a p-value of 45% and a Mann–Whitney test (which compares
medians) gives a p-value of 18%. We note there is no statistical evidence to
accept the reverse hypothesis H7a with either test.
The testing results for H2a are summarised in Table 7.7:
Table 7.7 Results of Tests on Hypothesis H7a
Test Model Direction P-value Interpretation
Non-parametric, H7a ROS Reverse 33% No Evidence
Parametric, H7a ROS Reverse 8% No Evidence
Non-parametric, H7a ROA Reverse 18% No Evidence
Parametric, H7a ROA Reverse 45% No Evidence
In summary, there is no reliable evidence to accept the reverse of alternative
hypothesis H7a for either ROA or ROS when the parametric and non-
paramagnetic tests are considered in unison. The null hypothesis H7n
therefore stands.
7.4.4 Summary of the Set
For M&A in aggregate and for cross-border deals there is some statistical
evidence to accept the alternative hypotheses H5a and H6a, and hence reject
the hypotheses H5n and H6n for M&A in aggregate and cross-border deals
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respectively, when ROS is used as a metric for financial efficiency; however
this is not observed when ROA is used. For cross-sector deals, there is no
evidence to accept H7a with either ROS or ROA.
7.5 Sector Effects and Technical Efficiency (H8, H9, H10)
7.5.1 Hypothesis 8
For the base model, the mean of the SDV for the companies with above-
median efficiency is 19174 and the mean SDV for the companies with below-
median efficiency is 4345, in the direction of that indicated in the alternative
hypothesis. Testing for significance using a Mann–Whitney test gives a p-
value of 18%. A one-sided Welch test gives a p-value of 4%. Following similar
logic to that proposed for the testing of H5a for the use of ROS, namely the
parametric test shows strong evidence although the mean of the parametric
and non-parametric tests is in the region of 10%, we conclude that there is
some statistical evidence to accept H8a on the basis of the DEA scores of the
base model. The testing results for H8a are summarised in Table 7.8:
Table 7.8 Results of Tests on Hypothesis H8a
Test Direction P-value Interpretation
Non-parametric, H8a Standard 18% No Evidence
Parametric, H8a Standard 4% Strong Evidence
On this basis H8n was rejected.
7.5.2 Hypothesis 9
For the base model, the mean of the SDV for the companies with above-
median efficiency is 4442 and the mean NDV for the companies with below-
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median efficiency is 1056, in the direction of that indicated in the alternative
hypothesis. Testing for significance using a Mann–Whitney test gives a p-
value of 26%. A one-sided Welch test gives a p-value of 4%. As the mean of
these scores is 15%, we conclude that there is no statistical evidence to
accept H9a or reject the null hypothesis.
Table 7.9 Results of Tests on Hypothesis H9a
Test Direction P-value Interpretation
Non-parametric, H9a Standard 26% No Evidence
Parametric, H9a Standard 4% Strong Evidence
There is no statistical evidence to accept the hypothesis H9a and the null
hypothesis H9n stands.
7.5.3 Hypothesis 10
For the base model, the mean of the SDV for the companies with above-
median efficiency is 744 and the mean SDV for the companies with below-
median efficiency is 472, in the direction of that indicated in the alternative
hypothesis. Testing for significance using a Mann–Whitney test gives a p-
value of 45%. A one-sided Welch test gives a p-value of 30%. We conclude
that there is no statistical evidence to accept H10a. The testing results for
H10a are summarised in Table 7.10:
Table 7.10 Results of Tests on Hypothesis H10a
Test Direction P-value Interpretation
Non-parametric, H10a Reverse 28% No Evidence
Parametric, H10a Reverse 30% No Evidence
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There is no statistical evidence to accept the hypothesis H10a and the null
hypothesis H10n stands.
7.5.4 Summary of the set
The main finding is that in aggregate the DEA efficiency scores do provide
some statistically significant evidence to accept the alternative hypothesis that
mergers are associated with higher technical efficiency in aggregate, when
SDV was considered to examine sector effects.
For cross-border deals the parametric test gave strong evidence to accept but
this was not supported by the non-parametric test and therefore a conclusion
of no evidence was drawn; for cross-sector deals neither test gave evidence to
accept the alternative hypotheses.
7.6 M&A and Financial Metrics (H11, H12, H13, H14)
7.6.1 Hypothesis 11
For M&A in aggregate, the mean SOA of the cross-sector NDV for the
companies with above-median efficiency is 0.62 and the mean NDV for the
companies with below-median efficiency is 1.03, in the direction of the
alternative hypothesis. Testing for significance using a Mann–Whitney test
gives a p-value of 40%. A one-sided Welch test gives a p-value of 12%.
The testing results for H11a are summarised in Table 7.11:
Table 7.11 Results of Tests on Hypothesis H11a
Test Direction P-value Interpretation
Non-parametric, H4a Standard 40% No Evidence
Parametric, H4a Standard 12% No Evidence
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There is no statistical evidence to accept the hypothesis H11a and the null
hypothesis H11n stands.
7.6.2 Hypothesis 12
For cross-border deals, the mean SOA of the cross-border NDV for the
companies with above-median efficiency is 0.23 and the mean NDV for the
companies with below-median efficiency is 0.31, in the direction of the
alternative hypothesis. Testing for significance using a Mann–Whitney test
gives a p-value of 45%. A one-sided Welch test gives a p-value of 35%. The
testing results for H12a are summarised in Table 7.12:
Table 7.12 Results of Tests on Hypothesis H12a
Test Direction P-value Interpretation
Non-parametric, H12a Standard 45% No Evidence
Parametric, H12a Standard 35% No Evidence
There is no statistical evidence to accept H12a and the null hypothesis H12n
stands.
7.6.3 Hypotheses 13 & 14
For cross-sector deals, the mean SOA of the cross-sector NDV for the
companies with above-median efficiency is 0.07 and the mean NDV for the
companies with below-median efficiency is 0.02, in the reverse direction of the
alternative hypothesis. If the reverse of H13a is tested, namely “For cross-
sector deals, firms with an above-median SOA have a higher MCT of NDV
than those with below-median SOA”, the significance using a Mann–Whitney
test gives a p-value of 7%. A one-sided Welch test gives a p-value of 3%.
Taken together, there is strong evidence to accept the reverse of hypothesis
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H13a because the parametric test indicates strong evidence and the mean of
the p-values is below the 5% threshold. The testing results for H13a are
summarised in Table 7.13:
Table 7.13 Results of Tests on Hypothesis H13a
Test Direction P-value Interpretation
Non-parametric, H4a Reverse 7% Some Evidence
Parametric, H4a Reverse 3% Strong Evidence
To summarise the reverse of the alternative hypothesis H13a has been
accepted; however Sheshkin (2011: 451) notes this cannot be a basis for
rejecting a null hypothesis. A non-directional alternative hypothesis, which will
be tested instead, is therefore tested.
Testing for significance using a Mann–Whitney test gives a p-value of 14%. A
one-sided Welch test gives a p-value of 6%. As the mean of these scores is
10%, we conclude that there is some (but not strong) statistical evidence to
accept H14a. The results are shown in Table 7.14:
Table 7.14 Results of Tests on Hypothesis H14a
Test P-value Interpretation
Non-parametric, H14a 14% No Evidence
Parametric, H14a 6% Strong Evidence
The alternative hypothesis H14a is accepted and the hull hypothesis H14n is
therefore rejected. Because H13n is the same as H14n this is also rejected.
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7.6.4 Summary of the Set
For H11 and H12, although the ratio of the means is in the direction that would
accept the alternative hypothesis and hence reject the null hypotheses, there
is insufficient statistical evidence to do so.
However, the cross-sector finding for H13 does show a statically significant
finding, associating increased SOA with increased cross-sector activity, in the
reverse direction of H13a. The null hypothesis cannot be rejected on this basis
and so the non-directional equivalent, H14a, was tested instead and some
evidence was found to accept this hypothesis and reject the null hypothesis.
The implications for financial measure selection are discussed in the next
chapter.
7.7 Summary of Findings
7.7.1 Collation of Findings
Table 7.15 summarises those tests where there was evidence to reject the null
hypothesis.
Table 7.15 Rejected Null Hypotheses
H1n There are CRS for pharmaceutical R&D
H5n Firms with an above-median financial efficiency have the same
MCT of NDV as those with below-median financial efficiency.
H6n Firms with an above-median financial efficiency have the same
MCT of NDV for cross-border deals as those with below-median
financial efficiency.
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H8n Firms with an above-median technical efficiency have the same
MCT of SDV as those with below-median technical efficiency.
H13n,
H14n
For cross-sector deals, firms with an above-median SOA have the
same MCT of NDV as those with below-median SOA.
All were rejected with some evidence, except for H1n which was rejected with
extremely strong evidence.
7.7.2 Check for Consistency
Both parametric and non-parametric tests have been considered and in most
cases they are in agreement on the presence or absence of statistical
evidence. However there are cases where the p-value of the parametric test is
below the threshold and the p-value of the non-parametric test is above the
threshold and each case has been assessed on its merits. The treatment is
however consistent and in all cases follows the rule:
If the p-value of the parametric test is below the threshold for evidence
and the mean of the parametric and non-parametric p-values is above the
threshold by no more than a fifth of the threshold value, then the test for
evidence is accepted.
The treatment of borderline cases is summarised below in Table 7.16.
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Table 7.16 Borderline Alternative Hypotheses
No. Hypothesis Parametric
p-value
Mean p-
value
Some evidence
H5a Firms with an above-median financial
efficiency [ROS] have a higher MCT of NDV
than those with below-median financial
efficiency.
3 11.5
H6a Firms with an above-median financial
efficiency [ROS] have a higher MCT of NDV
for cross-border deals than those with below-
median technical efficiency. (When using
ROS)
8 10
H8a Firms with an above-median technical
efficiency have a higher MCT of SDV than
those with below-median technical efficiency.
4 11
H14a For cross-sector deals, firms with an above-
median SOA does not have the same MCT of
NDV as those with below-median SOA.^
4 10
No evidence
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H7a Firms with an above-median financial
efficiency [ROS] have the same MCT of NDV
for cross-sector deals as those with below-
median financial efficiency.
8 20.5
H9a Firms with an above-median technical
efficiency have a higher MCT of SDV for
cross-border deals than those with below-
median technical efficiency.
4 15
^ H14a was assessed as ‘some evidence’ not ‘strong evidence’ because the
mean p-value was more than one fifth above the 5% threshold for ‘strong
evidence’.
Table 7.16 shows a consistent treatment of cases that seeks to balance the
risk of Type I errors (concluding a false alternative hypothesis is true by a
adopting a lax threshold) and a Type II error (concluding a true alternative
hypothesis is false by adopting a strict threshold). It can be seen that the
borderline has been drawn between the results for H8a and H9a: in both
cases the parametric p-value was 4% but in the former the mean of the
parametric and non-parametric tests was 11% judged to support a view of
some evidence but in the latter the mean was 15%, judged to represent no
evidence.
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8 Discussion of Results
8.1 Range of Findings
The five groups of hypotheses have addressed five different aspects of the
measurement of PAP:
– The returns to scale of the pharmaceutical R&D process. It is necessary
to establish this in order to select the most appropriate model for the
measurement of R&D comparative efficiency. This has yielded a very
strong conclusion on returns to scale for the process and shows DRS.
– The association of technical efficiency with M&A history. This has not
yielded statistically significant results, although this is itself a finding
(discussed later) and an indirect contribution to the understanding of the
Merger Paradox when contrasted with the findings on financial efficiency.
– The association of financial efficiency with M&A history. These findings
differ according to the financial measure chosen. However, a rationally
selected measure, ROS, does show a relation that is in opposition to the
merger paradox.
– The sector-level consequences of M&A. It has been found that
substantially more acquisitions by value are associated with technically
efficient firms than with less efficient firms.
– The examination of the interrelationship between two measures of
financial efficiency for the different types of deal. The results of the test
shows the choice of financial metric for PAP can lead to differing
conclusions and the ratio of ROS to ROA, SOA, was affected by the level
of historical cross-sector acquisitions.
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These findings on measures themselves depend on a robust process for
measure selection and are therefore supported by the systematic approach to
the selection of measures encapsulated in the 12 Design Principles.
Each of the five areas of results is now discussed in turn, focusing on the
findings, followed by a section on the qualitative findings for the selection of
measures for PAP (the Design Principles themselves were designed for a
general application, not specifically PAP).
The contributions arising from the findings are discussed in the following
section.
8.2 Returns to Scale of R&D
The strength of the linear relationship, when R&D output is measured by the
number of compounds, between the logarithm of the scale efficiency of R&D
and the logarithm of R&D expenditure (i.e. a power law) was a striking feature,
when perhaps more variability might have been expected given the role of
serendipity in R&D. VRS were established with p < 0.01% and the clarity of
the power-law relationship between returns to scale and scale efficiency may
have future econometric application.
The relationship was less clear when the numbers of compounds were
considered. A multiplicity of clinical trials, especially in the later stages when
expense can be an issue, may not be an indicator of higher efficiency. The
analysis of the ratio of clinical trials and compounds between companies in the
later stages of the pipeline does suggest a divergence of management
practice, whereas in the early stages when the safety of a compound has to
be established, divergence is less and there are lower ratios of compounds to
trials. The findings suggest (although in the absence of statistical tests) that
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the number clinical trials should not be considered an output measure in
preference to the number of compounds.
The DRS for pharmaceutical R&D has significant implications for the Merger
Paradox and these are discussed in the next sections.
8.3 The Association of Technical Efficiency with M&A History
The absence of a statistically significant relationship between technical
efficiency and merger history might at first sight seem disappointing, although
it is a finding in itself. There are many possible reasons for the absence of a
relationship at the firm level, given the multiplicity of motives for M&A. Some
acquirers choose to use the strength of their R&D pipeline, which is reflected
in market ratings and hence share price, to acquire potential competitors; in
these cases, there would be a strong association between acquisition history
and R&D efficiency. Conversely, there are other cases, where historical M&A
deals have been undertaken with the objective of achieving economies of
scale by the reduction of overheads costs in the face of weak pipelines; in
these cases an inverse relationship might be expected with M&A history and
technical efficiency. Examples of both were given in Section 6.12: Pfizer is an
example of an aggressive acquirer and the Sanofi-Aventis merger is an
example of two low productivity firms merging, with the lowering of fixed costs
being a plausible motive.
The methodology of this study has not included an event study so cannot
comment directly on whether M&A is damaging to the acquiring company.
Nonetheless the findings on economies of scale are unequivocal and because
an M&A deal inevitably leads to a larger company it can be expected that R&D
productivity will fall. Because the future prosperity of a pharmaceutical
company depends on its R&D productivity compared with competitors, it can
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be stated indirectly that the Merger Paradox has been confirmed in the
pharmaceutical sector: pharmaceutical M&A deals are popular but do not
improve the performance of the acquirer.
Similar comments also apply to cross-border mergers, tested by H3, and
cross-sector deals, tested by H4.
8.4 The Association of Financial Efficiency with M&A History
ROS was selected over ROA as a better measure of financial efficiency; this
was done because of the distortions, noted in the literature, inherent in ROA
when it is used to measure financial efficiency in a sector with substantial
intangible assets.
A statistically significant relationship has been established between financial
efficiency of the firm as measured by ROS, and that an improved ROS is
associated with higher historic merger activity; this is in contrast to the findings
for technical efficiency where no statistically significant relationship was found.
The contrast is further support of the Merger Paradox because although the
acquirer may have many motives for the deal (including an increase in ROS),
the change in financial efficiency is also likely to act as a qualifying factor, for
instance a deal that lowers financial efficiency is unlikely to proceed even if
there are other benefits. We therefore observe a divergence in incentives for
M&A, with an association with an increase in an accounting measure (ROS)
but no equivalent prospect of an increase in long-term operational
performance (technical R&D efficiency).
This argument is an elaboration of Angwin (2007) in which the multiplicity of
motives was recognised; although such a multiplicity undoubtedly exists and
even if the motives are not metric-related (e.g. the motive of elimination of a
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competitor to enhance market power), metrics can also act as a qualifying
factor for a deal to proceed. It is therefore necessary to consider a two-phase
model of M&A comprising initial motives and subsequent metric-related
constraints or qualifying factors, rather than motive alone.
There were very similar findings for cross-border deals; this is perhaps not
surprising because international firms now dominate the pharmaceutical
industry and the importance of the ‘cross-border’ effect may be attenuated and
many major cross-border deals did follow language-orientations, for example
USA/UK deals.
However, the ROS for cross-sector deals had no relation to acquisition history
and we later suggest that this arises because of the difference in ROS
between the pharmaceutical sector and the sectors in which pharmaceutical
companies make acquisitions.
Regarding the lack of statistically significant findings for ROA, this can be
explained by reference to the unreliability of the denominator, where
investments in intangible assets are not recognised as assets when the assets
are internally created. Even if the numerator of the measure were improved for
acquiring firms, then the effect of increased acquisitions leading to greater
recognition of assets would depress the effect of an improved ratio as reported
in the literature. The effect of acquisitions on the two measures is tested
directly later, where this effect has been observed but not to a level of
statistical significance.
8.5 The Sectoral Consequences of M&A
This thesis does not examine sector effects directly but it is possible to
associate the total value of deals with the surviving firms and their relative
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efficiency. H8a was confirmed, namely ‘Firms with an above-median technical
efficiency have a higher MCT of SDV than those with below-median technical
efficiency.’ This does have implications for the sector because it is has been
established that more acquisitions by monetary value are associated with
efficient firms than with the less efficient firms. The implication is that those
large firms who choose to acquire tend to be more efficient than small
acquiring firms and non-acquirers.
At the sectoral level, the implication is that M&A activity, where it does occur,
leads to a concentration of market power in the more efficient firms, which is
the underlying argument for a liberal M&A regime. There is a parallel with
findings from the financial M&A literature, where M&A is found to increase the
total wealth of shareholders in the acquiring and acquired firm, even if the
subsequent performance of the acquirer is indifferent.
For the individual pharmaceutical firm, however, it can be expected to become
less technically efficient following the acquisition because R&D efficiency
decreases with size, and if this occurs it may itself be acquired in the future.
8.6 Relationship between SOA and M&A
The testing of SOA for M&A in aggregate and for cross-border deals did not
lead to a higher NDV for firms with below-median SOA being found to be
statistically significant, even though this might have been expected from
consideration of accounting principles and previous academic literature.
For cross-sector M&A, however, there was strong statistical evidence that
firms with above-median SOA had a higher cross-sector NDV.
This is explicable by reference to industrial practice. Some sector acquisitions
tend to be into sectors that have operations elsewhere in the health value
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chain, especially companies that trade in medical goods, in order to obtain a
route to market. These companies tend to have elevated SOA ratios because
they are distributors and retailers, and exhibit a high turnover of goods through
the supply chain with a relatively small asset base (the retail and distribution
network).
8.7 Synthesis of Findings
The previous discussion has considered the implications of each quantitative
finding individually and some are valuable in their own right, for example the
establishment of a linear relationship between the logarithm of scale efficiency
and the logarithm of R&D expenditure. We now synthesise the findings in
order to establish their relevance to the main topic of this thesis: the
measurement of PAP in the pharmaceutical sector, as it relates to R&D.
The scale efficiency finding is important on several fronts. Firstly, it shows that
M&A, which leads to larger companies, can be expected to lower efficiency
unless off-setting gains in technical efficiency are to be found; no statistically
significant evidence has been found that this is the case. This finding is
therefore supportive of the Merger Paradox, namely an activity is continuing
which can be expected to lead to a lowering of performance in a crucial
business process.
However, the finding also provides a motive for the continuation of the
practice. If a large firm recognises that its own R&D is unproductive it is in the
position to temporarily redress this in the short term by the purchase of smaller
productive companies, even though both the acquiring and the acquired
company might have concerns regarding the effect on longer-term
performance. This is especially problematical in R&D where the resources
being purchased are largely intangible and therefore can be readily dissipated
146
following the merger, for example by the resignation of key staff. We therefore
see an additional pharmaceutical specific Merger Paradox, namely the
response of a pharmaceutical firm to declining R&D is likely to exacerbate the
problem. This also has implications for public policy, especially because the
productivity of R&D is declining at the sectoral level.
We now turn to the finding that if M&A in the sector as a whole is considered,
then it is associated with the most efficient companies; this may seem to
suggest that at the sectoral level M&A is functioning as it is intended, namely it
leads to a concentration of power with the more successful firms and the
elimination of the poorer performers. That may well be the case, because it is
possible that the share prices of the efficient firms permit them to make hostile
takeovers to increase their market power and eliminate competition, while
M&A permits the less productive to undertake non-hostile deals with a shared
objective of reducing fixed costs to improve efficiency. Therefore at a given
moment in time, the observation that the sector’s acquisitions are associated
with more technically efficient companies is not inconsistent with the finding
that historically M&A tends to lower performance. A similar effect is observed
at the disaggregated product-level within a pharmaceutical firm, where the
most successful products or technologies today are unlikely to remain so as
patents expire and new competition emerges; nonetheless despite the
certainty of this occurring it may still be rational to focus R&D investments on
the areas that are currently most successful in order to maximise the return on
R&D in the short term.
Although the motives for an M&A deal are diverse, the deals are unlikely to
proceed if they damage the financial performance of the firm. The findings that
acquisitions are associated with firms that are more financially efficient is
therefore fully consistent with the Merger Paradox because improved financial
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performance will act as a qualifying factor for a deal proceeding, whatever its
subsequent effect on the underlying fundamentals of the firm.
In summary, the findings point not so much to a Merger Paradox as to the
Paradoxes of Mergers. Not only do M&A deals continue when their effects on
long-term performance are likely to disappoint (if only because of scale
effects) but the behaviour seems fully rational to the acquirer; furthermore the
need for good accounting-based performance will ensure that when analysed
by conventional accounting measures, M&A will seem to be successful, at
least in the short term. Meanwhile, at the sector-level, it would seem that the
most efficient companies undertake acquisitions at any moment in time, even
though over time they may become less efficient as a result.
Moving on from the role of measurement in the Paradoxes of Mergers and
their motives to the narrower topic of measurement of PAP itself, the findings
highlight the difficulties of PAP measurement, especially where intangibles are
involved. The effect on M&A of the recognition of intangibles in ROA was
noted in earlier literature and was not refuted in this thesis. However, a
separate effect on the preferred alternative measure, namely ROS, has been
identified when cross-sector deals are considered, this effect arises from
diversification into retail and distribution from research-based manufacturing.
This reinforces the need for a PMF when studying M&A rather than relying
upon a single measure. Regarding financial measures, neither ROA nor ROS
should be relied upon on their own and non-financial measures are required to
consider the preservation of intangibles in the aftermath of a deal.
Furthermore, if a PMF for the external evaluation of M&A is to be used, then
there should be a theoretical basis for the selection of the measures, and the
RBV-based 12 Design Principles have shown themselves to be a practical
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approach through their application in designing a PMF for a pharmaceutical
firm.
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9 Contributions
9.1 Overview
This thesis examines the association of efficiency of the R&D process in the
major pharmaceutical firms with their history of M&A. Studies of PAP are
numerous, and their results diverse, however this thesis starts from the
premise that PAP is itself an intellectual construct based upon assumptions on
motives for the deal and the perspectives of relevant stakeholders. Therefore
prior to measuring PAP there has to be a thorough consideration of the
measures to be used.
From this initial stance on the assessment of PAP, this thesis contributes to
the field by first applying the RBV to the selection of multiple performance
measures for a PMF; this approach is encapsulated as a set of 12 Design
Principles that can be applied in any sector. The thesis then sheds new light
on the Merger Paradox, namely why M&A continue to be transacted when
historically their results seem to be disappointing overall. The thesis contrasts
PAP as measured by a PMF with PAP as measured by a conventional
financial measure: ROS. In essence, an association between above-median
ROS and increased acquisition activity was established, but the same
relationship was not established when a non-financial PMF was used. This
finding provides an incentive-related explanation for the Merger Paradox
linked to differing indications from financial and non-financial measures.
The thesis also examines PAP of subsets of acquisitions, namely cross-border
and cross-sector deals, to consider diversification effects and establishes a
contrast between the findings as they affect the individual firms and the effects
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at the sectoral level, which has parallels with earlier research using financial
event studies.
By adopting a novel means for the assessment of PAP, namely combining a
longitudinal view of acquisition history and a cross-sectional view of
comparative efficiency (that itself considers the longitudinal nature of the R&D
pipeline and the multiple outputs of the R&D process), this thesis has provided
a new application for DEA in the M&A literature that has not previously been
used to examine R&D. In doing so, the use of DEA has also established scale
efficiency factors for pharmaceutical R&D, clarifying earlier ambiguity in
findings in this field and recognising the multiple inputs and outputs of the
process.
A further empirical contribution is the examination of the relation between size
and frequency of M&A in the pharmaceutical sector and its consistency with a
power-law distribution.
Finally, the thesis examines the relative merits of ROS and ROA as a financial
measure and whether there is a statistically significant difference in the
conclusions on PAP arising from the use of the two different measures.
9.2 Contributions to the Acquisition Literature
The timing of the findings of the research are fortuitous because after four
decades of contradictory findings on PAP, there is now a focus on the
assumptions underlying this construct and especially the examination of the
original objectives for an acquisition (Angwin, 2007) and how one can
measure attainment of those objectives. This is related to the Merger Paradox,
which is concerned with the motives and their attainment, and currently the
most common explanations involve an element of agency theory, namely the
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divergence of motives between managers and shareholders. This research
suggests that agency theory is not required to explain the Merger Paradox, at
least in the pharmaceutical sector and the actions of managers are consistent
with improving a common financial measure under their control.
9.2.1 Reduction of Uncertainty
In undertaking an additional study in a well-researched area where there is
already a disparity of findings, there is a danger of adding another observation
that does not provide further insight. This is especially the case where meta-
analyses have concluded that previous studies, for example King et al. (2004),
have not identified the full range of moderating factors on PAP, and others
have concluded that there is little relation to the findings of studies where
different measurement principles have been employed, for example
Schoenberg (2006) and Papadakis & Thanos (2010).
The line of enquiry in this research has therefore been to reduce uncertainty
by consciously removing potential moderating factors from the research. By
focusing on one industry and analysing performance on the same set of
companies in two different ways, it was possible to establish that a
multiparameter, non-financial method of measurement and a common
financial measurement gave rise to differing conclusions. Although many other
factors may affect performance, the conclusions on differences in performance
as measured by financial and non-financial parameters have been
established.
9.2.2 Differences in Measured Performance
The lack of a statistically significant association between technical efficiency
and M&A history is a useful finding, especially when coupled with the
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presence of statistically significant findings showing diseconomies of scale in
R&D and in associations between M&A and ROS.
Because M&A leads to larger entities with larger R&D processes, this might be
expected to lead to a lower efficiency in the longer run, which might offset
shorter-term cost reductions from the deal (e.g. removal of duplicated posts or
premises). This is a natural explanation for the lack of association, coupled
with the possibility that some companies with lower technical efficiency may
choose to merge in order to seek short-term economies and buttress financial
performance.
Regarding PAP as measured financially, companies with above-median ROS
had a significantly higher historical incidence of acquisitions. A direct
comparison with an event-study approach using financial measures cannot be
made and indeed the findings of these event studies are not consistent
amongst themselves, possibly because of unidentified moderating factors, as
suggested by King et al. (2004).
A lack of association between ROA performance and M&A history may arise
from the shortcomings of that measure where intangible assets are significant,
despite it being the most popular accounting measure in PAP research. This is
a worrying finding but nonetheless a contribution to the M&A literature.
The thesis sheds much light on the Merger Paradox, whereby acquisitions
continue despite their disappointing non-financial outcomes (Schenk, 2008).
The transactions may improve ROS or be facilitated by higher ROS originally
(e.g. access to merger finance). This explanation is also consistent with
Schoenberg’s (2006) study in which it was suggested that approach to
measurement was an explanation for the variation in the findings of research
on PAP.
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9.2.3 Diversification
The research also examined the impact of diversification and the findings here
for cross-border deals were different from cross-border deals when ROS was
considered.
For cross-border deals, there was an association of such deals with
improvements in financial efficiency, similar to that for acquisitions as a whole,
however the cross-sector analysis did yield a strongly significant result for
ROS. This is in line with Shelton (1988) who reported: “Multivariate regression
analysis shows that acquisitions which permit the bidder access to new but
related markets create the most value with the least variance” with cross-
sector deals into retailing and wholesaling of health goods being associated
with poorer performance, unlike cross-border deals which offer access to new
markets for R&D-based products.
9.3 Contributions to the Performance Literature
There is a growing body of literature on performance measurement using
multiple measures in PMFs for an individual firm, but the choice of measures
has presumed a detailed knowledge of the internal operations of the company
to select the parameters. The development of a theoretical basis for the
solution of measures could assist in multiparameter measurement processes
in general. It is especially useful in the field of comparative efficiency analysis
that is frequently undertaken from outside the firm.
Any proposed theoretical approach should be capable of considering both
tangible and intangible inputs and outputs and be related to a theoretical base
that is widely accepted. The RBV meets both these requirements and has
evolved into the dominant theory, however relatively little attention has been
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paid to the measurement of resources within the RBV literature. By reviewing
the literature within the RBV, where measures were considered, a set of
criteria for selection of measures relevant to competitive advantage was
identified and used as a set of Design Principles. As well as being used to
select measures for this research, the Design Principles and Construction
Process could have further application in other sectors.
9.4 Contributions to the DEA Literature
The application of DEA to measure the effects of M&A has been confined to
date to short-term event studies that are not suitable for measuring R&D
efficiency in a sector that has a lengthy R&D pipeline. The analysis of the
efficiency of the R&D pipeline using data on its inputs for the majority of its
average duration and then using DEA in a cross-sectional analysis is a novel
form of the use of DEA for the analysis of M&A. In other respects the use of
DEA is conventional although the application is unusual in the effort taken to
measure intangible outputs directly rather than through the use of financial
surrogates for intangibles, for example revenue or share price, although the
pharmaceutical sector was consciously selected to enable this to be possible.
In summary, this research has extended the application of DEA, as well as
considering its field of application and the approach taken to the selection of
inputs and outputs to the DEA models.
9.5 Empirical Contributions
9.5.1 Returns to Scale
There have been earlier attempts in the literature to measure R&D
productivity, for example Graves and Langowitz (1993) used a simple unit
cost, examining approved compounds produced per unit of R&D expenditure,
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but they did not account for the multiple outputs of the R&D process.
Therefore application of a multiple input/output approach to the R&D pipeline
is itself a useful contribution.
DEA was selected even though it has not been extensively used to measure
the efficiency of the R&D process of a firm. The use of DEA to measure the
efficiency of the R&D process for pharmaceutical firms of a variety of sizes
provided the opportunity to determine if pharmaceutical R&D had CRS. It was
found not to and furthermore a clear relationship was found between scale
efficiency and a R&D scale parameter, which showed DRS, in contrast to the
Schumpeterian hypothesis (over IRS in R&D) and Jensen (1987) who found
that marginal productivity was not adversely affected by firm size.
From the view of industry practice, the industry has also been concerned with
a fall in the number of new drugs approved despite rising R&D costs, although
Cockburn (2006) suggests this is due to rising R&D input costs rather than
declining efficiency in conversion of inputs to outputs. The response of some
companies to declining internal efficiency has been to acquire R&D resources
externally, through acquisition, although this response is not universal.
Although acquisition will circumvent the effects of the R&D efficiency problem
in the short term, this research suggests that it may only add to the problem of
declining R&D efficiency in the long term, if the association with acquisitions
and lower productivity reflects a causal link.
9.5.2 Power Laws in M&A
Further empirical findings included the distribution of mergers by size and
establishing the limits of the power-law hypothesis, including the divergence of
the mega-mergers from the linear log–log relationship for this particular sector
(an elaboration on Park et al., 2010). However the research has not
156
established a power law conclusively because it has not eliminated alternative
explanations for the linear log–log relationship. The limits of the linear
relationship in pharmaceutical M&A in the chosen sample involved a surfeit of
mega-mergers and a lower than expected number of mergers in the size
range immediately below the mega-merger range. Beneath these large sizes,
a power law prevails indicating a self-organised critical system. This finding is
consistent with industry analysis, where there has been a conscious attempt to
consolidate the industry from the top, consisting of mergers of mid-tier
pharmaceutical companies in the second M&A wave and then the merger of
giants in the third M&A wave.
It was also found that following the removal of zeros from the statistics for
NDV, the statistical distribution follows a Poisson distribution, suggesting that
the normalisation of total deal value by cost of sales reveals the underlying
Poisson process (and thus confirms the validity of the normalisation factor).
9.5.3 Financial Metrics in M&A
The divergence of findings between the financial and non-financial metrics and
between different financial metrics was a major finding of the research and
adds further support for the use of a PMF over a single measure
(Schoenberg, 2006). However there is also a case for the use of using multiple
financial metrics, with the potential shortcomings of ROA being noted
previously and the limitations of ROS for analysing cross-sector deals being
established within this thesis. The finding relating to SOA, the ratio of ROS to
ROA, showed that particular types of deal (e.g. cross-sector deals) can have a
differential effect on common financial metrics.
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9.6 Directions of Future Research
Greater recognition of the role of chance in R&D productivity and the
sensitivity of the findings to this random element would be a fruitful area for
future research. The role of uncertainty in the analysis of DEA has been
considered by Dyson & Shale (2010), and the use of Monte Carlo simulation
to perturb the outputs from the R&D processes (the inputs are well defined) to
observe the effects on relative efficiency, and also the assessment of the
difference in the MCT of NDV between the subgroups of above- and below-
median efficiency would be useful.
Given the difference in results between ROS and ROA it would be possible to
consider measuring financial efficiency by some alternative parameter, such
as the residual income measure Economic Profit. Regarding normalisation
factors, the use of Cost of Sales to normalise the sum of the deals was the
most defensible choice, however examining other factors such as revenue, or
average R&D expenditure (on the grounds that an acquisition is an alternative
means of acquiring a stocked pipeline) in order to undertake a sensitivity
analysis could be worthwhile. A further refinement could be to adjust the
proportion of Cost of Sales figure for the costs that are related to generic
manufacture of pharmaceuticals, however this would prove difficult because
this information is not publicly disclosed.
The research has merely touched on the issue of causality by considering the
stated intentions of the four mega-mergers that seem to set off ‘aftershocks’
according to some hypotheses of merger dynamics. The next steps are to
extend the case-by-case analysis of major acquisitions to establish causality
with smaller deals and to analyse further the distribution relating size of deals
to their frequency.
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A. R&D Data
A.1 Introduction
The R&D data used in the models are a combination of primary data and
calculated data. The origins of the primary data and the adjustments are
detailed in this Appendix.
A.2 Historical R&D Data
The historical R&D expenditure in $million unadjusted for inflation is shown in
Table A.1 for the years from 2005 to 2001. These data are drawn from the
same source to enhance compatibility. If this source did not have data for a
particular firm or for a particular year, then the cells were left blank in Table
A.1.
Table A.1 Historical R&D Data in US$million Actual
Firm R&D 2005 R&D 2004 R&D 2003 R&D 2002 R&D 2001
Abbt 1821 1697 1624 1475 1492
Akzo 681 640 705 747 666
Alco 422 390 350 324 290
Alle 391 346 764 233 228
Amg 2314 2028 1655 1167 865
Astel 1214 1091 1221 562 547
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Astr 3379 3467 3012 3069 2687
Baus 178 163 150 128 122
Baxt 533 517 553 501 426
Baye 1188 1300 1555 1727 1973
Biog 748 686 534
BMS 2746 2500 2279 2206 2157
Boeh 1693 1534 1464 1623 1269
Ceph 125 134 102 82 64
Chug 424 408 369 411 405
CSL
Daic 1357 1241
Dain 253 149 136 130 112
Eisa 797 669 590 510 470
EliL 3026 2691 2350 2149 2235
Fore 410 294 234 205 158
Gene 1262 948 722 623 526
Genz 503 392 335 308 264
Gile
184
GSK 5709 5286 5215 5279 4826
John 6312 5203 4684 3957 3591
King
Kyow 239 207 2111 232 213
Lund 300 296 322 262 257
Merc 3848 4010 3280 2667 2456
Merk 721 612 630 621 596
Mits 410 431 432 413 293
Nova 4846 4171 3729 2843 2528
Novo 848 726 676 659 662
Nyco
Pfiz 7442 7684 7487 5208 4776
Roch 4579 4137 3825 3417 3125
Sano 5034 4935 1638 1516 1283
Schr 1865 1697 1469 1425 1312
Shio 276 251 255 267 262
Shir
Solv 437 366 354 335 276
185
Tais 197 198 207 252 275
Take 1417 1156 1046 972 792
Teva 369 338 214 165 107
UCB 642 454 264 268 211
Wats
Wyet 2749 2461 2094 2080 1870
A.3 Historical Sales Data
The estimation of a single parameter for historical R&D also requires the
revenue statistics for the years 2001 to 2005. These data are given below,
unadjusted for inflation. Blank cells indicate unavailable data.
Table A.2 Historical Revenue Data in $million Actual
Firm Rev. 2005 Rev. 2004 Rev. 2003 Rev. 2002 Rev. 2001
Abbt 22338 19680 17280 15280 13919
Akzo 4381 4197 4419 4990 5034
Alco 4369 3914 3407 3009 2748
Alle 2319 2946 1755 1385 1142
Amg 12430 10550 8356 5523 4016
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Astel 7434 7195 3851 3778 3544
Astr 23950 21426 18849 17841 16222
Baus 2335 2232 2020 1817 1666
Baxt 9849 9509 8904 8099 7342
Baye 11738 10031 11044 11667 13309
Biog 2423 2212 1852
BMS 19207 19380 18653 16208 16612
Boeh 11870 10155 9190 9436 8333
Ceph 1646 1641 1458 1223 1160
Chug 2773 2497 1972 2012 1794
CSL
Daic 6707 6552
Dain 1646 1276 1258 1272 1200
Eisa 4957 4369 4077 3777 3466
EliL 14645 13858 12583 11078 11543
Fore 2962 3160 2680 2246 1602
Gene 6633 4621 3300 2584 2044
Genz 2735 2201 1714 1329 1224
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Gile
GSK 39430 36383 38356 38614 37928
John 50514 47348 41862 36298 32317
King
Kyow 1769 1831 1813 1702 1691
Lund 1513 1623 1658 1583 1277
Merc 22012 22939 22486 21446 21199
Merk 4848 4943 6849 6994 7259
Mits 2019 2002 2012 2390 1957
Nova 32212 28247 24864 20877 18762
Novo 5631 4842 4363 4148 3901
Nyco
Pfiz 51298 52516 44736 32294 29024
Roch 28502 23695 25058 23640 23407
Sano 33999 31370 29019 9272 8077
Schr 9508 8272 8334 10180 9762
Shio 1653 1677 1681 2397 3504
Shir
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Solv 2826 2172 2281 2319 2202
Tais 2320 2388 2448 2343 2320
Take 9184 8295 8088 7605
Teva 5250 4790 3276 2519 2077
UCB 2941 2368 1838 1854 1793
Wats
Wyet 18776 17358 15851 14854 13984
A.4 Current R&D & Composite R&D Data
Column 2 of Table A.3 shows the R&D expenditure for 2006 and Column 3
shows the R&D expenditure for 2005, drawn from a source which allows direct
comparison between those two years. In most cases the 2005 data are the
same as shown in Column 2 of Table A.1 (for example ‘Abbt’ has an
expenditure of $1821 million in both cases) however there can be small
differences (for example ‘Akzo’ has an expenditure of $687m in the data
shown in Table A.3 but an expenditure of $681m in Table A.1).
It is necessary to adjust the 2005 R&D expenditure shown in Column 3 of
Table A.3 for 2005 for two effects:
 the rate of inflation of the US dollar from 2005 to 2006;
 the historic trend in R&D from 2001 to 2005 as shown in Table A.1.
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The first adjustment requires the inflation of the 2005 data by 3%4 to reflect
2006 prices. The second adjustment is more complex and is described below.
The data in Tables A.1 and A.2 (which are comparable between years) are
used to express R&D expenditure as a percentage of Revenue for each year.
The ratio of the percentage in 2005 to the average ratio for the years from
2001 to 20045 is then used to apply an adjustment factor (reflecting the historic
trend in R&D as a percentage of Revenue) to the 2005 R&D expenditure in
Column 3 of Table A.3. This calculation of the historic adjustment factor is
shown for each firm in Columns 4, 5 and 6 respectively of Table A.3.
The final column, Column 7 in Table A.3, shows the data used as in input to
the DEA model for historic DEA, which is the product of the Historic
Adjustment to reflect historic R&D expenditure as a percentage of Revenue
and the changing price levels from 2005 to 2006.
The adjustment can be expressed algebraically as:
Historic R&D DEA Input equals
Comparable 2005 R&D Expenditure
times Inflation adjustment to 2006 price levels
times average R&D as % sales 2001 to 2004
average R&D as % sales in 2005
The results of the calculation are shown in Table A.3.
4 http://data.bls.gov/cgi-bin/cpicalc.pl?cost1=1000&year1=2005&year2=2006
5 The R&D expenditure for the year 2005 is excluded from the calculation of the average, so as to avoid the
circularity of adjusting a figure for a historic trend that includes the figure itself.
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Table A.3 Current & Composite R&D Data in $million Actual
R&D
2006
R&D
2005
(comp.
to ’06)
R&D/Rev
2005
%
Mean
R&D/Rev
’04 – ’01
%
Historic
Adjustment
DEA
Input
for
Historic
R&D
Abbt 2255 1821 8.15% 9.60% 117.74% 2208
Akzo 741 687 15.54% 14.85% 95.54% 676
Alco 512 422 9.66% 9.25% 95.81% 416
Alle 1056 388 16.86% 23.02% 136.51% 546
Amg 3366 2314 18.62% 20.42% 109.71% 2615
Astel 1435 1214 16.33% 19.29% 118.15% 1477
Astr 3902 3379 14.11% 16.48% 116.82% 4066
Baus 197 178 7.62% 7.27% 95.42% 175
Baxt 614 533 5.41% 5.91% 109.19% 599
Baye 1791 1048 10.12% 14.17% 139.97% 1511
Biog 718 748 30.87% 29.92% 96.93% 747
BMS 3067 2746 14.30% 12.93% 90.43% 2558
Boeh 1977 1709 14.26% 15.87% 111.24% 1958
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Ceph 403 355 7.59% 6.85% 90.15% 330
Chug 467 428 15.29% 19.51% 127.62% 563
CSL 161 136 100.00% 140
Daic 1459 1357 20.23% 18.94% 93.62% 1308
Dain 350 253 15.37% 9.71% 63.19% 165
Eisa 926 797 16.08% 12.99% 80.78% 663
EliL 3129 3026 20.66% 19.21% 92.99% 2898
Fore 941 410 13.84% 9.26% 66.87% 282
Gene 1773 1262 19.03% 27.43% 144.16% 1874
Genz 650 503 18.39% 20.52% 111.60% 578
Gile 384 278 100.00% 286
GSK 6373 5781 14.48% 13.63% 94.14% 5605
John 7125 6462 12.50% 11.05% 88.41% 5885
King 254 263 100.00% 271
Kyow 268 264 13.51% 38.49% 284.91% 775
Lund 329 300 19.83% 18.58% 93.72% 290
Merc 4783 3848 17.48% 14.02% 80.21% 3179
Merk 772 728 14.87% 9.67% 65.00% 487
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Mits 403 410 20.31% 18.81% 92.64% 391
Nova 5349 4825 15.04% 14.21% 94.48% 4696
Novo 1063 856 15.06% 15.84% 105.16% 927
Nyco 47 36 100.00% 37
Pfiz 7599 7256 14.51% 15.99% 110.20% 8236
Roch 5258 4526 16.07% 15.13% 94.19% 4391
Sano 5565 5080 14.81% 13.40% 90.52% 4736
Schr 2188 1865 19.62% 16.39% 83.58% 1606
Shio 320 276 16.70% 14.30% 85.65% 243
Shir 387 339 100.00% 349
Solv 533 441 15.46% 14.84% 95.95% 436
Tais 244 197 8.49% 9.84% 115.87% 235
Take 1620 1417 15.43% 13.22% 85.66% 1250
Teva 495 369 7.03% 6.32% 89.96% 342
UCB 1024 888 21.83% 14.94% 68.44% 626
Wats 131 125 100.00% 129
Wyet 3109 2749 14.64% 13.69% 93.51% 2648
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A.5 Conclusion
The historic R&D data has been adjusted to arrive at a figure that best reflects
the inputs to the R&D process by adjusting for changes to the policy of R&D
expenditure (expressed as a expenditure as a percentage of Revenue) from
2001 onwards and applying an adjustment to the 2005 R&D expenditure and
adjusting for inflation. However the historic figure remains highly correlated to
the current figure (for 2006) and so the impact on the DEA results may be
limited as is the application or removal of input weight restrictions on the
relative weight of the current and historic R&D expenditure.
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B. Staff Data
B.1 Introduction
Some of the DEA models require the numbers of staff as an input. The model
input has been calculated by forming the arithmetic means of staff numbers
from 2001 to 2005, where that information is available; where not, estimates
are made from other sources. The primary data are summarised below.
B.2 Staff Data
The staff data are shown in Table B.1.
Table B.1 Staff Numbers
Company Staff
Staff
2005
Staff
2004
Staff
2003
Staff
2002
Staff
2001
Abbt 67155.6 59735 60617 72181 71819 71426
Akzo 64314 61340 61450 64580 67900 66300
Alco 12040 12700 12200 11900 11800 11600
Alle 5270.2 5055 5030 4930 4900 6436
Amg 12320 16500 14400 12900 10118 7682
Astel 11505.4 15000 15000 9062 9278 9187
Astr 60820 63500 64200 62600 59200 54600
Baus 12220 14000 12400 11600 11500 11600
195
Baxt 49780 47000 48000 51300 54600 48000
Baye 108060 93700 91700 115400 122600 116900
Biog 3777.667 3340 4266 3727
BMS 44000 43000 43000 44000 44000 46000
Boeh 33395.8 37406 35529 34221 31843 27980
Ceph 3851.75 3844 3851 3983 3729
Chug 5420.4 5357 5327 5680 5774 4964
CSL 10000
Daic 18605.5 18434 18777
Dain 3016.2 5142 2427 2480 2480 2552
Eisa 7953.8 9081 8295 7700 7433 7260
EliL 43100 42600 44500 45000 42900 40500
Fore 4624.8 5050 5136 4967 4240 3731
Gene 6727.4 9563 7646 6226 5252 4950
Genz 6325 8200 7000 5625 5600 5200
Gile 4000
GSK 102727 100728 100019 100919 104499 107470
John 109240 115600 109900 110600 108300 101800
196
King 2600
Kyow 6429.4 5800 5960 6294 6794 7299
Lund 4618 5155 5223 4534 3560
Merc 68540 61500 62600 63200 77300 78100
Merk 32202.8 29133 28877 34206 34504 34294
Mits 7138.8 5902 5917 6122 8733 9020
Nova 78970 90924 81392 78541 72877 71116
Novo 19038.8 22007 20285 18756 18005 16141
Nyco 12000
Pfiz 106200 106000 115000 122000 98000 90000
Roch 66309 68218 64594 65357 69659 63717
Sano 69942.8 97181 96439 93144 32436 30514
Schr 30780 32600 30500 30500 30500 29800
Shio 6285.2 4997 5522 5589 6149 9169
Shir 4000
Solv 29502 28730 26926 30139 30302 31413
Tais 5141.4 5191 5339 5477 4806 4894
Take 14645.8 15069 14510 14592 14547 14511
197
Teva 11606.6 14698 13813 10960 9576 8986
UCB 9804.2 8525 8598 11559 10326 10013
Wats 5830
Wyet 51713.6 49732 51401 52384 52762 52289
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C. Power Laws
C.1 Introduction
This appendix summarises the main features of a ‘power law’ and some of the
pitfalls in identifying a power law from empirical data. Power laws have
recently attracted attention by their apparent ubiquity; however this has now
been matched by a critical attitude to their identification. This appendix first
defines a power-law distribution and notes alternative distributions which might
also give rise to a similar ‘signature’, namely a straight line when the
distribution is plotted on a log/log scales. It concludes with a summary of the
relevance to the literature of this research and potential future work.
C.2 Definition of a Power Law
The characteristics of a power law are its scale invariance. To illustrate with
the simplest expression of a power law:
f(x) = k x a Eq. (C.1)
where x is an independent variable
k is a constant
a is a constant
If there is a scaling transformation given by:
y = c •.x Eq. (C.2)
where c is a constant
then:
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f(y) = c a • f(x) Eq. (C.3)
that is the functional form repaints the same with a change in scale. Eq. (C.1)
can be written in logarithmic form:
log f(x) = - a. log (x) + log (k) Eq. (C.4)
where x is an independent variable
k is a constant
a is a constant
Eq. (C.4) gives rise to a common means of identification of a power law, a
‘signature’, namely the observance of a straight line on a log/log graph.
Although this is a characteristic of a power law as defined above, two issues
arise.
The first is that power laws only apply for a range of variables and it is
necessary to establish the range over which the law holds. The second is that
other mathematical functions also can show a linear plot on a log/log graph
therefore it is necessary to eliminate these possibilities before a power law is
confirmed. These issues are now considered further.
C.3 Alternative Distributions
Clauset et al. (2009) considered four discrete and five continuous nonlinear
distributions, with the five continuous distributions were a power law; a power
law with cut-off, exponential, stretched exponential and log-normal.
After developing statistical testing methods using synthetic data, 24 actual
data sets which showed a straight-line log/log plot were tested in order to
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confirm a power law with empirical data. In only one case, the frequency of
words in the English language, could power law be confirmed and all other
possibilities excluded. In all but three cases the exponential could be excluded
but the log-normal and stretched exponential distributions were plausible
alternatives in nine cases. The authors then emphasise the importance of
looking at the underlying processes giving rise to the distribution rather than
relying on tests alone.
Farmer & Geanakoplos (2008) outlined several mechanisms for generating
power laws (as opposed to log-normal which are produced by multiplicative
processes) including maximisation of entropy (i.e. randomness), preferential
attachment (i.e. a quantity is allocated on the basis of how much is already
held) and critical systems (an example of a pile of sand is use to illustrate,
where a steady stream of sand will eventually lead to an avalanche of sand).
Mitzenmacher (2001) also considers generative models that produce both
power law and log-normal distributions.
C.4 Relevance to this Thesis
A linear plot on a log–log graph has been observed, which could represent
either a power law or log-normal behaviour. A plausible explanation for power-
law behaviour has been proposed by Park et al. (2010), namely self-
organising criticality (with an initial mega-merger leading to a cascade of
smaller events); the findings of the thesis are consistent with this hypothesis
but are not definitive in establishing a power law. Confirmation of that would
require further statistical analysis.
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D. DEA Model Data
Table D.1 DEA Model Inputs
Symbol for Input x1 x2 x3
Name of Firm Code R&D Expense
US$m, 2006
R&D Expense
US$m, Historic Mean
Staff
Numbers
Abbot
Laboratories
Abbt 2255 2208 67156
Akzo Nobell NV Akzo 741 676 64314
Alcon Inc. Alco 512 416 12040
Allergan Inc. Alle 1056 546 5270
Amgen Inc. Amg 3366 2615 12320
Astellas Pharma
Inc.
Astel 1435 1477 11505
AstraZeneca Plc Astr 3902 4066 60820
Bausch & Lomb
Inc.
Baus 197 175 12220
Baxter
International Inc.
Baxt 614 599 49780
Bayer AG Baye 1791 1511 108060
Biogen Idec Inc. Biog 718 747 3778
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Bristol Myers
Squibb Co.
BMS 3067 2558 44000
Boehringer
Ingelheim
Boeh 1977 1958 33396
Cephalon Ceph 403 330 3852
Chugai
Pharmaceutical
Chug 467 563 5420
CSL Ltd CSL 161 140 10000
Daiichi Sankyo
Co.
Daii 1459 1308 18606
Dainippon
Sumiformo
Dain 350 165 3016
Eisai Co. Eisa 926 663 7954
Eli Lilly and Co. EliL 3129 2898 43100
Forest
Pharmaceuticals
Fore 941 282 4625
Genentech Inc. Gene 1773 1874 6727
Genzyme Corp. Genz 650 578 6325
Gilead Sciences
Inc.
Gile 384 286 4000
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GlaxoSmithKline
Plc.
GSK 6373 5605 102727
Johnson &
Johnson
John 7125 5885 109240
King
Pharmaceuticals
King 254 271 2600
Kyowa Hakko
Kogyo
Kyow 268 247 6429
H Lundbeck Lund 329 290 4618
Merck & Co. Merc 4783 3179 68540
Merck KgaA Merk 772 487 32203
Mitsubishi
Pharma
Mits 403 391 7139
Novartis Nova 5349 4696 78970
Novo Nordisk As Novo 1063 927 19039
Nycomed Nyco 47 37 12000
Pfizer Inc. Pfiz 7599 8236 106200
Roche Roch 5258 4391 66309
Sanofi Aventis
Group
Sano 5565 4736 69943
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Schering-Plough
Corp.
Scher 2188 1606 30780
Shionogi & Co. Shio 320 243 6285
Shire Plc Shir 387 349 4000
Solvay SA Solv 533 436 29502
Taisho
Pharmaceutical
Tais 244 235 5141
Takeda
Pharmaceutical
Take 1620 1250 14646
Teva
Pharmaceutical
Teva 495 342 11607
UCB SA UCB 1024 626 9804
Watson
Pharmaceutical
Wats 131 129 5830
Wyeth Wyet 3109 2648 51714
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Table D.2 DEA Model Compounds (Comp.) Output Data
Symbol y5 y4 y3 y2 y1
Phase Awaiting
Approval
Phase 3
Comp.
Phase 2
Comp.
Phase 1
Comp.
Preclinical
Comp.
Abbt 3 9 7 11 10
Akzo 2 4 4 9 7
Alco 4 3 2 0 0
Alle 4 5 6 0 2
Amg 2 8 11 14 1
Astel 15 6 15 1 3
Astr 5 14 14 25 38
Baus 0 1 1 0 1
Baxt 0 1 1 0 2
Baye 9 15 16 14 2
Biog 1 8 11 1 10
BMS 9 7 4 8 1
Boeh 2 2 3 0 0
Ceph 1 5 5 0 4
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Chug 7 5 10 5 0
CSL 6 4 1 1 2
Daii 4 10 10 13 1
Dain 4 1 11 1 0
Eisa 8 7 7 8 2
EliL 6 11 21 12 8
Fore 3 4 3 0 3
Gene 1 13 12 15 3
Genz 6 8 8 8 8
Gile 2 3 1 2 3
GSK 23 24 30 40 1
John 8 23 8 8 1
King 1 4 3 0 0
Kyow 2 2 3 3 1
Lund 0 3 2 4 0
Merc 11 7 17 30 2
Merk 3 7 14 8 8
Mits 4 7 9 0 0
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Nova 15 30 28 26 9
Novo 2 5 5 6 0
Nyco 1 5 4 1 4
Pfiz 5 11 52 42 5
Roch 7 18 22 30 6
Sano 14 24 35 34 39
Scher 10 13 13 2 2
Shio 3 1 7 4 0
Shir 4 1 2 1 4
Solv 8 10 7 4 1
Tais 0 0 8 3 0
Take 7 14 12 5 1
Teva 0 5 6 0 4
UCB 4 7 4 0 1
Wats 2 2 0 1 0
Wyet 7 10 13 2 1
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Table D.3 DEA Model Clinical Trials Output Data
Sym-
bol
y5 y4 y3 y2 y1 Ratio Trials to Compounds
Phase
(Ph.)
Await
.Appr
(AA)
Ph. 3
(P3)
Ph. 2
(P2)
Ph. 1
(P1)
Precl
inic
(PC)
AA P3 P2 P1 PC
Abbt 8 10 10 15 11 2.67 1.11 1.43 1.36 1.10
Akzo 3 8 6 9 9 1.50 2.00 1.50 1.00 1.29
Alco 4 6 2 0 0 1.00 2.00 1.00
Alle 4 10 8 0 2 1.00 2.00 1.33 1.00
Amg 3 16 12 15 1 1.50 2.00 1.09 1.07 1.00
Astel 22 12 17 1 4 1.47 2.00 1.13 1.00 1.33
Astr 8 42 33 53 45 1.60 3.00 2.36 2.12 1.18
Baus 0 1 1 0 1 1.00 1.00 1.00
Baxt 0 1 1 1 2 1.00 1.00 1.00
Baye 11 24 32 15 2 1.22 1.60 2.00 1.07 1.00
Biog 3 24 18 1 11 3.00 3.00 1.64 1.00 1.10
BMS 11 14 8 9 1 1.22 2.00 2.00 1.13 1.00
Boeh 2 4 3 0 0 1.00 2.00 1.00
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Ceph 1 8 5 0 4 1.00 1.60 1.00 1.00
Chug 9 7 17 6 0 1.29 1.40 1.70 1.20
CSL 6 5 1 1 3 1.00 1.25 1.00 1.00 1.50
Daii 5 12 22 26 2 1.25 1.20 2.20 2.00 2.00
Dain 4 1 19 1 0 1.00 1.00 1.73 1.00
Eisa 10 12 24 10 2 1.25 1.71 3.43 1.25 1.00
EliL 7 19 28 12 12 1.17 1.73 1.33 1.00 1.50
Fore 4 5 4 0 4 1.33 1.25 1.33 1.33
Gene 1 46 21 20 4 1.00 3.54 1.75 1.33 1.33
Genz 6 12 10 10 10 1.00 1.50 1.25 1.25 1.25
Gile 4 3 2 3 4 2.00 1.00 2.00 1.50 1.33
GSK 27 35 87 49 1 1.17 1.46 2.90 1.23 1.00
John 15 48 9 9 1 1.88 2.09 1.13 1.13 1.00
King 1 4 7 0 0 1.00 1.00 2.33
Kyow 2 2 3 4 1 1.00 1.00 1.00 1.33 1.00
Lund 0 3 2 4 0 1.00 1.00 1.00
Merc 14 12 29 33 2 1.27 1.71 1.71 1.10 1.00
Merk 3 10 34 19 10 1.00 1.43 2.43 2.38 1.25
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Mits 5 11 11 0 0 1.25 1.57 1.22
Nova 21 42 38 30 10 1.40 1.40 1.36 1.15 1.11
Novo 7 7 9 11 0 3.50 1.40 1.80 1.83
Nyco 1 7 7 1 8 1.00 1.40 1.75 1.00 2.00
Pfiz 10 19 64 42 5 2.00 1.73 1.23 1.00 1.00
Roch 14 60 38 35 6 2.00 3.33 1.73 1.17 1.00
Sano 14 37 53 42 52 1.00 1.54 1.51 1.24 1.33
Scher 10 26 18 2 2 1.00 2.00 1.38 1.00 1.00
Shio 3 1 7 4 0 1.00 1.00 1.00 1.00
Shir 4 2 2 1 4 1.00 2.00 1.00 1.00 1.00
Solv 11 11 9 4 1 1.38 1.10 1.29 1.00 1.00
Tais 0 0 14 5 0 1.75 1.67
Take 8 23 29 10 1 1.14 1.64 2.42 2.00 1.00
Teva 0 6 8 0 4 1.20 1.33 1.00
UCB 6 13 6 0 1 1.50 1.86 1.50 1.00
Wats 2 2 0 1 0 1.00 1.00 1.00
Wyet 10 16 19 2 1 1.43 1.60 1.46 1.00 1.00
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Table D.4 DEA Efficiency Scores for Compounds as Outputs
Symbol ηk θk ek ln(ek) ln ((x1k +x2k)/2)
Firm VRS
Eff.
CRS
Eff.
Scale
Eff.
Log
Scale Eff.
Log Avg.
R&D
Abbt 53.3% 5.6% 10.5% -2.25494 7.711
Akzo 63.5% 11.4% 17.9% -1.7209 6.563
Alco 50.0% 22.6% 45.2% -0.79386 6.140
Alle 53.1% 15.8% 29.7% -1.21273 6.686
Amg 47.5% 4.5% 9.4% -2.36105 8.003
Astel 100.0% 27.9% 27.9% -1.27773 7.284
Astr 83.2% 7.1% 8.5% -2.46574 8.290
Baus 14.6% 4.6% 31.5% -1.15603 5.226
Baxt 10.7% 1.9% 17.9% -1.72307 6.408
Baye 100.0% 17.9% 17.9% -1.72284 7.409
Biog 78.5% 12.4% 15.8% -1.84477 6.596
BMS 55.1% 8.7% 15.8% -1.84215 7.942
Boeh 16.7% 3.0% 17.9% -1.72215 7.585
Ceph 55.9% 12.7% 22.7% -1.48295 5.903
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Chug 93.3% 41.2% 44.2% -0.81673 6.244
CSL 100.0% 100.0% 100.0% 0 5.014
Daii 77.1% 11.4% 14.8% -1.91103 7.233
Dain 97.2% 50.7% 52.2% -0.65005 5.550
Eisa 90.0% 29.4% 32.7% -1.1189 6.678
EliL 71.9% 7.5% 10.5% -2.25524 8.011
Fore 40.8% 16.4% 40.1% -0.91263 6.416
Gene 74.2% 9.0% 12.1% -2.10854 7.508
Genz 100.0% 30.4% 30.4% -1.19204 6.420
Gile 43.0% 17.9% 41.5% -0.87945 5.815
GSK 100.0% 12.0% 12.0% -2.12224 8.698
John 66.0% 4.2% 6.3% -2.7648 8.780
King 46.8% 15.2% 32.5% -1.12311 5.570
Kyow 38.6% 14.5% 37.6% -0.97846 5.552
Lund 41.4% 11.3% 27.3% -1.29768 5.734
Merc 75.8% 9.3% 12.3% -2.09723 8.289
Merk 100.0% 20.5% 20.5% -1.58451 6.445
Mits 92.3% 32.7% 35.5% -1.0367 5.984
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Nova 100.0% 10.2% 10.2% -2.28306 8.522
Novo 45.2% 7.8% 17.2% -1.75763 6.903
Nyco 100.0% 100.0% 100.0% 0 3.739
Pfiz 94.9% 5.6% 5.9% -2.83154 8.977
Roch 75.6% 6.2% 8.1% -2.50842 8.481
Sano 100.0% 9.8% 9.8% -2.31827 8.547
Scher 90.6% 15.5% 17.1% -1.76349 7.548
Shio 72.8% 33.2% 45.7% -0.78342 5.641
Shir 54.3% 28.4% 52.4% -0.64683 5.908
Solv 100.0% 46.8% 46.8% -0.75987 6.183
Tais 58.6% 18.1% 30.9% -1.1732 5.479
Take 91.2% 15.6% 17.1% -1.76728 7.269
Teva 52.0% 11.3% 21.7% -1.52662 6.037
UCB 55.7% 15.0% 27.0% -1.31015 6.715
Wats 43.8% 41.5% 94.9% -0.05219 4.867
Wyet 58.2% 7.4% 12.7% -2.06679 7.965
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Table D.5 DEA Efficiency Scores for Trials as Outputs
Symbol ηk θk ek ln(ek) ln ((x1k +x2k)/2)
Firm VRS
Eff.
CRS
Eff.
Scale
Eff.
Log
Scale Eff.
Log Avg.
R&D
Abbt 53.4% 21.0% 39.4% -0.93182 7.711
Akzo 56.2% 22.1% 39.4% -0.93184 6.563
Alco 54.8% 48.5% 88.6% -0.12149 6.140
Alle 72.5% 72.3% 99.8% -0.00152 6.686
Amg 52.5% 30.7% 58.4% -0.53722 8.003
Astel 100.0% 100.0% 100.0% 0 7.284
Astr 100.0% 47.7% 47.7% -0.7397 8.290
Baus 9.2% 8.7% 94.3% -0.0584 5.226
Baxt 7.8% 3.9% 49.4% -0.70459 6.408
Baye 100.0% 35.4% 35.4% -1.03815 7.409
Biog 100.0% 100.0% 100.0% 0 6.596
BMS 53.9% 25.8% 47.9% -0.73658 7.942
Boeh 14.1% 7.5% 53.1% -0.63236 7.585
Ceph 80.8% 67.7% 83.8% -0.17712 5.903
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Chug 100.0% 100.0% 100.0% 0 6.244
CSL 100.0% 100.0% 100.0% 0 5.014
Daii 84.5% 55.3% 65.5% -0.42351 7.233
Dain 100.0% 100.0% 100.0% 0 5.550
Eisa 100.0% 100.0% 100.0% 0 6.678
EliL 61.8% 27.7% 44.8% -0.80197 8.011
Fore 86.3% 85.7% 99.3% -0.0068 6.416
Gene 100.0% 100.0% 100.0% 0 7.508
Genz 98.0% 91.3% 93.1% -0.07112 6.420
Gile 77.6% 76.8% 99.0% -0.01027 5.815
GSK 100.0% 36.8% 36.8% -0.99975 8.698
John 88.4% 23.9% 27.0% -1.30784 8.780
King 100.0% 68.1% 68.1% -0.38465 5.570
Kyow 47.3% 42.5% 89.9% -0.10641 5.552
Lund 35.6% 33.3% 93.4% -0.06852 5.734
Merc 70.7% 23.3% 32.9% -1.11208 8.289
Merk 100.0% 78.5% 78.5% -0.2424 6.445
Mits 99.0% 98.0% 98.9% -0.01093 5.984
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Nova 99.1% 33.9% 34.2% -1.07342 8.522
Novo 58.8% 40.4% 68.7% -0.37484 6.903
Nyco 100.0% 100.0% 100.0% 0 3.739
Pfiz 70.4% 21.2% 30.1% -1.20163 8.977
Roch 100.0% 41.6% 41.6% -0.87618 8.481
Sano 100.0% 40.6% 40.6% -0.90077 8.547
Scher 91.5% 50.0% 54.6% -0.6047 7.548
Shio 57.9% 56.9% 98.2% -0.01797 5.641
Shir 68.9% 64.5% 93.7% -0.06514 5.908
Solv 100.0% 71.0% 71.0% -0.34217 6.183
Tais 100.0% 85.8% 85.8% -0.15332 5.479
Take 100.0% 66.6% 66.6% -0.40593 7.269
Teva 44.5% 36.4% 81.9% -0.19981 6.037
UCB 82.1% 75.3% 91.8% -0.08594 6.715
Wats 100.0% 52.9% 52.9% -0.63668 4.867
Wyet 55.9% 21.2% 38.0% -0.96742 7.965
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Table D.6 DEA Efficiency Scores for VRS for Alternative Input Assumptions
 ηk ηk
Firm Input:
R&D Only
Input:
R&D plus Staff
Abbt 53.3% 53.3%
Akzo 63.5% 63.5%
Alco 50.0% 53.0%
Alle 53.1% 76.1%
Amg 47.5% 75.3%
Astel 100.0% 100.0%
Astr 83.2% 83.2%
Baus 14.6% 14.8%
Baxt 10.7% 10.7%
Baye 100.0% 100.0%
Biog 78.5% 100.0%
BMS 55.1% 55.1%
Boeh 16.7% 16.9%
Ceph 55.9% 77.8%
Chug 93.3% 100.0%
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CSL 100.0% 100.0%
Daii 77.1% 86.0%
Dain 97.2% 100.0%
Eisa 90.0% 99.2%
EliL 71.9% 74.0%
Fore 40.8% 68.9%
Gene 74.2% 100.0%
Genz 100.0% 100.0%
Gile 43.0% 68.0%
GSK 100.0% 100.0%
John 66.0% 66.0%
King 46.8% 100.0%
Kyow 38.6% 57.8%
Lund 41.4% 47.6%
Merc 75.8% 77.5%
Merk 100.0% 100.0%
Mits 92.3% 100.0%
Nova 100.0% 100.0%
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Novo 45.2% 48.6%
Nyco 100.0% 100.0%
Pfiz 94.9% 94.9%
Roch 75.6% 76.0%
Sano 100.0% 100.0%
Scher 90.6% 93.1%
Shio 72.8% 80.9%
Shir 54.3% 76.5%
Solv 100.0% 100.0%
Tais 58.6% 68.6%
Take 91.2% 100.0%
Teva 52.0% 55.8%
UCB 55.7% 69.6%
Wats 43.8% 100.0%
Wyet 58.2% 59.1%
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Table D.7 ROS, ROA and SOA
Firm ROS (%) ROA (%) SOA
Abbt 7.64 6.17 0.81
AkzN 8.39 11.42 1.36
Alcn 27.53 26.26 0.95
Allg -4.16 -2.08 0.50
Amgn 20.68 9.62 0.47
Astel 11.79 8.50 0.72
AstrZ 22.83 23.04 1.01
BausL 0.65 1.85 2.85
Baxt 13.46 11.38 0.85
Bayr 6.06 6.29 1.04
Biog 12.20 2.50 0.20
Boeh 15.67 14.54 0.93
BrMS 8.85 7.74 0.87
Ceph 8.20 4.76 0.58
Chug 11.78 8.60 0.73
CSL 16.30 18.40 1.13
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Daic 9.47 6.89 0.73
Dain 6.26 5.20 0.83
Eisa 10.55 9.32 0.88
EliL 16.97 12.11 0.71
Fore 25.36 20.82 0.82
Gene 22.76 16.21 0.71
Genz -0.53 -0.10 0.18
Gild -39.30 -29.10 0.74
GSK 23.20 23.28 1.00
Hlun 12.00 10.11 0.84
John 20.73 17.74 0.86
King 14.53 8.68 0.60
Kyow 4.60 4.34 0.94
Merc 19.59 10.49 0.54
MerK 15.71 13.83 0.88
Mits 9.02 5.64 0.63
Nova 19.91 12.40 0.62
Novo 16.65 15.88 0.95
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Nyco -9.59 -0.91 0.09
Pfiz 39.98 17.01 0.43
RocH 18.74 11.70 0.62
Sano 14.12 5.47 0.39
Schr 10.79 7.96 0.74
Shio 11.58 5.53 0.48
Shir 15.50 8.30 0.54
Solv 8.42 8.25 0.98
Tais 13.22 5.66 0.43
Take 25.84 11.27 0.44
Teva 6.49 4.53 0.70
UCB 16.77 5.56 0.33
Wats -22.50 -0.12 0.01
Wyet 20.62 13.09 0.63
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Table D.8 SDV, Cost of Sales and NDV Data for Firms
DMU Ak Bk Ck Dk ak bk ck
Aggreg.
SDV
X-
border
SDV
X-
product
SDV
Cost of
Sales
Aggreg.
NDV
X-
border
NDV
X-
product
NDV
Abbt 11938 7674 3027 20759 0.58 0.37 0.15
AkzN 4452 4452 711 3245 1.37 1.37 0.22
Alcn 0 0 0 3549 0.00 0.00 0.00
Allg 490 0 230 3190 0.15 0.00 0.07
Amgn 18276 138 0 11318 1.61 0.01 0.00
Astl 0 0 0 6728 0.00 0.00 0.00
Astz 39021 39021 644 20412 1.91 1.91 0.03
Baus 1237 427 1009 2277 0.54 0.19 0.44
Baxt 2652 1055 801 8981 0.30 0.12 0.09
Bayr 14530 14530 10469 37750 0.38 0.38 0.28
Biog 0 0 0 2465 0.00 0.00 0.00
Boeh 0 0 0 11121 0.00 0.00 0.00
BrMS 8212 150 0 16329 0.50 0.01 0.00
Ceph 1998 810 0 1619 1.23 0.50 0.00
Chug 2590 0 0 2459 1.05 0.00 0.00
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CSL 1669 1669 0 2334 0.72 0.72 0.00
Daii 6290 0 0 6487 0.97 0.00 0.00
Dain 2224 0 0 1570 1.42 0.00 0.00
Eisi 265 265 0 4979 0.05 0.05 0.00
EliL 4381 0 0 13028 0.34 0.00 0.00
Fors 0 0 0 2988 0.00 0.00 0.00
Gene 408 0 0 7171 0.06 0.00 0.00
Genz 4710 107 250 3204 1.47 0.03 0.08
Gild 1396 0 0 4216 0.33 0.00 0.00
GSK 102218 10035 1453 32678 3.13 0.31 0.04
Hlun 236 0 236 1366 0.17 0.00 0.17
John 27524 489 5083 42271 0.65 0.01 0.12
King 5741 637 235 1700 3.38 0.37 0.14
Kyow 0 0 0 1590 0.00 0.00 0.00
Merc 6567 0 0 18202 0.36 0.00 0.00
MerK 2551 0 0 3917 0.65 0.00 0.00
Mits 0 0 0 1737 0.00 0.00 0.00
Nova 14629 14629 1859 29818 0.49 0.49 0.06
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Novo 0 0 0 5434 0.00 0.00 0.00
Nyco 0 0 0 4369 0.00 0.00 0.00
Pfiz 163448 7667 356 29034 5.63 0.26 0.01
RocH 25129 17138 2430 26229 0.96 0.65 0.09
Sano 71858 0 0 30612 2.35 0.00 0.00
Sche 1572 1167 405 9537 0.16 0.12 0.04
Shio 120 120 0 1481 0.08 0.08 0.00
Shir 6528 6528 0 1519 4.30 4.30 0.00
Slvy 112 0 0 2242 0.05 0.00 0.00
Tais 0 0 0 1937 0.00 0.00 0.00
Take 270 270 0 7414 0.04 0.04 0.00
Teva 3988 0 0 7862 0.51 0.00 0.00
UCBs 2973 2973 0 3934 0.76 0.76 0.00
Wats 2259 0 0 2424 0.93 0.00 0.00
Wyet 0 0 0 16154 0.00 0.00 0.00
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Table D.9 NDV and Pure Technical Efficiency (Base Model)
Firm VRS
Efficiency
ak
θk <M
ak
θk >M
bk
θk <M
bk
θk >M
ck
θk <M
ck
θk >M
Abbt 53.3% 0.58 0.37 0.15
AkzN 63.5% 1.37 1.37 0.22
Alcn 50.0% 0.00 0.00 0.00
Allg 53.1% 0.15 0.00 0.07
Amgn 47.5% 1.61 0.01 0.00
Astel 100.0% 0.00 0.00 0.00
AstrZ 83.2% 1.91 1.91 0.03
BausL 14.6% 0.54 0.19 0.44
Baxt 10.7% 0.30 0.12 0.09
Bayr 100.0% 0.38 0.38 0.28
Biog 78.5% 0.00 0.00 0.00
Boeh 55.1% 0.00 0.00 0.00
BrMS 16.7% 0.50 0.01 0.00
Ceph 55.9% 1.23 0.50 0.00
Chug 93.3% 1.05 0.00 0.00
CSL 100.0% 0.72 0.72 0.00
Daic 77.1% 0.97 0.00 0.00
Dain 97.2% 1.42 0.00 0.00
Eisa 90.0% 0.05 0.05 0.00
EliL 71.9% 0.34 0.00 0.00
Fore 40.8% 0.00 0.00 0.00
Gene 74.2% 0.06 0.00 0.00
Genz 100.0% 1.47 0.03 0.08
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Gild 43.0% 0.33 0.00 0.00
GSK 100.0% 3.13 0.31 0.04
Hlun 66.0% 0.17 0.00 0.17
John 46.8% 0.65 0.01 0.12
King 38.6% 3.38 0.37 0.14
Kyow 41.4% 0.00 0.00 0.00
Merc 75.8% 0.36 0.00 0.00
MerK 100.0% 0.65 0.00 0.00
Mits 92.3% 0.00 0.00 0.00
Nova 100.0% 0.49 0.49 0.06
Novo 45.2% 0.00 0.00 0.00
Nyco 100.0% 0.00 0.00 0.00
Pfiz 94.9% 5.63 0.26 0.01
RocH 75.6% 0.96 0.65 0.09
Sano 100.0% 2.35 0.00 0.00
Schr 90.6% 0.16 0.12 0.04
Shio 72.8% 0.08 0.08 0.00
Shir 54.3% 4.30 4.30 0.00
Solv 100.0% 0.05 0.00 0.00
Tais 58.6% 0.00 0.00 0.00
Take 91.2% 0.04 0.04 0.00
Teva 52.0% 0.51 0.00 0.00
UCB 55.7% 0.76 0.76 0.00
Wats 43.8% 0.93 0.00 0.00
Wyet 58.2% 0.00 0.00 0.00
Mean 0.74 0.91 0.33 0.21 0.06 0.03
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Table D.10 NDV and Pure Technical Efficiency (Staff Input)
Firm VRS
Efficiency
ak
θk <M
ak
θk >M
bk
θk <M
bk
θk >M
ck
θk <M
ck
θk >M
Abbt 53.3% 0.58 0.37 0.15
AkzN 63.5% 1.37 1.37 0.22
Alcn 53.0% 0.00 0.00 0.00
Allg 76.1% 0.15 0.00 0.07
Amgn 75.3% 1.61 0.01 0.00
Astel 100.0% 0.00 0.00 0.00
AstrZ 83.2% 1.91 1.91 0.03
BausL 14.8% 0.54 0.19 0.44
Baxt 10.7% 0.30 0.12 0.09
Bayr 100.0% 0.38 0.38 0.28
Biog 100.0% 0.00 0.00 0.00
Boeh 55.1% 0.00 0.00 0.00
BrMS 16.9% 0.50 0.01 0.00
Ceph 77.8% 1.23 0.50 0.00
Chug 100.0% 1.05 0.00 0.00
CSL 100.0% 0.72 0.72 0.00
Daic 86.0% 0.97 0.00 0.00
Dain 100.0% 1.42 0.00 0.00
Eisa 99.2% 0.05 0.05 0.00
EliL 74.0% 0.34 0.00 0.00
Fore 68.9% 0.00 0.00 0.00
Gene 100.0% 0.06 0.00 0.00
Genz 100.0% 1.47 0.03 0.08
Gild 68.0% 0.33 0.00 0.00
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GSK 100.0% 3.13 0.31 0.04
Hlun 66.0% 0.17 0.00 0.17
John 100.0% 0.65 0.01 0.12
King 57.8% 3.38 0.37 0.14
Kyow 47.6% 0.00 0.00 0.00
Merc 77.5% 0.36 0.00 0.00
MerK 100.0% 0.65 0.00 0.00
Mits 100.0% 0.00 0.00 0.00
Nova 100.0% 0.49 0.49 0.06
Novo 48.6% 0.00 0.00 0.00
Nyco 100.0% 0.00 0.00 0.00
Pfiz 94.9% 5.63 0.26 0.01
RocH 76.0% 0.96 0.65 0.09
Sano 100.0% 2.35 0.00 0.00
Schr 93.1% 0.16 0.12 0.04
Shio 80.9% 0.08 0.08 0.00
Shir 76.5% 4.30 4.30 0.00
Solv 100.0% 0.05 0.00 0.00
Tais 68.6% 0.00 0.00 0.00
Take 100.0% 0.04 0.04 0.00
Teva 55.8% 0.51 0.00 0.00
UCB 69.6% 0.76 0.76 0.00
Wats 100.0% 0.93 0.00 0.00
Wyet 59.1% 0.00 0.00 0.00
Mean 0.72 0.92 0.36 0.18 0.06 0.03
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Table D.11 SDV and Pure Technical Efficiency (Base Model)
Firm VRS
Efficiency
Ak
θk <M
Ak
θk >M
Bk
θk <M
Bk
θk >M
Ck
θk <M
Ck
θk >M
Abbt 53.3% 11938 7674 3027
AkzN 63.5% 4452 4452 711
Alcn 53.0% 0 0 0
Allg 76.1% 490 0 230
Amgn 75.3% 18276 138 0
Astel 100.0% 0 0 0
AstrZ 83.2% 39021 39021 644
BausL 14.8% 1237 427 1009
Baxt 10.7% 2652 1055 801
Bayr 100.0% 14530 14530 10469
Biog 100.0% 0 0 0
Boeh 55.1% 0 0 0
BrMS 16.9% 8212 150 0
Ceph 77.8% 1998 810 0
Chug 100.0% 2590 0 0
CSL 100.0% 1669 1669 0
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Daic 86.0% 6290 0 0
Dain 100.0% 2224 0 0
Eisa 99.2% 265 265 0
EliL 74.0% 4381 0 0
Fore 68.9% 0 0 0
Gene 100.0% 408 0 0
Genz 100.0% 4710 107 250
Gild 68.0% 1396 0 0
GSK 100.0% 102218 10035 1453
Hlun 66.0% 236 0 236
John 100.0% 27524 489 5083
King 57.8% 5741 637 235
Kyow 47.6% 0 0 0
Merc 77.5% 6567 0 0
MerK 100.0% 2551 0 0
Mits 100.0% 0 0 0
Nova 100.0% 14629 14629 1859
Novo 48.6% 0 0 0
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Nyco 100.0% 0 0 0
Pfiz 94.9% 163448 7667 356
RocH 76.0% 25129 17138 2430
Sano 100.0% 71858 0 0
Schr 93.1% 1572 1167 405
Shio 80.9% 120 120 0
Shir 76.5% 6528 6528 0
Solv 100.0% 112 0 0
Tais 68.6% 0 0 0
Take 100.0% 270 270 0
Teva 55.8% 3988 0 0
UCB 69.6% 2973 2973 0
Wats 100.0% 2259 0 0
Wyet 59.1% 0 0 0
Mean 4345 19174 1056 4442 472 744
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Table D.12 Association of NDV and ROS
Firm ROS a’k
rk <M
a’k
rk >M
b’k
rk <M
b’k
rk >M
c’k
rk <M
c’k
rk >M
Abbt 7.64 0.58 0.37 0.15
AkzN 8.39 1.37 1.37 0.22
Alcn 27.53 0.00 0.00 0.00
Allg -4.16 0.15 0.00 0.07
Amgn 20.68 1.61 0.01 0.00
Astel 11.79 0.00 0.00 0.00
AstrZ 22.83 1.91 1.91 0.03
BausL 0.65 0.54 0.19 0.44
Baxt 13.46 0.30 0.12 0.09
Bayr 6.06 0.38 0.38 0.28
Biog 12.20 0.00 0.00 0.00
Boeh 15.67 0.00 0.00 0.00
BrMS 8.85 0.50 0.01 0.00
Ceph 8.20 1.23 0.50 0.00
Chug 11.78 1.05 0.00 0.00
CSL 16.30 0.72 0.72 0.00
Daic 9.47 0.97 0.00 0.00
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Dain 6.26 1.42 0.00 0.00
Eisa 10.55 0.05 0.05 0.00
EliL 16.97 0.34 0.00 0.00
Fore 25.36 0.00 0.00 0.00
Gene 22.76 0.06 0.00 0.00
Genz -0.53 1.47 0.03 0.08
Gild -39.30 0.33 0.00 0.00
GSK 23.20 3.13 0.31 0.04
Hlun 12.00 0.17 0.00 0.17
John 20.73 0.65 0.01 0.12
King 14.53 3.38 0.37 0.14
Kyow 4.60 0.00 0.00 0.00
Merc 19.59 0.36 0.00 0.00
MerK 15.71 0.65 0.00 0.00
Mits 9.02 0.00 0.00 0.00
Nova 19.91 0.49 0.49 0.06
Novo 16.65 0.00 0.00 0.00
Nyco -9.59 0.00 0.00 0.00
Pfiz 39.98 5.63 0.26 0.01
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RocH 18.74 0.96 0.65 0.09
Sano 14.12 2.35 0.00 0.00
Schr 10.79 0.16 0.12 0.04
Shio 11.58 0.08 0.08 0.00
Shir 15.50 4.30 4.30 0.00
Solv 8.42 0.05 0.00 0.00
Tais 13.22 0.00 0.00 0.00
Take 25.84 0.04 0.04 0.00
Teva 6.49 0.51 0.00 0.00
UCB 16.77 0.76 0.76 0.00
Wats -22.50 0.93 0.00 0.00
Wyet 20.62 0.00 0.00 0.00
Mean 0.50 1.15 0.13 0.41 0.06 0.02
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Table D.13 Association of NDV and ROA
Firm ROA a’k
rk <M
a’k
rk >M
b’k
rk <M
b’k
rk >M
c’k
rk <M
c’k
rk >M
Abbt 6.17 0.58 0.37 0.15
AkzN 11.42 1.37 1.37 0.22
Alcn 26.26 0.00 0.00 0.00
Allg -2.08 0.15 0.00 0.07
Amgn 9.62 1.61 0.01 0.00
Astel 8.50 0.00 0.00 0.00
AstrZ 23.04 1.91 1.91 0.03
BausL 1.85 0.54 0.19 0.44
Baxt 11.38 0.30 0.12 0.09
Bayr 6.29 0.38 0.38 0.28
Biog 2.50 0.00 0.00 0.00
Boeh 14.54 0.00 0.00 0.00
BrMS 7.74 0.50 0.01 0.00
Ceph 4.76 1.23 0.50 0.00
Chug 8.60 1.05 0.00 0.00
CSL 18.40 0.72 0.72 0.00
Daic 6.89 0.97 0.00 0.00
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Dain 5.20 1.42 0.00 0.00
Eisa 9.32 0.05 0.05 0.00
EliL 12.11 0.34 0.00 0.00
Fore 20.82 0.00 0.00 0.00
Gene 16.21 0.06 0.00 0.00
Genz -0.10 1.47 0.03 0.08
Gild -29.10 0.33 0.00 0.00
GSK 23.28 3.13 0.31 0.04
Hlun 10.11 0.17 0.00 0.17
John 17.74 0.65 0.01 0.12
King 8.68 3.38 0.37 0.14
Kyow 4.34 0.00 0.00 0.00
Merc 10.49 0.36 0.00 0.00
MerK 13.83 0.65 0.00 0.00
Mits 5.64 0.00 0.00 0.00
Nova 12.40 0.49 0.49 0.06
Novo 15.88 0.00 0.00 0.00
Nyco -0.91 0.00 0.00 0.00
Pfiz 17.01 5.63 0.26 0.01
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RocH 11.70 0.96 0.65 0.09
Sano 5.47 2.35 0.00 0.00
Schr 7.96 0.16 0.12 0.04
Shio 5.53 0.08 0.08 0.00
Shir 8.30 4.30 4.30 0.00
Solv 8.25 0.05 0.00 0.00
Tais 5.66 0.00 0.00 0.00
Take 11.27 0.04 0.04 0.00
Teva 4.53 0.51 0.00 0.00
UCB 5.56 0.76 0.76 0.00
Wats -0.12 0.93 0.00 0.00
Wyet 13.09 0.00 0.00 0.00
Mean 0.70 0.95 0.28 0.26 0.044 0.041
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Table D.14 Association of Acquisition History and SOA
Firm SOA a’k
rk <M
a’k
rk >M
b’k
rk <M
b’k
rk >M
c’k
rk <M
c’k
rk >M
Abbt 0.81 0.58 0.37 0.15
AkzN 1.36 1.37 1.37 0.22
Alcn 0.95 0.00 0.00 0.00
Allg 0.50 0.15 0.00 0.07
Amgn 0.47 1.61 0.01 0.00
Astel 0.72 0.00 0.00 0.00
AstrZ 1.01 1.91 1.91 0.03
BausL 2.85 0.54 0.19 0.44
Baxt 0.85 0.30 0.12 0.09
Bayr 1.04 0.38 0.38 0.28
Biog 0.20 0.00 0.00 0.00
Boeh 0.93 0.00 0.00 0.00
BrMS 0.87 0.50 0.01 0.00
Ceph 0.58 1.23 0.50 0.00
Chug 0.73 1.05 0.00 0.00
CSL 1.13 0.72 0.72 0.00
Daic 0.73 0.97 0.00 0.00
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Dain 0.83 1.42 0.00 0.00
Eisa 0.88 0.05 0.05 0.00
EliL 0.71 0.34 0.00 0.00
Fore 0.82 0.00 0.00 0.00
Gene 0.71 0.06 0.00 0.00
Genz 0.18 1.47 0.03 0.08
Gild 0.74 0.33 0.00 0.00
GSK 1.00 3.13 0.31 0.04
Hlun 0.84 0.17 0.00 0.17
John 0.86 0.65 0.01 0.12
King 0.60 3.38 0.37 0.14
Kyow 0.94 0.00 0.00 0.00
Merc 0.54 0.36 0.00 0.00
MerK 0.88 0.65 0.00 0.00
Mits 0.63 0.00 0.00 0.00
Nova 0.62 0.49 0.49 0.06
Novo 0.95 0.00 0.00 0.00
Nyco 0.09 0.00 0.00 0.00
Pfiz 0.43 5.63 0.26 0.01
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RocH 0.62 0.96 0.65 0.09
Sano 0.39 2.35 0.00 0.00
Schr 0.74 0.16 0.12 0.04
Shio 0.48 0.08 0.08 0.00
Shir 0.54 4.30 4.30 0.00
Solv 0.98 0.05 0.00 0.00
Tais 0.43 0.00 0.00 0.00
Take 0.44 0.04 0.04 0.00
Teva 0.70 0.51 0.00 0.00
UCB 0.33 0.76 0.76 0.00
Wats 0.01 0.93 0.00 0.00
Wyet 0.63 0.00 0.00 0.00
Mean 1.03 0.62 0.31 0.23 0.02 0.07
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E. Acquisition Data
E.1 Introduction
The Thomson Banker database was the source of acquisition data. The
search criteria used are explained below and an annual analysis of the
acquisitions that arose is then presented. There is then a record of each
acquisition, characterised by date, value, and the sector and nation of the
acquirer and acquired company, sorted by eventual 'surviving' parent.
E.2 Search Criteria
The search criteria are shown in Table E.1
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Table E.1 Database Search Criteria
Request Operator Description Hits
Acquirer NAIC
(Code)
Include Medicinal and Botanical
Manufacturing
Pharmaceutical Preparation
Manufacturing
In-Vitro Diagnostic Substance
Manufacturing
Biological Product (except
Diagnostic) Manufacturing
13500
Acquirer Ultimate
Parent Primary
NAIC (Code)
Include Medicinal and Botanical
Manufacturing
Pharmaceutical Preparation
Manufacturing
In-Vitro Diagnostic Substance
Manufacturing
Biological Product (except
Diagnostic) Manufacturing
8906
Logical Set Request # 2
UNION Request # 3
13500
Date Effective/
Unconditional
Between 01/01/1993 to 31/12/2006 5816
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Ranking Value inc.
Net Debt of Target
($Mil)
Between 100 to HI 699
Per cent of Shares
Owned after
Transaction
Between 51 to HI 591
Four sectors have been chosen for the analysis namely Medicinal and
Botanical Manufacturing, Pharmaceutical Preparation Manufacturing, In-Vitro
Diagnostic Substance Manufacturing, and Biological Product (except
Diagnostic) Manufacturing. The acquisitions of interest are when the acquiring
firm or the ultimate acquiring firm fall within these sectors. There are 13,500
such deals.
The period of the analysis was from the start of 1993 to the end of 2006. This
reduces the numbers of deals within the criteria to 5,818. A threshold of the
deal value being above $100million was also set, reducing the number of
deals to 689. Finally, only deals leading to majority control were considered,
reducing the deal total to 591.
E.3 Annual Analysis
A breakdown of deals by year is given in Table E.2.
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Table E.2 Date Analysis
Date Value ($Mil) Share (%) No. Deals
1992 1,022.75 0.1 3
1993 8,962.57 1.0 13
1994 36,332.34 3.9 24
1995 31,792.50 3.4 24
1996 13,501.48 1.5 34
1997 25,894.22 2.8 36
1998 62,700.57 6.7 40
1999 145,714.96 15.7 42
2000 116,194.32 12.5 49
2001 65,090.71 7.0 46
2002 72,760.70 7.8 37
2003 33,593.12 3.6 48
2004 105,818.15 11.4 51
2005 137,117.64 14.8 82
2006 72,537.12 7.8 62
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Industry Total 929,033.13 100.0 591
The period of analysis encompasses both the peak of a merger wave and the
trough at its beginning.
E.4 Detailed Merger Data
The detailed merger data are provided along with an initial analysis. The
columns are described below:
 The first three columns provide details of the acquirer, the fourth and fifth
the value and date of the deal, and next three columns the details of the
acquired firm.
 There then follows three columns of analysis, namely whether the
acquisition can be traced to one of the Top 48 companies in the analysis
and whether it is a cross-border or cross-sector deal (a ‘1’ signifies that
this is the case).
 The next three columns give the values of the deals that are included in
the three cases.
The data in Table E.3 are presented in a table overleaf in landscape format.
Table E.3 Detailed Merger Data
Key:
Column Title Meaning
A Acquirer Name The name of the acquiring company
B Acquirer NAIC The NAIC code of the acquiring company
C Acquirer Nation The location of the acquiring company
D Value ($m) The value of the deal in US$ (million)
E Date The date of the transaction
F Target Name The name of the acquired company
G Target NAIC The NAIC code of the acquired company
H Target Nation The location of the acquired company
I Code The abbreviated code given to the acquirer for the subtotal analysis
J Ag Value equals 1 if the deal is part of the aggregate total
K Xb Value equals 1 if the deal is a cross-border total
L Xs Value equals 1 if the deal is a cross-sector total
M V(Ag) Value of deal if part of aggregate total
N V(Xb) Value of deal if part of cross-border total
O V(Xs) Value of deal if part of cross-sector total
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A B C D E F G H I J K L M N O
Acquirer Name Acquirer NAIC Acquirer
Nation
Value ($m) Date Target Name Target NAIC Target
Nation
Code Ag Xb Xs V(Ag) V(Xb) V(Xs)
3M Co Surgical and medical
instruments and apparatus
United States 1403 02/08/05 Cuno Inc Fluid power pumps and motors United States
3M Co Surgical and medical
instruments and apparatus
United States 140 02/03/04 Hornell
International AB
Ophthalmic goods Sweden
3M Co Surgical and medical
instruments and apparatus
United States 850 13/12/02 Corning Precision
Lens Inc
Plastics products, nec United States
Abbott Laboratories Pharmaceutical preparations United States 320 17/11/04 Experimental &
Applied Science
Food preparations, nec United States 1 1 320 320
Abbott Laboratories Pharmaceutical preparations United States 1170 06/04/04 TheraSense Inc Surgical and medical instruments
and apparatus
United States 1 1 1170 1170
Abbott Laboratories Pharmaceutical preparations United States 407 30/01/04 i-Stat Corp Surgical and medical instruments
and apparatus
United States 1 1 407 407
Abbott Laboratories Pharmaceutical preparations United States 160 27/08/03 ZonePerfect
Nutrition Co
Cereal breakfast foods United States 1 1 160 160
Abbott Laboratories Pharmaceutical preparations United States 210 30/06/03 Spinal Concepts
Inc
Orthopedic, prosthetic, and
surgical supplies
United States 1 1 210 210
Abbott Laboratories Pharmaceutical preparations United States 252 31/05/02 Hokuriku Seiyaku
Co Ltd
Pharmaceutical preparations Japan 1 1 252 252
Abbott Laboratories Pharmaceutical preparations United States 234 08/05/02 Biocompatibles Int-
Cardio Bus
Pharmaceutical preparations United
Kingdom
1 1 234 234
Abbott Laboratories Pharmaceutical preparations United States 355 05/12/01 Vysis Inc(BP PLC) In vitro and in vivo diagnostic
substances
United States 1 355
Abbott Laboratories Pharmaceutical preparations United States 6900 02/03/01 Knoll AG(BASF
AG)
Pharmaceutical preparations Germany 1 1 6900 6900
Abbott Laboratories Pharmaceutical preparations United States 640 19/11/99 Perclose Inc Surgical and medical instruments
and apparatus
United States 1 1 640 640
Abbott Laboratories Pharmaceutical preparations United States 167 10/07/98 International Murex
Tech Corp
In vitro and in vivo diagnostic
substances
Canada 1 1 167 167
Abbott Laboratories Pharmaceutical preparations United States 200 01/05/97 Sanofi
Pharmaceuticals-
Parente
Pharmaceutical preparations United States 1 200
Abbott Laboratories Pharmaceutical preparations United States 802 07/08/96 MediSense Inc In vitro and in vivo diagnostic
substances
United States 1 802
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Abbott Laboratories Pharmaceutical preparations United States 120 14/12/94 Puleva-Nutrition
Division
Fluid milk Spain 1 1 1 120 120 120
Abbt 14 5 7 11938 7674 3027
Actavis Group hf Pharmaceutical preparations Iceland 810 19/12/05 Alpharma Inc-
Generics Business
Pharmaceutical preparations United States
Actavis Group hf Pharmaceutical preparations Iceland 600 28/07/05 Amide
Pharmaceutical Inc
Pharmaceutical preparations United States
Actelion Pharmaceuticals
Ltd
Pharmaceutical preparations Switzerland 191 13/10/03 Axovan AG Pharmaceutical preparations Switzerland
Advanced Medical Inc Pharmaceutical preparations United States 400 26/11/96 IVAC Corp Surgical and medical instruments
and apparatus
United States
Affymetrix Inc Laboratory analytical
instruments
United States 114 21/10/05 ParAllele
BioScience Inc
Commercial physical and
biological research
United States
Ajinomoto Co Inc Flavoring extracts and flavoring
syrups, nec
Japan 183 02/12/02 Shimizu
Pharmaceutical Co
Pharmaceutical preparations Japan
Akzo Nobel NV Paints, varnishes, lacquers, &
allied products
Netherlands 711 26/11/99 Hoechst Roussel
Vet
Pharmaceutical preparations Germany 1 1 1 711 711 711
Akzo Nobel NV Paints, varnishes, lacquers, &
allied products
Netherlands 3741 07/07/98 Courtaulds PLC Cellulosic manmade fibers United
Kingdom
1 1 3741 3741
AkzN 2 2 1 4452 4452 711
Alkermes Inc Biological products, except
diagnostic substances
United States 115 01/02/99 Advanced
Inhalation
Research
Pharmaceutical preparations United States
Allergan Inc Pharmaceutical preparations United States 230 20/11/03 Oculex
Pharmaceuticals
Inc
Surgical and medical instruments
and apparatus
United States 1 1 230 230
Allergan Inc Pharmaceutical preparations United States 260 16/05/03 Bardeen Sciences
Co LLC
Pharmaceutical preparations United States 1 260
Allg 2 0 1 490 0 230
Alpharma Inc Pharmaceutical preparations United States 660 12/12/01 FH Faulding & Co-
Oral Pharma
Pharmaceutical preparations United States
Alpharma Inc Pharmaceutical preparations United States 300 02/05/00 Roche Hldg-Animal
Drug Bus
Pharmaceutical preparations United States
Alpharma Inc Pharmaceutical preparations United States 152 18/06/99 Isis Pharma
GmbH(Schwarz)
Pharmaceutical preparations Germany
Alpharma Inc Pharmaceutical preparations United States 198 07/05/98 Arthur H Cox & Co
Ltd(Hoechst)
Pharmaceutical preparations United
Kingdom
Altana Chemie AG Chemicals and chemical
preparations, nec
Germany 769 01/10/05 Eckart GmbH & Co
KG
Inorganic pigments Germany
ALZA Corp Pharmaceutical preparations United States 557 17/03/99 SEQUUS
Pharmaceuticals
Inc
Pharmaceutical preparations United States
249
ALZA Corp Pharmaceutical preparations United States 100 26/08/97 Therapeutic
Discovery Corp
Commercial physical and
biological research
United States
American Cyanamid Co Chemicals and chemical
preparations, nec
United States 742 03/06/93 Immunex Corp Biological products, except
diagnostic substances
United States
American Home Products
Corp
Pharmaceutical preparations United States 449 21/03/97 Solvay Duphar
BV(Solvay SA)
Pharmaceutical preparations Netherlands
American Home Products
Corp
Pharmaceutical preparations United States 1006 17/12/96 Genetics Institute
Inc
Pharmaceutical preparations United States
American Home Products
Corp
Pharmaceutical preparations United States 10054 21/12/94 American
Cyanamid Co
Chemicals and chemical
preparations, nec
United States
American Pacific Corp Chemicals and chemical
preparations, nec
United States 119 30/11/05 Aerojet Fine
Chemicals LLC
Pharmaceutical preparations United States
American Tropical Plants
Inc
Medicinal chemicals and
botanical products
United States 105 30/01/98 OPM-USA Inc Radio & TV broadcasting &
communications equipment
United States
Amersham International
PLC
Biological products, except
diagnostic substances
United
Kingdom
1345 22/10/97 Nycomed ASA Pharmaceutical preparations Denmark
Amersham Life Science Biological products, except
diagnostic substances
United
Kingdom
202 21/09/98 Molecular
Dynamics Inc
Laboratory analytical instruments United States
Amersham Life Science Biological products, except
diagnostic substances
United
Kingdom
373 06/08/97 Pharmacia Biotech
AB
Pharmaceutical preparations Sweden
Amersham PLC Biological products, except
diagnostic substances
United
Kingdom
1000 21/03/02 Amersham
Biosciences AB
Biological products, except
diagnostic substances
Sweden
Amgen Inc Biological products, except
diagnostic substances
United States 1285 13/08/04 Tularik Inc Pharmaceutical preparations United States 1 1285
Amgen Inc Biological products, except
diagnostic substances
United States 16685 16/07/02 Immunex Corp Biological products, except
diagnostic substances
United States 1 16685
Amgen Inc Biological products, except
diagnostic substances
United States 138 31/05/02 Roche-Filgrastm &
Pegrilgrastm
Pharmaceutical preparations Switzerland 1 1 138 138
Amgen Inc Biological products, except
diagnostic substances
United States 169 14/12/00 Kinetix
Pharmaceuticals
Inc
Biological products, except
diagnostic substances
United States 1 169
Amgn 4 1 0 18276 138 0
Arch Chemicals Inc Chemicals and chemical
preparations, nec
United States 219 05/04/04 Avecia Inc Chemicals and chemical
preparations, nec
United States
Arch Chemicals Inc Chemicals and chemical
preparations, nec
United States 184 22/08/00 Hickson
International PLC
Plastics materials and synthetic
resins
United
Kingdom
Arris Pharmaceuticals Corp Pharmaceutical preparations United States 170 09/01/98 Sequana
Therapeutics
In vitro and in vivo diagnostic
substances
United States
Asahi Breweries Ltd Malt beverages Japan 151 02/09/02 Kyowa Hakko
Kogyo-Alcohol Sale
Beer and ale Japan
Astra AB Pharmaceutical preparations Sweden 6090 01/07/98 Astra Merck
Inc(Merck & Co)
Drugs, drug proprietaries, and
druggists' sundries
United States 1 1 6090 6090
Astra AB Pharmaceutical preparations Sweden 320 16/05/95 Fisons PLC-
Pharmaceutical
Commercial physical and
biological research
United
Kingdom
1 1 320 320
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ZENECA Group PLC Pharmaceutical preparations United
Kingdom
31774 06/04/99 Astra AB Pharmaceutical preparations Sweden 1 1 31774 31774
ZENECA Group PLC Pharmaceutical preparations United
Kingdom
193 04/09/98 Orica Ltd-Pharm
Business
Pharmaceutical preparations Australia 1 1 193 193
ZENECA Group PLC Pharmaceutical preparations United
Kingdom
410 04/02/98 Ishihara Sangyo
Kaisha Ltd-US
Pesticides and agricultural
chemicals, nec
United States 1 1 1 410 410 410
ZENECA Group PLC Pharmaceutical preparations United
Kingdom
234 14/04/97 Salick Health Care
Inc
Kidney dialysis centers United States 1 1 1 234 234 234
AstrZ 6 6 2 39021 39021 644
Axcan Pharma Inc Pharmaceutical preparations Canada 145 18/11/03 Aventis SA-
Carafete,4 Others
Pharmaceutical preparations United States
Axcan Pharma Inc Pharmaceutical preparations Canada 108 30/09/99 Scandipharm Inc Drugs, drug proprietaries, and
druggists' sundries
United States
Barr Laboratories Inc Pharmaceutical preparations United States 638 24/10/01 Duramed
Pharmaceuticals
Inc
Pharmaceutical preparations United States
Bausch & Lomb Inc Ophthalmic goods United States 200 26/09/05 Sino Concept
Technology Ltd
Investors, nec Hong Kong 1 1 1 200 200 200
Bausch & Lomb Inc Ophthalmic goods United States 227 08/08/00 Chauvin Pharmaceutical preparations France 1 1 227 227
Bausch & Lomb Inc Ophthalmic goods United States 380 05/01/98 Storz Instrument
Co
Surgical and medical instruments
and apparatus
United States 1 1 380 380
Bausch & Lomb Inc Ophthalmic goods United States 300 29/12/97 Chiron
Vision(Chiron
Corp)
Surgical and medical instruments
and apparatus
United States 1 1 300 300
Bausch & Lomb Inc Ophthalmic goods United States 129 02/08/93 Dahlberg Inc Orthopedic, prosthetic, and
surgical supplies
United States 1 1 129 129
BausL 5 2 4 1237 427 1009
Baxter Healthcare Corp Pharmaceutical preparations United States 305 20/12/02 Wyeth-Certain ESI
Lederle Asts
Pharmaceutical preparations United States 1 305
Baxter Healthcare Corp Pharmaceutical preparations United States 219 20/08/01 Cook
Pharmaceutical
Solutions
Pharmaceutical preparations United States 1 219
Baxter International Inc Biological products, except
diagnostic substances
United States 148 05/05/02 Fusion Medical
Technologies
Surgical and medical instruments
and apparatus
United States 1 1 148 148
Baxter International Inc Biological products, except
diagnostic substances
United States 396 26/06/00 North American
Vaccine Inc
Biological products, except
diagnostic substances
United States 1 396
Baxter International Inc Biological products, except
diagnostic substances
United States 182 07/03/00 Althin Medical AB Surgical and medical instruments
and apparatus
Sweden 1 1 1 182 182 182
Baxter International Inc Biological products, except
diagnostic substances
United States 189 04/05/98 Somatogen Inc Biological products, except
diagnostic substances
United States 1 189
Baxter International Inc Biological products, except
diagnostic substances
United States 104 03/04/98 Ohmeda-
Pharmaceutical
Prod Div
Medicinal chemicals and botanical
products
United States 1 104
Baxter International Inc Biological products, except
diagnostic substances
United States 235 31/03/98 Bieffe Medital SpA-
Dialysis
Electromedical and
electrotherapeutic apparatus
Switzerland 1 1 1 235 235 235
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Baxter International Inc Biological products, except
diagnostic substances
United States 236 17/03/97 Research Medical
Inc
Surgical and medical instruments
and apparatus
United States 1 1 236 236
Baxter International Inc Biological products, except
diagnostic substances
United States 213 17/02/97 Immuno
International AG
Pharmaceutical preparations Switzerland 1 1 213 213
Baxter International Inc Biological products, except
diagnostic substances
United States 206 30/01/97 Immuno
International AG
Pharmaceutical preparations Switzerland 1 1 206 206
Baxter International Inc Biological products, except
diagnostic substances
United States 219 19/12/96 Immuno
International AG
Pharmaceutical preparations Switzerland 1 1 219 219
Baxt 12 5 4 2652 1055 801
Bayer AG Medicinal chemicals and
botanical products
Germany 2961 03/01/05 Roche Holding AG-
Over-The
Pharmaceutical preparations Switzerland 1 1 2961 2961
Bayer AG Medicinal chemicals and
botanical products
Germany 6646 03/06/02 Aventis
CropScience Hldg
SA
Pesticides and agricultural
chemicals, nec
France 1 1 1 6646 6646 6646
Bayer AG Medicinal chemicals and
botanical products
Germany 106 01/02/01 Syngenta AG-
Mikado Herbicide
Pesticides and agricultural
chemicals, nec
Switzerland 1 1 1 106 106 106
Bayer AG Medicinal chemicals and
botanical products
Germany 327 24/10/00 Sybron Chemicals
Inc
Chemicals and chemical
preparations, nec
United States 1 1 1 327 327 327
Bayer AG Medicinal chemicals and
botanical products
Germany 2450 31/03/00 Lyondell Chemical-
Polyils Bus
Petroleum refining United States 1 1 1 2450 2450 2450
Bayer AG Medicinal chemicals and
botanical products
Germany 1100 30/11/98 Chiron Diagnostics
Corp
Pharmaceutical preparations United States 1 1 1100 1100
Bayer AG Medicinal chemicals and
botanical products
Germany 580 02/01/96 Monsanto Co-
Styrenics Plastics
Plastics products, nec United States 1 1 1 580 580 580
Bayer(India)Ltd Pharmaceutical preparations India 360 16/05/03 Bayer CropScience
India Ltd
Pesticides and agricultural
chemicals, nec
India 1 1 1 360 360 360
Bayr 8 8 6 14530 14530 10469
Becton Dickinson & Co Surgical and medical
instruments and apparatus
United States 195 26/08/99 Clontech
Laboratories Inc
Biological products, except
diagnostic substances
United States
Becton Dickinson & Co Surgical and medical
instruments and apparatus
United States 452 03/04/98 Ohmeda-Medical
Devices Div
Surgical and medical instruments
and apparatus
United States
Berna Biotech AG Biological products, except
diagnostic substances
Switzerland 234 05/08/02 Rhein Biotech NV Biological products, except
diagnostic substances
Netherlands
Berna Biotech AG Biological products, except
diagnostic substances
Switzerland 110 04/03/00 Green Cross
Vaccine Corp
Biological products, except
diagnostic substances
South Korea
BioMarin Pharmaceutical
Inc
Pharmaceutical preparations United States 190 18/05/04 Ascent Pediatrics
Inc
Pharmaceutical preparations United States
BioMarin Pharmaceutical
Inc
Pharmaceutical preparations United States 141 22/08/02 Glyko Biomedical
Ltd
In vitro and in vivo diagnostic
substances
United States
bioMerieux Pierre Fabre Surgical and medical
instruments and apparatus
France 285 03/07/01 Organon Tek-In
Vitro Diagn Bus
In vitro and in vivo diagnostic
substances
Netherlands
Bio-Rad Laboratories Inc Laboratory analytical
instruments
United States 210 04/10/99 Pasteur Sanofi
Diagnostics
Medicinal chemicals and botanical
products
France
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Biovail Corp Pharmaceutical preparations Canada 130 02/06/03 Wyeth-Ativan &
Isordil Rights
Pharmaceutical preparations United States
Biovail Corp Pharmaceutical preparations Canada 190 11/12/02 Pharma PASS LLC Pharmaceutical preparations United States
Biovail Corp Pharmaceutical preparations Canada 410 29/12/01 Aventis-Product
Line
Pharmaceutical preparations United States
Biovail Corp Pharmaceutical preparations Canada 213 06/10/00 DJ Pharma Pharmaceutical preparations United States
Biovail Corp International Pharmaceutical preparations Canada 166 12/11/99 Fuisz Technologies
Ltd
Pharmaceutical preparations United States
BOC Group PLC Industrial gases United
Kingdom
109 12/07/93 Huels AG-
Hydrogen
Business
Industrial gases Germany
Boots Co PLC Pharmaceutical preparations United
Kingdom
340 07/12/00 Procter & Gamble-
Clearasil
Pharmaceutical preparations United States
Boots Co PLC Pharmaceutical preparations United
Kingdom
278 01/10/97 Hermal Kurt
Herrman(Merck E)
Pharmaceutical preparations Germany
Boots Healthcare
International
Pharmaceutical preparations United
Kingdom
179 26/09/96 Lutsia(Roussel-
Uclaf/Hoechst)
Perfumes, cosmetics, and other
toilet preparations
France
Boots Healthcare
International
Pharmaceutical preparations United
Kingdom
179 20/09/96 Laboratoires
Lutsia(Roussel)
Perfumes, cosmetics, and other
toilet preparations
France
Bracco SpA Pharmaceutical preparations Italy 881 22/03/00 Merck,Bracco-
Contrast Imaging
X-Ray apparatus & tubes & other
irradiation equip.
Italy
Bradley Pharmaceuticals
Inc
Pharmaceutical preparations United States 183 10/08/04 Bioglan Pharma
Inc
Pharmaceutical preparations United States
Bristol-Myers Squibb Co Pharmaceutical preparations United States 7800 02/10/01 DuPont
Pharmaceuticals
Co
Pharmaceutical preparations United States 1 7800
Bristol-Myers Squibb Co Pharmaceutical preparations United States 150 11/03/96 Argentia SA Pharmaceutical preparations Argentina 1 1 150 150
Bristol-Myers Squibb Co Pharmaceutical preparations United States 262 04/01/95 Calgon Vestal
Laboratories
Medicinal chemicals and botanical
products
United States 1 262
BrMS 3 1 0 8212 150 0
Cambrex Corp Pharmaceutical preparations United States 145 04/06/01 Bio Science
Contract Prodn Cor
Medicinal chemicals and botanical
products
United States
Cambrex Corp Industrial organic chemicals,
nec
United States 132 03/10/97 BioWhittaker Inc In vitro and in vivo diagnostic
substances
United States
Cambrex Corp Industrial organic chemicals,
nec
United States 130 12/10/94 Akzo Nobel-Nobel
Pharma
Medicinal chemicals and botanical
products
Netherlands
Cargill Inc Soybean oil mills United States 284 12/04/05 Seara Alimentos
SA
Sausages and other prepared
meat products
Brazil
Cargill Inc Soybean oil mills United States 1068 10/05/02 Cerestar Wet corn milling France
Cargill Inc Soybean oil mills United States 429 04/04/02 Cerestar Wet corn milling France
Cargill Inc Soybean oil mills United States 440 30/04/01 Agribrands
International Inc
Prepared animal feeds, except for
dogs and cats
United States
253
Cargill Inc Soybean oil mills United States 140 02/12/98 Grandes Molinos
de Venezuela
Flour and other grain mill products Venezuela
Celera Genomics Corp Commercial physical and
biological research
United States 140 16/11/01 AXYS
Pharmaceuticals
Inc
Pharmaceutical preparations United States
Celgene Corp Pharmaceutical preparations United States 110 21/10/04 Penn T Pharmaceutical preparations United
Kingdom
Celgene Corp Pharmaceutical preparations United States 198 01/09/00 Signal
Pharmaceuticals
Inc
Commercial physical and
biological research
United States
Cell Pathways Holdings Inc Pharmaceutical preparations United States 151 03/11/98 Tseng
Laboratories Inc
Computer peripheral equipment,
nec
United States
Cell Therapeutics Inc Pharmaceutical preparations United States 137 02/01/04 Novuspharma SpA Pharmaceutical preparations Italy
Centocor Inc In vitro and in vivo diagnostic
substances
United States 335 24/03/98 Roche Healthcare-
Centocor Mktg
Drugs, drug proprietaries, and
druggists' sundries
United States
Cephalon Inc Pharmaceutical preparations United States 360 22/12/05 Zeneus Holdings
Ltd
Pharmaceutical preparations United
Kingdom
1 1 360 360
Cephalon Inc Pharmaceutical preparations United States 170 19/07/05 CTI Technologies
Inc-Trisenox
Pharmaceutical preparations United States 1 170
Cephalon Inc Pharmaceutical preparations United States 150 14/06/05 Salmedix Inc Commercial physical and
biological research
United States 1 150
Cephalon Inc Pharmaceutical preparations United States 430 12/08/04 CIMA Labs Inc Pharmaceutical preparations United States 1 430
Cephalon Inc Pharmaceutical preparations United States 450 28/12/01 Laboratoire L
Lafon
Pharmaceutical preparations France 1 1 450 450
Cephalon Inc Pharmaceutical preparations United States 438 11/10/00 Anesta Corp Biological products, except
diagnostic substances
United States 1 438
Ceph 6 2 0 1998 810 0
Chattem Inc Pharmaceutical preparations United States 165 24/03/98 Bristol-Myers-Ban
Anti-Perspir
Perfumes, cosmetics, and other
toilet preparations
United States
Chiron Corp Biological products, except
diagnostic substances
United States 789 08/07/03 PowderJect
Pharmaceuticals
PLC
Biological products, except
diagnostic substances
United
Kingdom
Chiron Corp Biological products, except
diagnostic substances
United States 699 22/09/00 PathoGenesis
Corp
Biological products, except
diagnostic substances
United States
Chiron Corp Biological products, except
diagnostic substances
United States 125 01/04/98 Behringwerke AG-
Human Vaccine
Biological products, except
diagnostic substances
Germany
Chiron Corp Biological products, except
diagnostic substances
United States 110 31/03/98 Chiron Behring
GmbH & Co
Biological products, except
diagnostic substances
Germany
Chiron Corp Biological products, except
diagnostic substances
United States 112 02/10/95 Viagene Inc Commercial physical and
biological research
United States
Chiron Corp Biological products, except
diagnostic substances
United States 616 05/01/95 Ciba-Corning
Diag,Biocine
Pharmaceutical preparations United States
Chiroscience Group PLC Pharmaceutical preparations United
Kingdom
112 19/12/96 Darwin Molecular
Corp
Commercial physical and
biological research
United States
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Christian Hansen Holding
A/S
Food preparations, nec Denmark 103 09/12/98 Ingredients
Technology Corp
Food preparations, nec United States
Chugai Pharmaceutical Co
Ltd
Pharmaceutical preparations Japan 2590 01/10/02 Nippon Roche KK Pharmaceutical preparations Japan 1 2590
Chug 1 0 0 2590 0 0
Ciba Specialty Chemicals Chemicals and chemical
preparations, nec
Switzerland 584 03/06/04 Raisio Chemicals
Oy
Industrial inorganic chemicals, nec Finland
Ciba Specialty Chemicals Chemicals and chemical
preparations, nec
Switzerland 2501 12/03/98 Allied Colloids
Group PLC
Industrial organic chemicals, nec United
Kingdom
Ciba-Geigy AG Pharmaceutical preparations Switzerland 357 22/12/94 Rhone-Poulenc
Rorer-US and Can
Pharmaceutical preparations United States
Ciba-Geigy AG Pharmaceutical preparations Switzerland 140 07/01/93 Fisons PLC-North
American
Pharmaceutical preparations United States
Connetics Corp Pharmaceutical preparations United States 123 04/03/04 Hoffman-Soriatane
Rights
Pharmaceutical preparations United States
Cooper Cos Inc Ophthalmic goods United States 1130 06/01/05 Ocular Sciences
Inc
Ophthalmic goods United States
Cordis Corp Surgical and medical
instruments and apparatus
United States 400 16/10/97 Biosense Inc Electromedical and
electrotherapeutic apparatus
Israel
Corgentech Inc Biological products, except
diagnostic substances
United States 130 15/12/05 AlgoRx
Pharmaceuticals
Inc
Pharmaceutical preparations United States
Corixa Corp Biological products, except
diagnostic substances
United States 819 22/12/00 Coulter
Pharmaceuticals
Inc
Biological products, except
diagnostic substances
United States
Creative BioMolecules Inc Biological products, except
diagnostic substances
United States 104 01/08/00 Ontogeny Inc Health and allied services, nec United States
CSL Ltd Pharmaceutical preparations Australia 925 31/03/04 Aventis Behring
LLC
Biological products, except
diagnostic substances
United States 1 1 925 925
CSL Ltd Pharmaceutical preparations Australia 152 08/09/01 Nabi Inc-Plasma
Collection
Biological products, except
diagnostic substances
United States 1 1 152 152
CSL Ltd Pharmaceutical preparations Australia 592 30/08/00 ZLB Central
Laboratory Blood
Biological products, except
diagnostic substances
Switzerland 1 1 592 592
CSL 3 3 0 1669 1669 0
Dade International Inc In vitro and in vivo diagnostic
substances
United States 525 08/05/96 EI du Pont de
Nemmours-In
Inorganic pigments United States
Sankyo Co Ltd Pharmaceutical preparations Japan 6290 28/09/05 Daiichi
Pharmaceutical Co
Ltd
Pharmaceutical preparations Japan 1 6290
Daic 1 0 0 6290 0 0
Dainippon Pharm Co Ltd Pharmaceutical preparations Japan 2224 01/10/05 Sumitomo
Pharmaceuticals
Co
Pharmaceutical preparations Japan 1 2224
Dain 1 0 0 2224 0 0
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Diosynth BV Pharmaceutical preparations Netherlands 190 15/06/01 Covance
Biotechnology
Services
Pharmaceutical preparations United States
Dow Italia Spa(Dow
Chemicals)
Medicinal chemicals and
botanical products
Italy 300 04/01/96 INCA Intl(Enichem
SpA/ENI/IT)
Custom compounding of
purchased plastics resins
Italy
Dr Reddy's Laboratories
Ltd
Pharmaceutical preparations India 211 01/04/00 Cheminor Drugs
Ltd
Pharmaceutical preparations India
DSM NV Chemicals and chemical
preparations, nec
Netherlands 686 02/02/05 NeoResins Plastics materials and synthetic
resins
Netherlands
DSM NV Chemicals and chemical
preparations, nec
Netherlands 1915 30/09/03 Roche Holding AG-
Vitamins
Medicinal chemicals and botanical
products
Switzerland
DSM NV Chemicals and chemical
preparations, nec
Netherlands 800 14/12/00 Catalytica
Pharmaceuticals
Inc
Industrial inorganic chemicals, nec United States
DSM NV Chemicals and chemical
preparations, nec
Netherlands 1729 11/05/98 Koninklijke Gist-
Brocades NV
Industrial organic chemicals, nec Netherlands
Duramed Pharmaceuticals
Inc
Pharmaceutical preparations United States 282 10/11/05 FEI Womens
Health LLC
Medical, dental, and hospital
equipment & supplies
United States
Duramed Pharmaceuticals
Inc
Pharmaceutical preparations United States 142 08/09/05 Organon Pharm
USA Inc-Mircette
Pharmaceutical preparations United States
Eisai Co Ltd Pharmaceutical preparations Japan 265 27/04/04 Elan Corp-
Zonegan Rights
Pharmaceutical preparations United States 1 1 265 265
Eisa 1 1 0 265 265 0
Elan Corp PLC Biological products, except
diagnostic substances
Ireland-Rep 1860 10/11/00 Dura
Pharmaceuticals
Inc
Pharmaceutical preparations United States
Elan Corp PLC Biological products, except
diagnostic substances
Ireland-Rep 601 15/05/00 Liposome Co Inc Pharmaceutical preparations United States
Elan Corp PLC Biological products, except
diagnostic substances
Ireland-Rep 183 31/12/99 Axogen Ltd Pharmaceutical preparations Bermuda
Elan Corp PLC Biological products, except
diagnostic substances
Ireland-Rep 150 01/10/98 NanoSystems
LLC(Eastman
Kodak)
Pharmaceutical preparations United States
Elan Corp PLC Biological products, except
diagnostic substances
Ireland-Rep 773 14/08/98 Neurex Corp Biological products, except
diagnostic substances
United States
Elan Corp PLC Biological products, except
diagnostic substances
Ireland-Rep 150 01/06/98 Carnrick
Laboratories Inc
Drugs, drug proprietaries, and
druggists' sundries
United States
Elan Corp PLC Biological products, except
diagnostic substances
Ireland-Rep 398 02/03/98 Sano Corp Pharmaceutical preparations United States
Elan Corp PLC Biological products, except
diagnostic substances
Ireland-Rep 141 30/10/96 Advanced
Therapeutic
Systems
Pharmaceutical preparations Bermuda
Elan Corp PLC Biological products, except
diagnostic substances
Ireland-Rep 576 01/07/96 Athena
Neurosciences Inc
Pharmaceutical preparations United States
Elders Australia Ltd Farm management services Australia 207 28/10/93 Elders Ltd Farm management services Australia
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Eli Lilly & Co Pharmaceutical preparations United States 381 12/02/04 Applied Molecular
Evolution
Biological products, except
diagnostic substances
United States 1 381
Eli Lilly & Co Pharmaceutical preparations United States 4000 21/11/94 PCS Health
Systems
Data processing services United States 1 4000
EliL 2 0 0 4381 0 0
Enaleni
Pharmaceuticals(Pty)
Pharmaceutical preparations South Africa 186 31/10/05 Cipla
Medpro(Pty)Ltd
Pharmaceutical preparations South Africa
Enzon Inc Biological products, except
diagnostic substances
United States 360 22/11/02 Elan Corp Plc-
Abelcet Rights &
Pharmaceutical preparations United States
Epitope Inc In vitro and in vivo diagnostic
substances
United States 255 28/09/00 STC Technologies
Inc
Pharmaceutical preparations United States
Ercros SA Chemicals and chemical
preparations, nec
Spain 218 02/06/05 Uralita SA-
Chemical Divisions
Chemicals and chemical
preparations, nec
Spain
Evotech BioSystems AG Pharmaceutical preparations Germany 459 29/09/00 Oxford Asymmetry
International
Pharmaceutical preparations United
Kingdom
Exelixis Inc Biological products, except
diagnostic substances
United States 104 08/01/02 Genomica Corp Computer programming services United States
Fidia Farmaceutici SpA Pharmaceutical preparations Italy 186 29/05/03 Antibioticos SA Pharmaceutical preparations Spain
Fisher Scientific Intl Inc Surgical and medical
instruments and apparatus
United States 150 03/08/05 Lancaster
Laboratories Inc
Commercial physical and
biological research
United States
Fisher Scientific Intl Inc Surgical and medical
instruments and apparatus
United States 3669 02/08/04 Apogent
Technologies Inc
Laboratory apparatus and
furniture
United States
Fisher Scientific Intl Inc Surgical and medical
instruments and apparatus
United States 330 01/03/04 Oxoid Holdings Ltd In vitro and in vivo diagnostic
substances
United
Kingdom
Fisher Scientific Intl Inc Surgical and medical
instruments and apparatus
United States 786 03/09/03 Perbio Science AB Surgical and medical instruments
and apparatus
Sweden
Fisher Scientific Intl Inc Surgical and medical
instruments and apparatus
United States 205 05/11/01 Cole-Parmer
Instrument Co
Chemicals and allied products,
nec
United States
Fisher Scientific Intl Inc Surgical and medical
instruments and apparatus
United States 138 15/02/01 Covance Inc-
Pharmaceutical
Packing and crating United States
Fisher Scientific Intl Inc Surgical and medical
instruments and apparatus
United States 310 17/10/95 Fisons Scientific
Equip,Curtin
Medical, dental, and hospital
equipment & supplies
United
Kingdom
Fresenius AG Pharmaceutical preparations Germany 472 11/12/98 Pharmacia &
Upjohn-Nutrition
Pharmaceutical preparations Sweden
Fresenius AG Pharmaceutical preparations Germany 4236 30/09/96 National Medical
Care Inc
Medical, dental, and hospital
equipment & supplies
United States
Fujirebio Inc Pharmaceutical preparations Japan 168 11/11/04 SRL Inc Commercial physical and
biological research
Japan
Fukujin Co Ltd Pharmaceutical preparations Japan 205 29/09/03 Azwell Inc Pharmaceutical preparations Japan
Galen Holdings PLC Pharmaceutical preparations United
Kingdom
484 27/03/03 Pfizer Inc-
Estrostep,Loestrin
Pharmaceutical preparations United States
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Galen Holdings PLC Pharmaceutical preparations United
Kingdom
295 23/01/03 Eli Lilly-
Sales,Marketing
Rts
Pharmaceutical preparations United States
Galen Holdings PLC Pharmaceutical preparations United
Kingdom
551 28/09/00 Warner Chilcott
PLC
Pharmaceutical preparations Ireland-Rep
Genentech Inc Biological products, except
diagnostic substances
United States 408 24/06/05 Biogen Idec-
Biologics Mnfr Fac
Biological products, except
diagnostic substances
United States 1 408
Gene 1 0 0 408 0 0
Genome Therapeutics
Corp
Biological products, except
diagnostic substances
United States 104 06/02/04 Genesoft Inc Biological products, except
diagnostic substances
United States
Gensia Sicor Inc Pharmaceutical preparations United States 140 28/02/97 Rakepoll Holding
BV(Rakepoll)
Offices of holding companies, nec Netherlands 1 140
Genzyme Biosurgery Biological products, except
diagnostic substances
United States 427 18/12/00 Biomatrix Inc Medicinal chemicals and botanical
products
United States 1 427
Genzyme Corp Biological products, except
diagnostic substances
United States 595 01/07/05 Bone Care Intl Inc Pharmaceutical preparations United States 1 595
Genzyme Corp Biological products, except
diagnostic substances
United States 415 06/01/05 Wyeth-
Sales,Marketing
Rights
Pharmaceutical preparations United States 1 415
Genzyme Corp Biological products, except
diagnostic substances
United States 949 21/12/04 ILEX Oncology Inc Pharmaceutical preparations United States 1 949
Genzyme Corp Biological products, except
diagnostic substances
United States 215 03/05/04 Impath Physician
Services
Commercial nonphysical research United States 1 215
Genzyme Corp Biological products, except
diagnostic substances
United States 535 15/09/03 SangStat Medical
Corp
Pharmaceutical preparations United States 1 535
Genzyme Corp Biological products, except
diagnostic substances
United States 225 27/09/01 Novazyme
Pharmaceuticals
Inc
Pharmaceutical preparations United States 1 225
Genzyme Corp Biological products, except
diagnostic substances
United States 993 14/12/00 GelTex
Pharmaceuticals
Inc
Biological products, except
diagnostic substances
United States 1 993
Genzyme Corp Biological products, except
diagnostic substances
United States 107 29/10/96 Neozyme II Corp Pharmaceutical preparations British Virgin 1 1 107 107
Genzyme Corp Biological products, except
diagnostic substances
United States 250 02/07/96 Deknatel Snowden
Pencer
Surgical and medical instruments
and apparatus
United States 1 1 250 250
Genz 10 1 1 4710 107 250
Gilead Sciences Inc Biological products, except
diagnostic substances
United States 123 15/09/03 Equity Office-
Foster City
Colleges, universities, and
professional schools
United States 1 123
Gilead Sciences Inc Biological products, except
diagnostic substances
United States 407 23/01/03 Triangle
Pharmaceuticals
Inc
Pharmaceutical preparations United States 1 407
Gilead Sciences Inc Biological products, except
diagnostic substances
United States 866 29/07/99 NeXstar
Pharmaceuticals
Inc
Pharmaceutical preparations United States 1 866
Gild 3 0 0 1396 0 0
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Glaxo Holdings PLC Pharmaceutical preparations United
Kingdom
605 21/11/96 Nippon Glaxo Pharmaceutical preparations Japan 1 1 605 605
Glaxo Holdings PLC Pharmaceutical preparations United
Kingdom
13408 16/03/95 Wellcome PLC Pharmaceutical preparations United
Kingdom
1 13408
Glaxo Wellcome PLC Pharmaceutical preparations United
Kingdom
78775 27/12/00 SmithKline
Beecham PLC
Medicinal chemicals and botanical
products
United
Kingdom
1 78775
Glaxo Wellcome PLC Pharmaceutical preparations United
Kingdom
106 08/01/99 Amoun
Pharmaceuticals
{APIC}
Pharmaceutical preparations Egypt 1 1 106 106
Glaxo Wellcome PLC Pharmaceutical preparations United
Kingdom
220 28/01/98 Polfa
Poznan(Poland)
Pharmaceutical preparations Poland 1 1 220 220
GlaxoSmithKline PLC Pharmaceutical preparations United
Kingdom
1388 08/12/05 ID Biomedical Corp Biological products, except
diagnostic substances
Canada 1 1 1388 1388
GlaxoSmithKline PLC Pharmaceutical preparations United
Kingdom
349 12/07/05 Corixa Corp Biological products, except
diagnostic substances
United States 1 1 349 349
GlaxoSmithKline PLC Pharmaceutical preparations United
Kingdom
547 03/09/04 Sanofi-Synthelabo-
Drugs
Pharmaceutical preparations France 1 1 547 547
SmithKline Beecham Corp Pharmaceutical preparations United States 2300 27/05/94 Diversified
Pharmaceutical
Offices and clinics of doctors of
medicine
United States 1 1 2300 2300
SmithKline Beecham PLC Medicinal chemicals and
botanical products
United
Kingdom
1453 16/01/01 Block Drug Co Dental equipment and supplies United States 1 1 1 1453 1453 1453
SmithKline Beecham PLC Medicinal chemicals and
botanical products
United
Kingdom
141 05/01/96 Abtei Pharma-
Vertriebs GmbH
Drugs, drug proprietaries, and
druggists' sundries
Germany 1 1 141 141
SmithKline Beecham PLC Medicinal chemicals and
botanical products
United
Kingdom
2925 02/11/94 Sterling Winthrop
Inc
Pharmaceutical preparations United States 1 1 2925 2925
GSK 12 10 1 102218 10035 1453
Global Pharm Dvlp Inc Biological products, except
diagnostic substances
United States 125 30/09/05 Quintiles-Business
Units(3)
Biological products, except
diagnostic substances
United States
Global Pharmaceutical
Corp
Pharmaceutical preparations United States 139 15/12/99 Impax
Pharmaceuticals
Inc
Pharmaceutical preparations United States
Grasim Industries Ltd Pulp mills India 275 06/07/04 Larsen & Toubro
Ltd-Cement
Cement, hydraulic India
Guidant Corp Surgical and medical
instruments and apparatus
United States 291 15/11/99 CardioThoracic
Systems Inc
Electromedical and
electrotherapeutic apparatus
United States
Guidant Corp Surgical and medical
instruments and apparatus
United States 810 01/02/99 SulzerMedica-
Electrophysiology
Electromedical and
electrotherapeutic apparatus
United States
Guidant Corp Surgical and medical
instruments and apparatus
United States 121 31/12/98 InControl Inc Orthopedic, prosthetic, and
surgical supplies
United States
Guidant Corp Surgical and medical
instruments and apparatus
United States 190 19/12/97 EndoVascular
Technologies Inc
Surgical and medical instruments
and apparatus
United States
H Lundbeck A/S Pharmaceutical preparations Denmark 135 06/03/03 Synaptic
Pharmaceutical
Corp
Pharmaceutical preparations United States 1 1 135 135
H Lundbeck A/S Pharmaceutical preparations Denmark 101 02/02/01 Lundbeck GmbH Pharmaceutical preparations Germany 1 1 101 101
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Hlun 2 0 2 236 0 236
Hafslund Nycomed AS Pharmaceutical preparations Norway 450 03/10/94 Sterling Winthrop-
Med Image
Electromedical and
electrotherapeutic apparatus
United States
Herba-Apotheker AG Medicinal chemicals and
botanical products
Austria 125 12/09/97 Chemosan-Union
AG
Medicinal chemicals and botanical
products
Austria
Hisamitsu Pharmaceutical Pharmaceutical preparations Japan 136 01/04/05 Biomedics Pharmaceutical preparations Japan
Human Genome Sciences
Inc
In vitro and in vivo diagnostic
substances
United States 120 08/09/00 Principia
Pharmaceutical
Corp
Biological products, except
diagnostic substances
United States
ICN Pharmaceuticals Inc Pharmaceutical preparations United States 187 22/08/03 Ribapharm Inc Biological products, except
diagnostic substances
United States
ID Biomedical Corp Biological products, except
diagnostic substances
Canada 116 09/09/04 Shire Biologics Biological products, except
diagnostic substances
Canada
IDEC Pharmaceuticals
Corp
Biological products, except
diagnostic substances
United States 6059 12/11/03 Biogen Inc Biological products, except
diagnostic substances
United States
Immunex Corp Biological products, except
diagnostic substances
United States 468 01/01/02 Greenwich
Holdings Inc
Pharmaceutical preparations United States
Inhale Therapeutic
Systems Inc
Pharmaceutical preparations United States 191 29/06/01 Shearwater Corp Pharmaceutical preparations United States
Inhale Therapeutic
Systems Inc
Pharmaceutical preparations United States 200 09/01/01 Bradford Particle
Design PLC
Commercial physical and
biological research
United
Kingdom
Intercare Group PLC Pharmaceutical preparations United
Kingdom
122 26/10/00 Macarthy Group
Ltd(Cinven)
Pharmaceutical preparations United
Kingdom
Inverness Med Innovations
Inc
In vitro and in vivo diagnostic
substances
United States 149 20/12/01 Unipath
Ltd(Unilever PLC)
Surgical and medical instruments
and apparatus
United
Kingdom
Invitrogen Corp Biological products, except
diagnostic substances
United States 131 06/10/05 BioSource
International Inc
In vitro and in vivo diagnostic
substances
United States
Invitrogen Corp Biological products, except
diagnostic substances
United States 388 01/04/05 Dynal Biotech ASA Biological products, except
diagnostic substances
Norway
Invitrogen Corp Biological products, except
diagnostic substances
United States 486 10/02/04 BioReliance Corp Commercial physical and
biological research
United States
Invitrogen Corp Biological products, except
diagnostic substances
United States 325 22/08/03 Molecular Probes
Inc
Chemicals and allied products,
nec
United States
Invitrogen Corp Biological products, except
diagnostic substances
United States 402 14/09/00 Life Technologies
Inc(Dexter)
Biological products, except
diagnostic substances
United States
Invitrogen Corp Biological products, except
diagnostic substances
United States 1660 14/09/00 Dexter Corp Adhesives and sealants United States
Invitrogen Corp Biological products, except
diagnostic substances
United States 127 02/02/00 Research Genetics
Inc
Commercial physical and
biological research
United States
Ion Beam Applications SA Electromedical and
electrotherapeutic apparatus
Belgium 225 22/07/99 Sterigenics
International Inc
Business services, nec United States
IVAX Corp Pharmaceutical preparations United States 272 11/05/05 Phoenix Scientific
Inc
Pharmaceutical preparations United States
IVAX Corp Pharmaceutical preparations United States 453 29/06/01 Laboratorio Chile
SA
Pharmaceutical preparations Chile
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IVAX Corp Pharmaceutical preparations United States 605 30/12/94 Zenith
Laboratories Inc
Pharmaceutical preparations United States
IVAX Corp Pharmaceutical preparations United States 585 28/03/94 McGaw Inc Pharmaceutical preparations United States
Jazz Pharmaceuticals Inc Pharmaceutical preparations United States 131 27/06/05 Orphan Medical
Inc
Pharmaceutical preparations United States
Johnson & Johnson Pharmaceutical preparations United States 387 03/06/05 Closure Medical
Corp
Surgical and medical instruments
and apparatus
United States 1 1 387 387
Johnson & Johnson Pharmaceutical preparations United States 230 04/04/05 TransForm
Pharmaceuticals
Inc
Pharmaceutical preparations United States 1 230
Johnson & Johnson Pharmaceutical preparations United States 2449 29/04/03 Scios Inc Pharmaceutical preparations United States 1 2449
Johnson & Johnson Pharmaceutical preparations United States 320 18/04/02 Tibotec-Virco NV Medical laboratories Belgium 1 1 320 320
Johnson & Johnson Pharmaceutical preparations United States 1300 21/11/01 Inverness Medical-
Diabetes
Electromedical and
electrotherapeutic apparatus
United States 1 1 1300 1300
Johnson & Johnson Pharmaceutical preparations United States 10213 22/06/01 ALZA Corp Pharmaceutical preparations United States 1 10213
Johnson & Johnson Pharmaceutical preparations United States 4861 06/10/99 Centocor Inc In vitro and in vivo diagnostic
substances
United States 1 4861
Johnson & Johnson Pharmaceutical preparations United States 3360 05/11/98 Depuy Inc(Corange
Ltd)
Orthopedic, prosthetic, and
surgical supplies
United States 1 3360
Johnson & Johnson Pharmaceutical preparations United States 296 31/07/97 Biopsys Medical
Inc
Surgical and medical instruments
and apparatus
United States 1 1 296 296
Johnson & Johnson Pharmaceutical preparations United States 118 24/03/97 Innotech Inc Electromedical and
electrotherapeutic apparatus
United States 1 1 118 118
Johnson & Johnson Pharmaceutical preparations United States 1789 23/02/96 Cordis Corp X-Ray apparatus & tubes & other
irradiation equip.
United States 1 1 1789 1789
Johnson & Johnson Pharmaceutical preparations United States 124 05/04/95 Mitek Surgical
Products
Surgical and medical instruments
and apparatus
United States 1 1 124 124
Johnson & Johnson Pharmaceutical preparations United States 1008 30/11/94 Eastman Kodak-
Clinical
In vitro and in vivo diagnostic
substances
United States 1 1008
Johnson & Johnson Pharmaceutical preparations United States 900 03/10/94 Neutrogena Corp Soap & other detergents, except
specialty cleaners
United States 1 1 900 900
Johnson & Johnson Pharmaceutical preparations United States 169 09/12/93 Roc(LVMH-Moet
Hennessy L Vuit)
Perfumes, cosmetics, and other
toilet preparations
France 1 1 1 169 169 169
John 15 2 8 27524 489 5083
Johnson Matthey PLC Chemicals and chemical
preparations, nec
United
Kingdom
404 01/11/02 ICI Synetix Industrial inorganic chemicals, nec United
Kingdom
Johnson Matthey PLC Chemicals and chemical
preparations, nec
United
Kingdom
206 09/07/01 Meconic PLC Drugs, drug proprietaries, and
druggists' sundries
United
Kingdom
Johnson Matthey PLC Chemicals and chemical
preparations, nec
United
Kingdom
216 06/02/98 Cookson Matthey
Ceramics and
Pottery products, nec United
Kingdom
Johnson Matthey PLC Chemicals and chemical
preparations, nec
United
Kingdom
164 06/10/95 Advance Circuits
Inc
Printed circuit boards United States
Kalbe Farma PT Pharmaceutical preparations Indonesia 473 20/12/05 Enseval Drugs, drug proprietaries, and
druggists' sundries
Indonesia
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KCP Income Fund Perfumes, cosmetics, and other
toilet preparations
Canada 215 17/05/05 CCL Industries Inc-
North Amer
Metal cans United States
Kemira Oyj Chemicals and chemical
preparations, nec
Finland 191 06/04/05 Verdugt BV Chemicals and chemical
preparations, nec
Netherlands
Kemira Oyj Chemicals and chemical
preparations, nec
Finland 444 01/04/05 Finnish Chemicals
Oy
Chemicals and chemical
preparations, nec
Finland
Kemira Oyj Chemicals and chemical
preparations, nec
Finland 138 30/01/02 Vinings Industries Industrial organic chemicals, nec United States
King Pharmaceuticals Inc Pharmaceutical preparations United States 750 13/06/03 Elan Corp PLC-
Primary Care
Pharmaceutical preparations United States 1 750
King Pharmaceuticals Inc Pharmaceutical preparations United States 235 08/01/03 Meridian Medical
Technologies
Electromedical and
electrotherapeutic apparatus
United States 1 1 235 235
King Pharmaceuticals Inc Pharmaceutical preparations United States 275 31/12/02 Aventis-
Intale,Tilade,Suner
cid
Pharmaceutical preparations France 1 1 275 275
King Pharmaceuticals Inc Pharmaceutical preparations United States 115 29/05/02 Ortho-McNeil
Pharmaceutical
Pharmaceutical preparations United States 1 115
King Pharmaceuticals Inc Pharmaceutical preparations United States 285 09/08/01 Bristol-Myers
Squibb-US Rights
Pharmaceutical preparations United States 1 285
King Pharmaceuticals Inc Pharmaceutical preparations United States 3363 31/08/00 Jones
Pharmaceutical Inc
Pharmaceutical preparations United States 1 3363
King Pharmaceuticals Inc Pharmaceutical preparations United States 356 25/02/00 Medco Research
Inc
Pharmaceutical preparations United States 1 356
King Pharmaceuticals Inc Pharmaceutical preparations United States 363 22/12/98 Hoechst Marion
Roussel-Prods
Pharmaceutical preparations Germany 1 1 363 363
King 8 2 1 5741 637 235
Knoll
Pharmaceuticals(Abbott)
Pharmaceutical preparations United States 450 05/03/01 Hokuriku Seiyaku
Co Ltd
Pharmaceutical preparations Japan
Koninklijke Numico NV Dry, condensed, and
evaporated dairy products
Netherlands 529 24/06/05 Mellin SpA Canned specialties Italy
Koninklijke Numico NV Dry, condensed, and
evaporated dairy products
Netherlands 1747 10/07/00 Rexall Sundown
Inc
Pharmaceutical preparations United States
Koninklijke Numico NV Dry, condensed, and
evaporated dairy products
Netherlands 2546 11/08/99 General Nutrition
Cos Inc
Miscellaneous food stores United States
Kos Pharmaceuticals Inc Pharmaceutical preparations United States 200 05/03/04 Aventis Pharm-
Azmacort Rights
Pharmaceutical preparations United States
Kowa Co Ltd Pharmaceutical preparations Japan 130 13/11/03 Nikken Chemicals
Co Ltd
Pharmaceutical preparations Japan
Kuraray Co Ltd Chemicals and chemical
preparations, nec
Japan 238 17/01/02 Clariant AG-
PVA/PVB
Plastics materials and synthetic
resins
Switzerland
Mallinckrodt Inc In vitro and in vivo diagnostic
substances
United States 1864 15/09/97 Nellcor Puritan-
Bennett
Electromedical and
electrotherapeutic apparatus
United States
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Marion Merrell Dow Inc Pharmaceutical preparations United States 275 05/10/93 Rugby-Darby
Group Cos-Drug
Bus
Medical, dental, and hospital
equipment & supplies
United States
Matrix Laboratories Ltd Pharmaceutical preparations India 203 04/10/05 Docpharma NV Pharmaceutical preparations Belgium
Mayne Group Ltd Pharmaceutical preparations Australia 105 26/04/04 aaiPharma-
Injectable Prod
Pharmaceutical preparations United States
Mayne Group Ltd Pharmaceutical preparations Australia 153 29/09/02 Queensland Med
Laboratory Grp
Medical laboratories Australia
Meda AB Pharmaceutical preparations Sweden 909 28/09/05 VIATRIS GmbH &
Co KG
Pharmaceutical preparations Germany
Meda AB Pharmaceutical preparations Sweden 135 20/01/05 Novartis AG-Brand
Rights(2)
Pharmaceutical preparations Switzerland
Medeus Pharma Ltd Pharmaceutical preparations United
Kingdom
120 12/02/04 Elan-Certain
European Bus
Pharmaceutical preparations Ireland-Rep
Medicis Pharmaceutical
Corp
Pharmaceutical preparations United States 160 10/03/03 HA North American
Sales AB
In vitro and in vivo diagnostic
substances
United States
Medicis Pharmaceutical
Corp
Pharmaceutical preparations United States 136 15/11/01 Ascent Pediatrics
Inc
Pharmaceutical preparations United States
MedImmune Inc Biological products, except
diagnostic substances
United States 1740 15/01/02 Aviron Biological products, except
diagnostic substances
United States
MedImmune Inc Biological products, except
diagnostic substances
United States 393 23/11/99 US Bioscience Inc Pharmaceutical preparations United States
Merck & Co Inc Pharmaceutical preparations United States 461 19/07/01 Rosetta
Inpharmatics Inc
Commercial physical and
biological research
United States 1 461
Merck & Co Inc Pharmaceutical preparations United States 185 21/06/00 Provantage Health
Services
Management consulting services United States 1 185
Merck & Co Inc Pharmaceutical preparations United States 5921 18/11/93 Medco
Containment
Services Inc
Drugs, drug proprietaries, and
druggists' sundries
United States 1 5921
Merc 3 0 0 6567 0 0
Merck KGaA Pharmaceutical preparations Germany 935 28/07/99 VWR Scientific
Products Corp
Professional equipment and
supplies, nec
United States 1 935
Merck KGaA Pharmaceutical preparations Germany 225 02/05/96 Seven Seas
Ltd(Hanson PLC)
Medicinal chemicals and botanical
products
United
Kingdom
1 225
Merck KGaA Pharmaceutical preparations Germany 1391 17/10/95 Merck AG Pharmaceutical preparations Switzerland 1 1391
MerK 3 0 0 2551 0 0
MGI PHARMA Inc Pharmaceutical preparations United States 203 03/10/05 Guilford
Pharmaceuticals
Inc
Pharmaceutical preparations United States
Miles Inc Pharmaceutical preparations United States 1000 03/11/94 Sterling Winthrop-
NA OTC Drug
Drugs, drug proprietaries, and
druggists' sundries
United States
Miles Inc Pharmaceutical preparations United States 101 18/04/94 ChemDesign
Corp(Bayer Corp)
Industrial organic chemicals, nec United States
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Millennium
Pharmaceuticals Inc
Pharmaceutical preparations United States 2174 12/02/02 COR Therapeutics
Inc
Pharmaceutical preparations United States
Millennium
Pharmaceuticals Inc
Pharmaceutical preparations United States 557 22/12/99 LeukoSite Inc Pharmaceutical preparations United States
Millipore Corp Laboratory analytical
instruments
United States 151 27/01/97 Tylan General Inc Process control instruments United States
Millipore Corp Laboratory analytical
instruments
United States 125 31/12/96 Amicon Inc(Natl
Med Care Inc)
Laboratory analytical instruments United States
Monsanto Co Pesticides and agricultural
chemicals, nec
United States 26772 31/03/00 Pharmacia &
Upjohn Inc
Pharmaceutical preparations United States
Monsanto Co Pesticides and agricultural
chemicals, nec
United States 2382 07/12/98 DeKalb Genetics
Corp
Commercial physical and
biological research
United States
Monsanto Co Pesticides and agricultural
chemicals, nec
United States 1400 30/10/98 Cargill-International
Seed Ope
Grain and field beans Mexico
Monsanto Co Pesticides and agricultural
chemicals, nec
United States 523 16/07/98 Plant Breeding Intl
Cambridge
Ornamental floriculture and
nursery products
United
Kingdom
Monsanto Co Pesticides and agricultural
chemicals, nec
United States 945 04/09/97 Holden's
Foundation Seeds
Ornamental floriculture and
nursery products
United States
Monsanto Co Pesticides and agricultural
chemicals, nec
United States 243 21/05/97 Calgene
Inc(Monsanto Co)
Ornamental floriculture and
nursery products
United States
Monsanto Co Pesticides and agricultural
chemicals, nec
United States 240 03/02/97 Asgrow
Agronomics(Semin
is)
Ornamental floriculture and
nursery products
United States
Monsanto Co Pesticides and agricultural
chemicals, nec
United States 150 21/05/96 Agracetus-
Transgenic Plant
Bus
Commercial physical and
biological research
United States
Monsanto Co Pesticides and agricultural
chemicals, nec
United States 1075 21/02/95 Kelco Biopolymers Industrial organic chemicals, nec United States
Monsanto Co Pesticides and agricultural
chemicals, nec
United States 400 14/05/93 Chevron Chemical
Co-Ortho
Pesticides and agricultural
chemicals, nec
United States
Mylan Laboratories Inc Pharmaceutical preparations United States 188 05/10/98 Penederm Inc Pharmaceutical preparations United States
Nabi Biopharmaceuticals Biological products, except
diagnostic substances
United States 101 05/08/03 Braintree Labs Inc-
PhosLo
Pharmaceutical preparations United States
Natraceutical SA Biological products, except
diagnostic substances
Spain 104 04/05/05 Braes Group Ltd Flavoring extracts and flavoring
syrups, nec
United
Kingdom
NBTY Inc Pharmaceutical preparations United States 115 01/08/05 Solgar Vitamin &
Herb Co
Medicinal chemicals and botanical
products
United States
NBTY Inc Pharmaceutical preparations United States 250 25/07/03 Rexall Sundown
Inc
Pharmaceutical preparations United States
NBTY Inc Pharmaceutical preparations United States 169 08/08/97 Holland &
Barrett(Lloyds)
Miscellaneous food stores United
Kingdom
NeoSan Pharm(AaiPharma
Inc)
Pharmaceutical preparations United States 100 30/08/01 Astrazeneca AB-
Critical Care
Pharmaceutical preparations Sweden
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North American Biologicals
Inc
Biological products, except
diagnostic substances
United States 160 30/11/95 Univax Biologics
Inc
Biological products, except
diagnostic substances
United States
NOVA Chemicals Corp Plastics materials and synthetic
resins
Canada 185 31/01/00 Royal Dutch/Shell
Group-
Plastics materials and synthetic
resins
Netherlands
Novartis AG Pharmaceutical preparations Switzerland 660 31/08/05 Bristol-Myers
Squibb Co-US
Pharmaceutical preparations United States 1 1 660 660
Novartis AG Pharmaceutical preparations Switzerland 933 26/07/05 Eon Labs Inc Pharmaceutical preparations United States 1 1 933 933
Novartis AG Pharmaceutical preparations Switzerland 1504 21/07/05 Eon Labs Inc Pharmaceutical preparations United States 1 1 1504 1504
Novartis AG Pharmaceutical preparations Switzerland 5685 06/06/05 Hexal AG Pharmaceutical preparations Germany 1 1 5685 5685
Novartis AG Pharmaceutical preparations Switzerland 225 01/04/03 Pfizer Inc-Enablex
Brand
Pharmaceutical preparations United States 1 1 225 225
Novartis AG Pharmaceutical preparations Switzerland 851 18/11/02 Lek(Slovenia) Pharmaceutical preparations Slovenia 1 1 851 851
Novartis AG Pharmaceutical preparations Switzerland 421 24/04/01 Hazal
Finance(Negma)
Investment advice France 1 1 1 421 421 421
Novartis AG Pharmaceutical preparations Switzerland 1634 21/12/00 SB-
Famvir,Vectavir/De
navir
Pharmaceutical preparations United
Kingdom
1 1 1634 1634
Novartis AG Pharmaceutical preparations Switzerland 143 31/08/98 Oriental Chemical
Inds-Crop
Pesticides and agricultural
chemicals, nec
South Korea 1 1 1 143 143 143
Novartis AG Pharmaceutical preparations Switzerland 910 03/07/97 Merck-Crop
Protection
Business
Pesticides and agricultural
chemicals, nec
United States 1 1 1 910 910 910
Novartis Generics(Novartis
AG)
Pharmaceutical preparations Austria 101 01/01/01 BASF Pharma-
Euro Generics Bus
Pharmaceutical preparations Germany 1 1 101 101
Novartis Medical Nutrition Medicinal chemicals and
botanical products
Switzerland 385 17/02/04 Mead Johnson-
Adult Nut Bus
Food preparations, nec United States 1 1 1 385 385 385
Novartis Pharma AG Pharmaceutical preparations Switzerland 612 09/05/03 Idenix
Pharmaceuticals
Inc
Pharmaceutical preparations United States 1 1 612 612
Sandoz GmbH Pharmaceutical preparations Austria 565 16/08/04 Sabex Inc Pharmaceutical preparations Canada 1 1 565 565
Nova 14 14 4 14629 14629 1859
Omega Pharma NV Pharmaceutical preparations Belgium 122 03/09/04 Medestea
International Srl
Pharmaceutical preparations Italy
Omega Pharma NV Pharmaceutical preparations Belgium 164 28/06/04 Pfizer-European
Brands
Pharmaceutical preparations Belgium
Omega Pharma NV Pharmaceutical preparations Belgium 118 15/12/00 Chefaro
International(Akzo
NV)
Pharmaceutical preparations Netherlands
Omega Pharma NV Pharmaceutical preparations Belgium 139 08/09/00 Fagron
Farmaceuticals(Fa
gron)
Drugs, drug proprietaries, and
druggists' sundries
Netherlands
Omnicare Inc Drug stores and proprietary
stores
United States 235 15/08/05 RxCrossroads LLC Health and allied services, nec United States
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Omnicare Inc Drug stores and proprietary
stores
United States 269 12/08/05 ExcelleRx Inc Pharmaceutical preparations United States
Omnicare Inc Drug stores and proprietary
stores
United States 2067 28/07/05 NeighborCare Inc Skilled nursing care facilities United States
Omnicare Inc Drug stores and proprietary
stores
United States 402 16/01/03 NCS HealthCare
Inc
Drug stores and proprietary stores United States
Omnicare Inc Drug stores and proprietary
stores
United States 115 08/01/02 American
Pharmaceutical
Svcs
Drug stores and proprietary stores United States
Omnicare Inc Drug stores and proprietary
stores
United States 255 17/09/98 United
Professional Cos
Drugs, drug proprietaries, and
druggists' sundries
United States
Omnicare Inc Drug stores and proprietary
stores
United States 152 29/06/98 IBAH Inc Pharmaceutical preparations United States
Omnicare Inc Drug stores and proprietary
stores
United States 252 16/09/97 American
Medserve Corp
Drugs, drug proprietaries, and
druggists' sundries
United States
Oriental Chemical Inds Co
Ltd
Chemicals and chemical
preparations, nec
South Korea 208 30/04/00 Korea Steel
Chem(Pohang
Iron)
Steel works, blast furnaces, and
rolling mills
South Korea
Ortho Biotech Products LP Biological products, except
diagnostic substances
United States 134 09/08/01 Pharmamar Pharmaceutical preparations Spain
Ortho-McNeil Pharm Inc Pharmaceutical preparations United States 245 30/06/05 Peninsula
Pharmaceuticals
Inc
Biological products, except
diagnostic substances
United States
OSI Pharmaceuticals Inc Pharmaceutical preparations United States 721 14/11/05 Eyetech
Pharmaceuticals
Inc
Pharmaceutical preparations United States
OSI Pharmaceuticals Inc Pharmaceutical preparations United States 200 21/12/01 Gilead Sciences
Inc-Oncology A
Pharmaceutical preparations United States
PAREXEL International
Corp
Biological products, except
diagnostic substances
United States 109 01/03/98 PPS Europe Ltd Management consulting services United
Kingdom
Patheon Inc Pharmaceutical preparations Canada 442 23/12/04 Mova
Pharmaceuticals
Corp
Pharmaceutical preparations Puerto Rico
Perrigo Co Biological products, except
diagnostic substances
United States 922 17/03/05 Agis
Industries(1983)Ltd
Pharmaceutical preparations Israel
Pfizer Inc Pharmaceutical preparations United States 1791 14/09/05 Vicuron
Pharmaceuticals
Inc
Biological products, except
diagnostic substances
United States 1 1791
Pfizer Inc Pharmaceutical preparations United States 527 05/05/05 Angiosyn Inc Biological products, except
diagnostic substances
United States 1 527
Pfizer Inc Pharmaceutical preparations United States 118 12/11/04 Meridica Ltd Pharmaceutical preparations United
Kingdom
1 1 118 118
Pfizer Inc Pharmaceutical preparations United States 372 02/11/04 Slough-Global
Research Center
Commercial physical and
biological research
United States 1 372
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Pfizer Inc Pharmaceutical preparations United States 620 01/10/04 Aventis SA-
Campto Cancer
Drug
Pharmaceutical preparations France 1 1 620 620
Pfizer Inc Pharmaceutical preparations United States 126 26/03/04 CSL Ltd-Animal
Health Business
Biological products, except
diagnostic substances
Australia 1 1 126 126
Pfizer Inc Pharmaceutical preparations United States 1198 11/02/04 Esperion
Therapeutics Inc
Pharmaceutical preparations United States 1 1198
Pfizer Inc Pharmaceutical preparations United States 60704 15/04/03 Pharmacia Corp Pharmaceutical preparations United States 1 60704
Pfizer Inc Pharmaceutical preparations United States 88771 19/06/00 Warner-Lambert
Co
Pharmaceutical preparations United States 1 88771
Pfizer Inc Pharmaceutical preparations United States 156 16/03/95 NAMIC USA Corp Surgical and medical instruments
and apparatus
United States 1 1 156 156
Pfizer Inc Pharmaceutical preparations United States 1450 19/01/95 SmithKline
Beecham Animal
Hlth
Drugs, drug proprietaries, and
druggists' sundries
United States 1 1450
Pharmacia & Upjohn Inc Pharmaceutical preparations United States 613 31/08/99 SUGEN Inc Commercial physical and
biological research
United States 1 613
Pharmacia Corp Pharmaceutical preparations United States 200 01/07/02 AT&T Corp-
Headquarters,Bask
ing
Operators of nonresidential
buildings
United States 1 1 200 200
Upjohn Co Pharmaceutical preparations United States 6802 02/11/95 Pharmacia AB Pharmaceutical preparations Sweden 1 1 6802 6802
Pfiz 14 4 2 163448 7667 356
Pharm Prod Dvlp Inc Commercial physical and
biological research
United States 481 26/09/96 Applied Bioscience
Intl(IMS)
Testing laboratories United States
Pharmaceutical Resources
Inc
Pharmaceutical preparations United States 145 10/06/04 Kali Laboratories
Inc
Pharmaceutical preparations United States
Pharmacopeia Inc Biological products, except
diagnostic substances
United States 127 14/06/98 Molecular
Simulations Inc
Prepackaged Software United States
Phoenix Int Beteligungs
GmbH
Pharmaceutical preparations Germany 231 15/12/03 Tamro Oyj Drugs, drug proprietaries, and
druggists' sundries
Finland
Phoenix Int Beteligungs
GmbH
Pharmaceutical preparations Germany 102 14/08/03 Tamro Oyj Drugs, drug proprietaries, and
druggists' sundries
Finland
PLIVA dd Pharmaceutical preparations Croatia 212 22/06/02 Sobel USA
Inc(Sobel BV)
Pharmaceutical preparations United States
Prestige Brands
International
Perfumes, cosmetics, and other
toilet preparations
United States 335 10/01/03 Abbott
Laboratories-
Murine
Pharmaceutical preparations United States
Probitas Pharma SA Pharmaceutical preparations Spain 149 25/09/01 SeraCare Inc Specialty outpatient facilities, nec United States
Procter & Gamble Co Soap & other detergents,
except specialty cleaners
United States 57227 01/10/05 Gillette Co Cutlery United States
Procter & Gamble Co Soap & other detergents,
except specialty cleaners
United States 208 03/07/04 Laboratorios Vita-
Commercial
Pharmaceutical preparations Spain
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Procter & Gamble Co Soap & other detergents,
except specialty cleaners
United States 2000 30/06/04 Procter & Gamble-
Hutchison Ltd
Soap & other detergents, except
specialty cleaners
China
Procter & Gamble Co Soap & other detergents,
except specialty cleaners
United States 1214 30/06/04 Wella AG Perfumes, cosmetics, and other
toilet preparations
Germany
Procter & Gamble Co Soap & other detergents,
except specialty cleaners
United States 1591 10/09/03 Wella AG Perfumes, cosmetics, and other
toilet preparations
Germany
Procter & Gamble Co Soap & other detergents,
except specialty cleaners
United States 4530 02/09/03 Wella AG Perfumes, cosmetics, and other
toilet preparations
Germany
Procter & Gamble Co Soap & other detergents,
except specialty cleaners
United States 4950 16/11/01 Bristol-Myers
Squibb-Clairol
Perfumes, cosmetics, and other
toilet preparations
United States
Procter & Gamble Co Soap & other detergents,
except specialty cleaners
United States 259 08/10/99 Recovery
Engineering Inc
Service industry machines, nec United States
Procter & Gamble Co Soap & other detergents,
except specialty cleaners
United States 2300 01/09/99 IAMs Co Dog, cat, and pet food United States
Procter & Gamble Co Soap & other detergents,
except specialty cleaners
United States 113 17/08/99 Long Chen Paper
Co Ltd-
Paper mills Taiwan
Procter & Gamble Co Soap & other detergents,
except specialty cleaners
United States 375 15/04/99 Prosan(CMPC,Pro
cter & Gamble)
Paper mills Argentina
Procter & Gamble Co Soap & other detergents,
except specialty cleaners
United States 170 31/12/97 Loreta y Pena
Pobre SA de CV
Paper mills Mexico
Procter & Gamble Co Soap & other detergents,
except specialty cleaners
United States 169 26/11/97 Ssangyong Paper
Co
Sanitary paper products South Korea
Procter & Gamble Co Soap & other detergents,
except specialty cleaners
United States 1976 21/07/97 Tambrands Inc Sanitary paper products United States
Procter & Gamble Co Soap & other detergents,
except specialty cleaners
United States 220 28/06/96 Kimberly-Clark-4
Businesses
Sanitary paper products United States
Procter & Gamble Co Soap & other detergents,
except specialty cleaners
United States 150 29/08/94 Giorgio Beverly
Hills(Avon)
Perfumes, cosmetics, and other
toilet preparations
United States
Procyon Biopharma Inc Biological products, except
diagnostic substances
Canada 155 21/04/03 Pharmacor Inc In vitro and in vivo diagnostic
substances
Canada
Protein Design Labs Inc Biological products, except
diagnostic substances
United States 509 24/03/05 ESP Pharma Inc Pharmaceutical preparations United States
Protein Design Labs Inc Biological products, except
diagnostic substances
United States 108 07/04/03 Eos Biotechnology Pharmaceutical preparations United States
Proteo Inc(Proteo Mkgt
Inc)
Commercial physical and
biological research
United States 183 25/04/02 Proteo Marketing
Inc
Pharmaceutical preparations United States
pSiVida Ltd Pharmaceutical preparations Australia 104 13/10/05 Control Delivery
Systems Inc
Pharmaceutical preparations United States
Qiagen NV Biological products, except
diagnostic substances
Netherlands 120 30/06/00 Operon
Technologies Inc
Biological products, except
diagnostic substances
United States
QLT Inc Biological products, except
diagnostic substances
Canada 734 19/11/04 Atrix Laboratories
Inc
Commercial physical and
biological research
United States
Recordati SpA Pharmaceutical preparations Italy 102 28/06/00 Bouchara SA Pharmaceutical preparations France
Rengo Co Ltd Corrugated and solid fiber
boxes
Japan 638 01/04/99 Settsu Corp Paperboard mills Japan
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Revco DS Inc Pharmaceutical preparations United States 379 23/12/96 Big B Inc Drug stores and proprietary stores United States
Revco DS Inc Pharmaceutical preparations United States 658 15/07/94 Hook-SupeRx Inc Drug stores and proprietary stores United States
Rexall Sundown Inc Pharmaceutical preparations United States 108 10/01/00 MET-Rx Nutrition
Inc
Medicinal chemicals and botanical
products
United States
Roche Holding AG Pharmaceutical preparations Switzerland 181 25/07/05 GlycArt
Biotechnology AG
Biological products, except
diagnostic substances
Switzerland 1 181
Roche Holding AG Pharmaceutical preparations Switzerland 1254 13/02/04 IGEN International
Inc
Pharmaceutical preparations United States 1 1 1254 1254
Roche Holding AG Pharmaceutical preparations Switzerland 1189 28/11/03 Disetronic Holding
AG
Surgical and medical instruments
and apparatus
Switzerland 1 1 1189 1189
Roche Holding AG Pharmaceutical preparations Switzerland 1230 31/12/00 SmithKline
Beecham PLC-
Kytril
Pharmaceutical preparations United
Kingdom
1 1 1230 1230
Roche Holding AG Pharmaceutical preparations Switzerland 4313 16/06/99 Genentech Inc Biological products, except
diagnostic substances
United States 1 1 4313 4313
Roche Holding AG Pharmaceutical preparations Switzerland 10200 05/03/98 Corange Ltd Pharmaceutical preparations Bermuda 1 1 10200 10200
Roche Holding AG Pharmaceutical preparations Switzerland 1100 31/03/97 Tastemaker Industrial organic chemicals, nec United States 1 1 1100 1100
Roche Holding AG Pharmaceutical preparations Switzerland 5371 03/11/94 Syntex Corp Pharmaceutical preparations United States 1 5371
Roche Holding AG Pharmaceutical preparations Switzerland 141 08/02/93 Fisons PLC-
Australian,New
Perfumes, cosmetics, and other
toilet preparations
Australia 1 1 1 141 141 141
Hoffmann-La Roche Inc Pharmaceutical preparations United States 150 31/07/02 Memory
Pharmaceuticals
Corp-
Pharmaceutical preparations United States 1 150
RocH 10 5 3 25129 17138 2430
Roussel-Uclaf SA Pharmaceutical preparations France 140 04/07/95 Dow Chemical Co-
Latin American
Pharmaceutical preparations Brazil
Roussel-Uclaf SA Pharmaceutical preparations France 239 11/02/94 Albert Roussel
Pharma,1 other
Pharmaceutical preparations Germany
Salix Pharmaceuticals Ltd Pharmaceutical preparations United States 182 30/09/05 InKine
Pharmaceutical Co
Biological products, except
diagnostic substances
United States
Sanofi-Aventis SA Pharmaceutical preparations France 664 12/07/05 Hoechst AG Manmade organic fibers, except
cellulosic
Germany 1 1 1 664 664 664
Sanofi-Synthelabo SA Pharmaceutical preparations France 65657 20/08/04 Aventis SA Pharmaceutical preparations France 1 65657
Rhone-Poulenc Rorer Inc Pharmaceutical preparations United States 2559 20/10/95 Fisons PLC Pharmaceutical preparations United
Kingdom
1 1 2559 2559
Rhone-Poulenc Rorer Inc Pharmaceutical preparations United States 150 13/02/95 Applied Immune
Sciences Inc
Surgical and medical instruments
and apparatus
United States 1 1 150 150
Elf Sanofi SA Pharmaceutical preparations France 1825 03/10/94 Sterling Winthrop-
Prescription
Drugs, drug proprietaries, and
druggists' sundries
United States 1 1 1825 1825
Elf Sanofi SA Pharmaceutical preparations France 1003 18/06/93 Yves Saint Laurent
SA
Men's and boys' clothing, nec France 1 1 1003 1003
Sano 6 71858
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Saturn Pharmaceuticals
Inc
Pharmaceutical preparations United States 140 01/07/05 Odyssey Pharm
Inc-Sanctura
Pharmaceutical preparations United States
Schein Pharmaceutical Inc Pharmaceutical preparations United States 229 01/09/95 Marsam
Pharmaceuticals
Inc
Pharmaceutical preparations United States
Schering AG Pharmaceutical preparations Germany 380 16/07/02 Immunex Corp-
Leukine Business
Pharmaceutical preparations United States 1 1 380 380
Schering AG Pharmaceutical preparations Germany 137 03/07/02 Collateral
Therapeutics Inc
Commercial physical and
biological research
United States 1 1 137 137
Schering AG Pharmaceutical preparations Germany 314 02/08/96 Leiras(Huhtamaki
Oy)
Biological products, except
diagnostic substances
Finland 1 1 314 314
Schering AG Pharmaceutical preparations Germany 336 23/07/96 Jenapharm
GmbH(Gehe AG)
Medicinal chemicals and botanical
products
Germany 1 1 336 336
Schering-Plough Corp Pharmaceutical preparations United States 405 01/07/97 Mallinckrodt
Veterinary Inc
Prepared animal feeds, except for
dogs and cats
United States 1 1 405 405
Schr 5 4 1 1572 1167 405
Schwarz Pharma AG Pharmaceutical preparations Germany 116 15/08/95 Reed &
Carnrick(Block
Drug Co)
Pharmaceutical preparations United States
Schwarz Pharma Kremers-
Urban
Pharmaceutical preparations United States 178 06/06/95 Central
Pharmaceuticals
Pharmaceutical preparations United States
Schwarz Pharma Kremers-
Urban
Pharmaceutical preparations United States 116 06/06/95 Reed & Carnrick-
Certain Assets
Pharmaceutical preparations United States
Serologicals Corp Biological products, except
diagnostic substances
United States 202 14/10/04 Upstate Group Inc In vitro and in vivo diagnostic
substances
United States
Serono International SA Biological products, except
diagnostic substances
Switzerland 162 05/11/02 Genset SA Biological products, except
diagnostic substances
France
Shanghai Indl Hldg Ltd Offices of holding companies,
nec
Hong Kong 120 05/07/00 Active Services
Group Ltd
Investors, nec Hong Kong
Shield Diagnostics Group
PLC
In vitro and in vivo diagnostic
substances
United
Kingdom
118 27/05/99 Axis Biochemicals
AS
Medicinal chemicals and botanical
products
Norway
Shionogi & Co Ltd Pharmaceutical preparations Japan 120 14/01/93 Eli Lilly & Co-
Capsule Bus
Pharmaceutical preparations United States 1 1 120 120
Shio 1 1 0 120 120 0
Shire Pharmaceuticals
Group
Pharmaceutical preparations United
Kingdom
163 29/12/97 Richwood
Pharmaceutical Co
Inc
Drugs, drug proprietaries, and
druggists' sundries
United States 1 1 163 163
Shire Pharmaceuticals
Group
Pharmaceutical preparations United
Kingdom
171 24/03/97 Pharmavene Inc Pharmaceutical preparations United States 1 1 171 171
Shire Pharmaceuticals Grp
PLC
Pharmaceutical preparations United
Kingdom
1347 28/07/05 Transkaryotic
Therapies Inc
Biological products, except
diagnostic substances
United States 1 1 1347 1347
Shire Pharmaceuticals Grp
PLC
Pharmaceutical preparations United
Kingdom
3782 11/05/01 BioChem Pharma
Inc
Pharmaceutical preparations Canada 1 1 3782 3782
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Shire Pharmaceuticals Grp
PLC
Pharmaceutical preparations United
Kingdom
1066 23/12/99 Roberts
Pharmaceutical
Corp
Pharmaceutical preparations United States 1 1 1066 1066
Shir 5 5 0 6528 6528 0
Sigma Co Ltd Pharmaceutical preparations Australia 513 02/12/05 Arrow
Pharmaceuticals
Ltd
Pharmaceutical preparations Australia
Sigma-Aldrich Corp Chemicals and chemical
preparations, nec
United States 370 01/03/05 JRH Biosciences
Inc
Biological products, except
diagnostic substances
United States
Sika AG Chemicals and chemical
preparations, nec
Switzerland 458 19/12/05 Sarna Kunststoff
Holding AG
Plastics materials and synthetic
resins
Switzerland
SkyePharma PLC Pharmaceutical preparations United
Kingdom
446 03/05/96 Jago Holding AG Offices of holding companies, nec Switzerland
Snia SpA Industrial organic chemicals,
nec
Italy 116 22/01/03 Centerpulse-Heart
Valve Bus
Orthopedic, prosthetic, and
surgical supplies
United States
Solvay Pharmaceuticals
SA
Pharmaceutical preparations Belgium 112 21/07/99 Unimed
Pharmaceuticals
Inc
Pharmaceutical preparations United States 1 112
Solv 1 0 0 112 0 0
Sorin Biomedica SpA Pharmaceutical preparations Italy 267 18/05/99 COBE
Cardiovascular(CO
BE Lab)
Surgical and medical instruments
and apparatus
United States
Sosei Co Ltd Biological products, except
diagnostic substances
Japan 185 30/08/05 Arakis Ltd Pharmaceutical preparations United
Kingdom
SRF Ltd Synthetic rubber (vulcanizable
elastomers)
India 103 28/10/96 Ceat Tyres-Nylon
Tyre Cord Uni
Tire cord and fabrics India
STADA Arzneimittel AG Pharmaceutical preparations Germany 108 08/02/05 OAO Nizhpharm Pharmaceutical preparations Russian Fed
Suzuken Co Ltd Pharmaceutical preparations Japan 160 30/07/98 Akiyama Inc Drugs, drug proprietaries, and
druggists' sundries
Japan
Takeda Pharmaceutical Co
Ltd
Pharmaceutical preparations Japan 270 01/03/05 Syrrx Inc Biological products, except
diagnostic substances
United States 1 1 270 270
Take 1 1 0 270 270 0
Talecris Biotherapeutics
Hldg
Pharmaceutical preparations United States 590 01/04/05 NPS
BioTherapeutics
Inc
Biological products, except
diagnostic substances
United States
Terumo Corp Laboratory analytical
instruments
Japan 170 18/11/02 Vascutek
Ltd(Centerpulse
AG)
Orthopedic, prosthetic, and
surgical supplies
United
Kingdom
Terumo Corp Laboratory analytical
instruments
Japan 110 30/06/99 3M-Cardiovascular
Business
Surgical and medical instruments
and apparatus
United States
Teva Pharm Inds Ltd Pharmaceutical preparations Israel 3165 22/01/04 SICOR Inc Pharmaceutical preparations United States 1 3165
Teva Pharm Inds Ltd Pharmaceutical preparations Israel 285 05/04/00 Novopharm
Ltd(Dan Family
Hold)
Pharmaceutical preparations Canada 1 285
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Teva Pharm Inds Ltd Pharmaceutical preparations Israel 350 31/05/96 Biocraft
Laboratories Inc
Pharmaceutical preparations United States 1 350
Teva Pharmaceutical USA
Inc
Pharmaceutical preparations United States 187 20/09/99 Copley
Pharmaceutical Inc
Pharmaceutical preparations United States 1 187
Teva 4 0 0 3988 0 0
UCB SA Pharmaceutical preparations Belgium 2473 06/07/04 Celltech Group
PLC
Commercial physical and
biological research
United
Kingdom
1 1 2473 2473
UCB SA Pharmaceutical preparations Belgium 500 31/01/03 Solutia Inc-
Specialty Chem
Bus
Chemicals and chemical
preparations, nec
United States 1 1 500 500
UCB 2 2 0 2973 2973 0
Valeant Pharm Intl Inc Pharmaceutical preparations United States 324 01/03/05 Xcel
Pharmaceuticals
Inc
Pharmaceutical preparations United States
Versicor Inc Biological products, except
diagnostic substances
United States 153 03/03/03 Biosearch Italia
SpA
Biological products, except
diagnostic substances
Italy
Vertex Pharmaceuticals Inc Pharmaceutical preparations United States 556 18/07/01 Aurora Biosciences
Corp
Laboratory analytical instruments United States
VI Technologies Inc Biological products, except
diagnostic substances
United States 152 11/03/05 Panacos
Pharmaceuticals
Inc
Biological products, except
diagnostic substances
United States
VIMRx Pharmaceuticals
Inc
Pharmaceutical preparations United States 120 18/12/97 Baxter Healthcare
Corp
Medical laboratories United States
ViroPharma Inc Pharmaceutical preparations United States 116 10/11/04 Eli Lilly-Vanconcin
Rights
Pharmaceutical preparations United States
Warner Chilcott PLC Pharmaceutical preparations Ireland-Rep 180 16/02/00 Bristol-Myers-
Women's Prods(3)
Pharmaceutical preparations United States
Warner-Lambert Co Pharmaceutical preparations United States 2132 17/05/99 Agouron
Pharmaceuticals
Inc
Pharmaceutical preparations United States
Warner-Lambert Co Pharmaceutical preparations United States 1050 01/07/96 Warner Wellcome
Consumer Hlth
Drugs, drug proprietaries, and
druggists' sundries
United
Kingdom
Warner-Lambert Co Pharmaceutical preparations United States 142 22/03/93 Wilkinson Sword
Group Ltd
Cutlery United
Kingdom
Watson Pharmaceuticals
Inc
Pharmaceutical preparations United States 178 12/02/03 Novatis AG-
Fiorinal Brands
Pharmaceutical preparations United States 1 178
Watson Pharmaceuticals
Inc
Pharmaceutical preparations United States 184 17/11/00 Makoff R&D
Laboratories Inc
Pharmaceutical preparations United States 1 184
Watson Pharmaceuticals
Inc
Pharmaceutical preparations United States 899 28/08/00 Schein
Pharmaceutical Inc
Pharmaceutical preparations United States 1 899
Watson Pharmaceuticals
Inc
Pharmaceutical preparations United States 297 18/01/99 TheraTech Inc Pharmaceutical preparations United States 1 297
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Watson Pharmaceuticals
Inc
Pharmaceutical preparations United States 131 28/02/97 Oclassen
Pharmaceuticals
Inc
Pharmaceutical preparations United States 1 131
Watson Pharmaceuticals
Inc
Pharmaceutical preparations United States 571 17/07/95 Circa
Pharmaceuticals
Inc
Pharmaceutical preparations United States 1 571
Wats 6 0 0 2259 0 0
Welfide Corp Pharmaceutical preparations Japan 1207 01/10/01 Mitsubishi-Tokyo
Pharmaceutica
Pharmaceutical preparations Japan
Whittaker Corp Pharmaceutical preparations United States 118 10/04/96 Xyplex
Inc(Raytheon Co)
Computer terminals United States
Xanodyne Pharmaceuticals
Inc
Pharmaceutical preparations United States 209 25/07/05 aaiPharma Inc-
Pharm Division
Biological products, except
diagnostic substances
United States
Yamanouchi
Pharmaceutical Co
Pharmaceutical preparations Japan 7223 01/04/05 Fujisawa
Pharmaceutical Co
Ltd
Pharmaceutical preparations Japan
Yoshitomi Pharmaceutical
Inds
Pharmaceutical preparations Japan 1010 01/04/98 Green Cross Corp Biological products, except
diagnostic substances
Japan
Zentiva NV Pharmaceutical preparations Czech
Republic
102 12/10/05 Venoma Holdings
Ltd
Investors, nec Romania
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